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Haemostasis, the highly regulated process of blood clotting after vascular damage, 
depends on a delicate interplay between bleeding and clotting. A shift of the 
haemostatic balance towards a prothrombotic state contributes to the development of 
obstructive clot formation in the venous system, and venous thrombosis. 
The incidence of venous thrombosis is estimated to be around 1-2 per 1000 persons 
per year and increases exponentially with age up to about 5 per 1000 persons per year 
in the elderly.[1,2] Venous thrombosis commonly manifests as deep vein thrombosis 
of the leg, where it can cause symptoms of pain, redness and swelling. In about one 
third of the patients embolization occurs and parts of a clot lodges in the vasculature 
of the lung, termed pulmonary embolism. Pulmonary emboli present with symptoms 
of shortness of breath and chest pain on inspiration and are lethal in up to 20% of 
the cases.[1,3] Thrombosis rarely occurs, in about 10% of the total cases of venous 
thrombosis, in other veins of, e.g. the arms, retina, mesentery and portal vein or the 
cerebral sinus.[4]
It was in the 13th century that the first case of venous thrombosis that we know of was 
described.[5] Deep vein thrombosis was reported in the right leg of a young man in 
France. Several hypotheses were suggested through the centuries for understanding 
the mechanism underlying venous thrombosis. It was only in 1856 that Virchow 
proposed the modern pathogenesis of thrombosis, now known as Virchow’s triad. [6] 
This triad explains thrombosis as a result of changes in blood flow, damage of the vessel 
wall and changes in blood composition. Over the years a long list of risk factors for 
venous thrombosis has arisen, all of which can be fitted under at least one of the three 
components of the triad.[7] 
Recurrent venous thrombosis
After a first event recurrent venous thrombosis is common, which is associated with 
considerable comorbidity, mortality and health-care costs. Five-year cumulative 
incidence of recurrences is reported to be around 25%.[8-10] Case fatality rates of 
recurrent venous thrombosis are estimated at 11% during the first three months of 
anticoagulant treatment and the rate of fatal recurrent venous thrombosis is 0.3-0.5% 
per year after discontinuation of anticoagulant treatment.[11,12]
Secondary prevention of recurrent venous thrombosis could greatly reduce the number 
of events. Secondary prevention can be achieved in two ways, either by elimination of 
modifiable risk factors or by extending the anticoagulant treatment period in patients 
at high risk of recurrence. For this we need knowledge of risk factors and/ or predictors 
of recurrent venous thrombosis. 
The difference between a risk factor and a predictor is that risk factors are causally 
related to the outcome of interest, in this case recurrent venous thrombosis, while 
predictors are associated with the outcome, but are not a causal factor for the outcome 
per se. For example, carrying a lighter in your pocket is not causally associated with an 
outcome such as lung cancer. However it will be able to predict an increased risk of lung 
cancer, since people carrying a lighter in their pockets are more often smokers than 
people who do not carry a lighter. Smoking is the risk factor for lung cancer. 
To prevent recurrent venous thrombosis we need knowledge of both predictors 
ánd risk factors for recurrence. Ideally, we find information on modifiable risk factors. 
Modifiable risk factors are factors we can advise patients to refrain from or factors we 
can intervene on, and in that way decrease the patient’s risk of recurrence. This is in 
contrast to genetic factors that cannot be readily intervened on. The focus of this thesis 
will therefore not be on genetics. In this thesis the association between a modifiable 
risk factor and recurrence is described in both Chapters 7 and 8. The second option for 
prevention of recurrent venous thrombosis is by extending the anticoagulant treatment 
period. However, such life-long treatment is not feasible in all patients, considering 
the substantial risk of major haemorrhage (1-2% per year)[13,14], and should be 
targeted at high risk patients only. Estimating the risk of recurrent venous thrombosis 
has proven to be challenging while knowledge of good predictors is much needed.[15] 
These predictors can be either factors purely predictive of recurrences (Chapter 6) or 
risk factors for recurrence (Chapters 2, 4, 9).
Despite that risk factors for a first venous thrombotic event are well known, for 
recurrent venous thrombosis this is not the case. It appeared that the risk profile for a 
first event cannot be directly translated to recurrent events. For example, age is strongly 
associated with first events[3], while it is not, or at most very weakly, associated with 
recurrent venous thrombosis.[8,16,17] The same is true for the presence of genetic 
thrombophilia.[18]
Some risk factors for recurrent venous thrombosis have been described in the 
literature, of which the most important ones are the absence of a transient provoking 
risk factor at time of the first event and the presence of active cancer.[19] However, 
only a proportion of the patients can be classified as such. Additionally, male sex has 
proven to be a moderately strong risk factor for recurrent venous thrombosis.[20-22] 







Factor Relation with recurrent venous thrombosis* 
Unprovoked vs provoked 1st event Strong[23]
Presence of active cancer Strong[8,9,24]
Proximal vs distal deep vein thrombosis Strong[25,26]
D-dimer levels (measured after discontinuation 
anticoagulant treatment)
Strong[28-30]
Male sex Moderately strong[20,22]
Antiphospholipid syndrome Moderately strong[27]
Residual thrombosis in proximal veins Moderately strong[31,32]
Hereditary thrombophilia Weak, controversial[18,33-35]
Overweight/ obesity Weak[36]
* Strong denotes: relative risk >2; Moderately strong: relative risk ~2; Weak: relative risk <1.5 
The aim of this thesis is to identify additional modifiable risk factors for as well as 
factors that might be able to predict recurrent venous thrombotic events. 
Study populations
The MEGA study
The MEGA (Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis) study is a large case-control study into risk factors for venous thrombosis.
[37] Between March 1999 and August 2004, 4956 consecutive patients with an 
objectively diagnosed first deep vein thrombosis of the leg or pulmonary embolism were 
included. Patients were aged 18-70 years and were enrolled from six anticoagulation 
clinics in the Netherlands. Anticoagulation clinics monitor all patients taking vitamin K 
antagonists in a well-defined geographical area. Control subjects, without a history of 
venous thrombosis, were partners of the patients (n=3297) or collected via random 
digit dialing (n=3000). All participants filled in a detailed questionnaire on their medical 
history and the presence of possible risk factors for venous thrombosis. Additionally, 
blood was collected from cases three months after discontinuation of anticoagulant 
treatment or one year after the event if cases continued anticoagulant treatment for 
more than one year. Controls who were partners of the cases provided blood at the 
same time as the case. Controls from the random digit dialing group provided blood 
within a few weeks after the questionnaire was sent.
The MEGA follow-up study
Of 4956 patients included in the MEGA study, 4731 gave written informed consent for 
future follow-up on recurrent venous thrombosis (MEGA follow-up study).[38] The aim 
of the MEGA follow-up study was to assess the incidence of recurrent events and to 
identify new risk factors and predictors of recurrences. The MEGA follow-up study is to 
date the largest non-register based study on recurrent venous thrombosis.
In diagnosing recurrent venous thrombosis it is sometimes challenging to distinguish 
between new thrombosis and extensions of a previous lesion (residual thrombosis). 
We aimed to make a clear distinction between the two and collected as many data 
as possible on recurrences during follow-up from different sources of information. 
Between June 2008 and July 2009 patients were asked whether they had developed 
a recurrent venous thrombotic event by means of a short answer form. Furthermore, 
between 2007 and 2009 the vital status of all MEGA follow-up patients was obtained 
from the Dutch population register and causes of death from the national registry of 
death certificates. Data from the answering forms, causes of death, anticoagulation 
clinics and discharge letters from treating physicians were combined to make a 
classification of certain and uncertain recurrences.
Data on the presence of risk factors or predictors for recurrent venous thrombosis 
were additionally obtained via different sources of information. First, all patients were 
asked to complete a questionnaire on potential risk factors after their first event. 
Second, our data were linked to the Dutch hospital data register which covers complete, 
nationwide data on hospital admissions since 1986. Third, all patient records were 
linked to the SFK register (the Dutch Foundation for Pharmaceutical Statistics).[39] 
Outline of this thesis
In Chapter 2 results from the MEGA follow-up study are reported and an accurately 
determined incidence rate of recurrent venous thrombosis using a strict definition 
of recurrence is presented. Additionally the influence of the previously described 
risk factors male sex and type of the first event (provoked or unprovoked) on risk of 
recurrence was studied.
Cancer has been shown to be one of the strongest risk factors for venous 
thrombosis. Of all first venous thrombotic events about 20-30% are cancer-related.[40-
43] Furthermore, cancer increases the risk of a first venous thrombotic event four- to 
seven-fold.[9,37,44,45] To obtain a better insight in this relationship and to obtain an 
idea of current knowledge with regard to the risk of recurrent venous thrombosis in 
patients with cancer, Chapter 3 presents an extensive review of the literature on this 
topic. 
Few studies have investigated the risk of recurrent venous thrombosis in patients 
with cancer. However, all of these studies report an increased recurrence risk.
[8,9,24,46] The relation between cancer, diagnosed either before or after the first 
venous thrombotic event, and recurrent venous thrombosis in the MEGA follow-up 
study is presented in Chapter 4. Furthermore, recurrence risks were studied separately 
for different types of cancer and for different time periods after cancer diagnosis, which 







Despite a lot of research on the topic the pathophysiology underlying the relation 
between cancer and venous thrombosis is largely unknown. The relation between 
cancer and venous thrombosis is strong; however, not every patient with cancer 
develops thrombosis. To obtain a better insight in this relation plasma levels of 
coagulation factors, both procoagulant and anticoagulant, were studied in patients 
with and without cancer and patients with and without venous thrombosis (Chapter 
5). 
Levels of coagulation factor VIII have been shown to be strongly related to first 
venous thrombotic events.[47] Only a few studies, mostly with rather small sample 
sizes, studied the relation between factor VIII and recurrent venous thrombosis and 
showed contradictory results.[18,48,49] In Chapter 6 the predictive value of factor 
VIII levels for recurrent venous thrombosis in the MEGA follow-up study is described. 
Additionally, the effect of adding factor VIII to an existing prediction model for recurrent 
thrombosis was studied. 
An important risk factor for a first venous thrombotic event is the use of oral 
contraceptives because of its high prevalence.[50-52] In Chapter 7 the aim was to 
study the risk of recurrent venous thrombosis in women who continue or start using 
hormonal contraceptives after a first venous thrombotic event and to see whether 
taking away this risk factor could reduce recurrence risk. 
Another modifiable risk factor for venous thrombosis is seated immobility. It has 
been shown that for a first venous thrombotic event the risk is increased by immobility, 
such as during a long-haul flight, other types of travel or a sedentary lifestyle.[53-56] 
Chapter 8 discusses whether the risk of recurrent venous thrombosis is additionally 
increased after such periods of seated immobility and whether prophylactic measures 
could potentially decrease the recurrence risk. 
Infections are currently not considered provoking risk factors for a first venous 
thrombotic event. However, a relation between infectious and inflammatory diseases 
and thrombosis has been shown before.[57-59] The risk of both first and recurrent 
venous thrombosis during periods of antibiotic use, as a proxy for infectious diseases, is 
presented in Chapter 9. Additionally the joint effect of both antibiotic use and genetic 
thrombophilia on the risk of venous thrombosis is discussed.
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Chapter
Incidence and characteristics of recurrent 
venous thrombosis in a large cohort of 
patients with a first venous thrombosis
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The reported incidence of recurrent venous thrombosis (VT) varies widely. 
Objectives 
The aim of this study was to estimate the incidence of a recurrent event and the effect 
of location, age, and sex in a large cohort of patients with a first VT. 
Patients 
We followed 4731 patients with a first VT between 1999 and 2004 (MEGA study) 
until 2008-2009. Recurrences were adjudicated from self-reported information in 
questionnaires, anticoagulation clinics, and discharge letters. We calculated incidence 
rates and hazard ratios (HR) to estimate the effect of various factors on recurrence. 
Results 
673 patients (14.2%) had a recurrent event. The overall incidence rate was 27.9 per 
1000 person years (95%CI, 25.8-30.0). The cumulative incidence at 5 years was 11.3%. 
An idiopathic first thrombosis was a risk factor for recurrence in men and women. Men 
had a higher risk of recurrence than women regardless of location or the presence of 
a provoking factor (HR overall: 2.2 (95%CI, 1.9-2.6). Age did not affect recurrence risk. 
Conclusions 
This study provides precise and valid estimates of recurrence risk, which is substantial 
at about 3% per year. For duration of treatment, sex, type of first event and location of 
first event may need to be taken into account.
 
Introduction
Venous thrombosis is a multi-causal disease that occurs in 1-3 per 1000 persons per 
year.[1,2] It is associated with substantial mortality and morbidity including recurrence. 
The cumulative incidence of recurrent venous thrombosis is much higher than that of a 
first event and varies between studies from 4-11% within the first year to 12-30% within 
five years after the first event.[3-7] Incidence rates of recurrence also vary between 
studies, from 25 to 46 per 1000 person-years.[5,7] Sources of this variation include 
definition of recurrence, setting and size of study (clinical versus research setting) and 
starting point of follow-up. 
In contrast to a first event, only few risk factors are known to be associated with the 
risk of recurrent thrombosis, such as male sex, the presence of a malignancy, and an 
idiopathic first venous event.[3,5,7-14] Age, which is the strongest risk factor for a 
first event does not, or only slightly, increase the risk of recurrence.[5,9-13] However, 
the separate effects of age, male sex, and an idiopathic first venous thrombosis are 
not well established, mainly as a result of small sample sizes of the studies reported 
so far, different cut-off points for age, and different definitions for idiopathic venous 
thrombosis.
The best way to prevent recurrence is by anticoagulant treatment. However, this has 
the drawback of a major bleeding risk, which, if it were to be given indiscriminately, is 
not outweighed by the prevention of thrombosis. Therefore, duration of anticoagulant 
treatment is limited, and the optimal duration is not well known, despite several trials 
into this.[15-18] 
A recent study showed that recurrent events do not occur at random sites.[19] The 
ability to predict the location of recurrence may influence the duration of treatment 
especially when a pulmonary embolism (PE) as recurrent event is more likely than a 
deep vein thrombosis (DVT) of the leg. 
To address all questions mentioned above, we performed a large follow-up study of 
almost 5000 patients with a first venous thrombosis. In this study, we estimated risk 
of recurrence, the separate associations of age, sex, and an idiopathic first thrombosis 
with the risk of recurrence, the effect of different durations of anticoagulation, and the 
relation between site of first and recurrent events. 
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Patients were included from the MEGA study[20,21], a large population-based case-
control study into risk factors for a first venous thrombosis, which included consecutive 
patients at six anticoagulation clinics in the Netherlands between March 1999 and 
September 2004. In total, 5182 cases and 6297 controls were included. From the cases, 
patients with a deep venous thrombosis of the leg, pulmonary embolism (PE), or both 
were included and patients with a venous thrombosis of the upper extremity were 
excluded from this analysis (follow-up data reported previously [20]). Of 4956 patients 
eligible for follow-up 225 indicated that they did not want to participate in a follow-
up study and were therefore excluded (Figure 1) leaving 4731 patients for the follow-
up study. This study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center and all participants gave written informed consent.
Information about recurrences was retrieved in two ways, i.e., from the patients 
themselves via a short questionnaire and from the anticoagulation clinics, which 
monitor all outpatients’ anticoagulant treatment with vitamin K antagonists. The short 
questionnaire consisted of two questions: 1)“Did you have a recurrent event?” and 
2)“By which doctor was it diagnosed?” Questionnaires were sent by mail between June 
2008 and July 2009. When questionnaires were not returned, questions were asked by 
telephone interview. During the same period, information on possible recurrences of 
all patients was obtained from the anticoagulation clinic where they were included for 
their first event and, in case they moved house, at the clinic near their new address. 
Information on duration of anticoagulant treatment was also obtained from the 
anticoagulation clinics. 
For all potential recurrences found by the questionnaire, anticoagulation clinic, or both, 
discharge letters were requested from the clinician who diagnosed the recurrence 
according to the patient or the clinic.
Definition of recurrence
A decision rule regarding certainty of diagnosis was made according to the information 
collected for each patient. Reported recurrences were classified into certain and 
uncertain recurrences. In this study certain recurrences were used as endpoint and 
patients with an uncertain recurrence were censored at time of their uncertain 
recurrence, since they were definitely recurrence-free until that time.
To be classified as a certain recurrence, a reported recurrence should fulfil one of the 
following criteria. 
1. A discharge letter was present concluding a diagnosis of recurrence, based on 
available clinical and radiological data. This recurrence should be in a different vein 
or in a different part of the body than the first event. The discharge letter had to 
contain information about instrumental diagnostic procedures. If location of either 
first or second thrombosis was not known, an event was still classified as certain if 
at least three months had passed since the first thrombosis. 
2. A discharge letter was not available (e.g., when the treating physician was unknown) 
but both the anticoagulation clinic and the patient reported a recurrence at a clearly 
different location than the first event (contralateral leg, DVT after PE or vice versa) 
or a time period of more than a year had passed between the two events (Figure 2).
3. A registered cause of death from PE or DVT at least six months after the first event. 
Uncertain recurrences were defined by four criteria, one of which had to apply: 
4. A diagnosis of a possible recurrence in the discharge letter, where clinical and 
radiological data could not distinguish between an extension of the first and a new 
thrombotic event. 
5. A discharge letter was not available but both the patient and the anticoagulation 
clinic reported a recurrence within a year after the first event. 
6. Information was only available from either the patient or the anticoagulation clinic.
7. A registered cause of death from PE or DVT within six months after the first event.
Statistical analysis
End of follow-up was defined as the date of a recurrent event and, in the absence of 
a recurrence, the date of filling in the short questionnaire. If patients did not fill in a 
questionnaire they were censored at the last date we knew them to be recurrence 
free. This could be either the last visit to the anticoagulant clinic, date of death or 
emigration, or the last moment the patient was known to be recurrence-free from 
information of the MEGA case-control study (Figure 1). Duration of follow-up was 
calculated in two ways, i.e., by starting follow-up at 1) the date of the first event or 
2) the date of discontinuation of anticoagulant therapy. Both incident rates and 
cumulative incidences of recurrence were calculated from these two starting points. 
In order to find a range of incidences which includes the true incidence of recurrence, 
we calculated, as a sensitivity analysis, incidences for all possible recurrences combined 
(certain and uncertain) and separately for certain recurrences with both starting points 
of follow-up. Additionally we refined our incidence estimation by a multiple imputation 
analysis in patients with an uncertain recurrence. With the multiple imputation analysis 
the recurrence status of the uncertain recurrences was estimated using information on 
all comorbidities and risk factors present at time of first thrombosis.[14,19] 
Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, 
plaster cast, hormone use (oral contraceptives and hormone therapy) or pregnancy, 
Chapter 2
24
Incidence and characteristics of recurrent venous thrombosis
25 
2 2
all within three months before the event, or puerperium or active malignancy at the 
time of the event. Kaplan-Meier curves adjusted for competing risks were estimated 
for men, women, and patients with an idiopathic and provoked first venous thrombosis 
separately. Incidence rates were calculated for men, women, and idiopathic and 
provoked cases separately in different age categories to study risk patterns for these 
three factors.
For the analysis on risk factors and optimal duration of anticoagulation, only certain 
recurrences were used and uncertain recurrences were censored at the time of 
reported recurrence. Hazard ratios (HR) were estimated for all potential risk factors, 
and all HRs were adjusted for age and sex when applicable. All HRs were estimated 
with follow-up starting at time of first venous thrombosis. The effect of male sex was 
also studied in a restricted analysis excluding women who used hormones at time of 
first thrombotic event as well as women who were or had recently been pregnant at 
that time. Age was studied both as a continuous and a categorical variable with 10-year 
age categories. These effects were studied in all patients and in patients without cancer 
and life-long anticoagulants separately. These restrictions were done to determine the 
effect of these risk factors in those without another strong risk factor of thrombosis 
(cancer) and in those who cannot be treated longer than they already were (lifelong 
treatment).
First and recurrent events were compared for location (lungs or leg). Left versus right-
sided first and recurrent thrombosis of the leg were analysed. Observed numbers 
versus expected numbers when locations and sides would be random were calculated 
as well as HRs for site of recurrence per site of first thrombosis.
For the analysis of the effect of duration of anticoagulation therapy, patients with 
malignancies at the time of thrombosis were excluded. Duration of anticoagulation 
therapy was calculated in months. Survival curves were made for patients who used 
anticoagulation therapy for 3, 4-6, 7-12, and >12 months. Survival curves were adjusted 
for competing risks due to death and included only recurrences that occurred after 
discontinuation of anticoagulant therapy. 
Analyses were performed with SPSS version 21.0 (Chicago, Ill) and STATA SE version 12 
























Mean age of patients at time of first venous thrombosis was 48 years and 54% of patients 
were women. Mean duration of follow-up was 5.1 years when follow-up started at 
time of venous thrombosis and 5.0 years when follow-up started after discontinuation 
of anticoagulation. Total volumes of follow-up were 24 124 and 20 031 person-years 
respectively. In total 79% of patients (n=3729) had a complete follow-up of whom 2837 
filled in the questionnaire and 892 were followed until recurrence. 1002 (21%) patients 
did not complete follow-up either due to death (n=99) or emigration (n=3) without 
recurrence, or did not reply to further queries after a last visit at the anticoagulation 
clinic (n=489) or at a later point in time during follow-up (n=411) (Figure 1). 
Recurrences
We obtained information about recurrence status from 3757 patients. 972 possible 
recurrences were found that needed to be confirmed. From the information obtained 
from clinicians, we concluded that 80 of these were not recurrences but were either 
post-thrombotic syndrome or suspected recurrences that were subsequently excluded 
by ultrasound or CT-scan. Therefore, 892 recurrences could be further classified. 
Of these, 673 patients were classified to have a certain recurrence according to the 
criteria listed in the Methods section. 593 patients fulfilled criterion 1) for certain 
recurrence. Fifty-eight patients were identified as a certain recurrence with criterion 2) 
and 22 patients with criterion 3). 219 patients had an uncertain recurrence of which 32 
fulfilled criterion 4), 19 criterion 5), 159 criterion 6), and 9 criterion 7). 
Incidence of recurrence
When follow-up started at time of first venous thrombosis, we found an incidence of 
27.9 per 1000 person-years (95%CI, 25.8-30.0) when only certain recurrences were 
taken into account. When certain and uncertain recurrences were counted as recurrent 
events, as a sensitivity analysis, we found an incidence of 37.0 per 1000 person-years 
(95%CI, 34.6-39.4) (Table 1). These incidence rates corresponded to a 5-year cumulative 
incidence of 11% and 15%, respectively. 
Of the 673 certain recurrences, 61 (9%) occurred during anticoagulation therapy 
prescribed after the first thrombotic event, whereas 53 of the 219 uncertain recurrences 
(24%) occurred during treatment. When follow-up was started after discontinuation of 
anticoagulation treatment, the incidence of recurrence was 30.6 per 1000 person-years 
(95%CI, 28.1-33.0) when only certain recurrences were taken into account and 38.8 
(95%CI, 36.1-41.6) per 1000 person-years when both certain and uncertain recurrences 
were taken into account. When recurrence status was imputed in the group who had 
uncertain recurrences the incidence of recurrence became 29.4 (95%CI, 27.4-31.7) per 
1000 person-years when follow-up started at time of first venous thrombosis and 32.0 
(95%CI, 29.6-34.6) when follow-up started after discontinuation of treatment (Table 1). 
Recurrence rate was highest during the first 1.5 years, i.e., 54 per 1000 (95%CI, 45-65) 
person-years at 1 year and 42 per 1000 (95%CI, 33-52) person-years at 1.5 years, and 
decreased to 25 per 1000 (95%CI, 18-34) person-years after 4 years. After this time the 
incidence of recurrence remained stable at 25 per 1000 person-years. 
Risk factors 
Table 2 shows incidences of recurrence stratified by age, sex, and whether the first 
venous thrombosis was idiopathic or not. Incidence rates were in all instances higher 
for men than women. No clear effect of age was seen in any of the categories. 
Men had a 2.2-fold (95%CI, 1.9-2.6) increased rate of recurrence compared with 
women (Figure 3, Table 3). After exclusion of women who used hormones, or were 
pregnant at time of first thrombosis the relative rate increased to a 2.8-fold (95%CI, 2.2-
3.6) increased rate in men. Age at time of first venous thrombosis was not associated 
with an increased risk of recurrence (Table 3). 
Patients with a first idiopathic thrombosis had a 2.0-fold (95%CI, 1.7-2.3) increased 
rate of recurrence compared with patients with a provoked first thrombosis. However, 
after adjustment for sex this rate ratio diminished to 1.4 (95%CI, 1.2-1.7). 
Incidence of recurrent thrombosis was higher in men than in women, regardless 
whether the first event was provoked or idiopathic, i.e., the incidence after a provoked 
first event in men: 35.5 per 1000 person-year (95%CI, 29.4-39.5) and in women: 16.5 
per 100 person-years (95%CI, 14.2-18.8) and the incidence after an idiopathic first 
event in men: 47.6 per 1000 person-years (95%CI, 41.7-53.5) and in women: 28.2 per 
1000 person-years (95%CI, 20.1-36.3). The increased rate of recurrent thrombosis 
after an idiopathic first event was present in both men (HR 1.4 (95%CI, 1.1-1.6)) and 
women (HR 1.7 (95%CI, 1.3-2.5))(Figure 2). Exclusion of patients with cancer and life-
long treatment did not lead to more than trivial changes in these estimates (Table 3).
Location of recurrent and first thrombosis
Sixty-two percent of recurrences were DVTs, 31% were PEs, 5% had DVT+PE, and 1% 
of recurrences were in a different location (upper extremity, portal vein, intestines or 
sinus) (Table 4a). Recurrences occurred more than expected at the same location as 
the first event (Table 4a). Patients with DVT were 1.5-fold (95%CI, 1.1-1.9) more likely 
to have a DVT as second event than patients with a PE. Patients with a first PE were 
1.9-fold (95%CI, 1.4-2.8) more likely to suffer a recurrent PE than those with a first DVT 
or with a DVT+PE. 
In patients who had a first DVT in their left leg, the side of the recurrent DVT 
appeared to be equally distributed whereas in patients who had a first DVT in their 
right leg, the chance of a recurrent event in the right leg was slightly higher (60%, 
95%CI, 50%-66%) than a recurrent event in the left leg (Table 4b).
 
Anticoagulation therapy for the initial event
For this analysis, 575 patients with malignancy were excluded as these patients often 
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Table 4a Location first versus recurrent thrombosis, observed versus expected.
Recurrence
1st event DVT PE DVT+PE Other Total
DVT 319 (267) 71 (99) 23 (58) 4 (0) 424
PE 44 (99) 105 (37) 4 (21) 1 (0) 157
DVT + PE 51 (58) 29 (21) 9 (13) 3 (0) 92
Total 414 (424) 205 (157) 36 (92) 8 (0) 673
N observed (N expected)
Table 4b. Side of DVT.
Recurrence
1st event Left Right Both
Left 79 (50%, CI95 42%-57%) 78 (49%, CI95 42%-57%) 2 (1%)
Right 54 (40%, CI95 32%-48%) 81 (60%, CI95 50%-66%) 0
Both 1 0 0
have treatment for prolonged periods of time or for life. Of the 4156 patients without 
malignancy, duration of anticoagulation therapy for the initial event was obtained for 
4053 (98%) patients. Most patients received 4-6 months of anticoagulation treatment 
after the first venous thrombosis (Figure 3). Patients with a clear provoking factor were 
slightly more likely to have received less than 4 months of treatment than those with 
a first idiopathic venous thrombosis (30% vs. 25%). Figure 3 shows the cumulative 
incidence of recurrence over time for four different duration periods of anticoagulation. 
This Figure shows that the curves for the different durations of anticoagulation therapy 
run parallel indicating that the risk of recurrence is equal after discontinuation of 
anticoagulation regardless of duration. 
Chapter 2
32




































































































































































































































































































Figure 3. Cumulative risk of recurrence for different durations of treatment when follow-up 
started at time of first venous thrombosis.
Total N 1-3 months oac 
N (%)
4-6 months oac 
N (%)
7-12 months oac 
N (%)
>12 months oac 
N (%)
3603 1027 (29) 1637 (45) 724 (20) 215 (6)
- Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, plaster 
cast or hormone use (oral contraceptives and hormone replacement therapy), and pregnancy 
within three months before the event, and without active malignancies or puerperium.








In this large follow-up study of 4731 patients with a first venous thrombosis followed 
for a total follow-up time of 24 124 person-years we found 683 certain recurrent events 
for an incidence rate of 27.9 per 1000 person-years and a cumulative incidence of 3% 
after one year. We found male sex to be a risk factor for recurrence with a 2.2-fold 
increased rate (95%CI, 1.9-2.6). Overall, an idiopathic first thrombosis was associated 
with a 1.4-fold increased rate (95%CI, 1.2-1.7). Increasing age was not associated with 
recurrence risk. When we studied different durations of anticoagulation therapy we 
found no difference in recurrence risk after discontinuation. 
To establish the true incidence of recurrence we performed a sensitivity analysis. 
We found an incidence of 27.9 per 1000 person-years when only certain recurrences 
were taken into account and 37.0 per 1000 person-years when both certain and 
uncertain recurrences were taken into account. The range of incidences of recurrent 
thrombosis we report is similar but more precise than incidences previously reported.
[3-6,11,21,22] Additional to small study sizes, the variation in incidence rates found in 
the literature may be explained by different definitions of start of follow-up (starting at 
time of thrombosis or at discontinuation of treatment). Both methods of defining start 
of follow-up are justifiable, but lead to results that should be interpreted differently. 
To start follow-up at date of first event has the advantage that recurrences during 
anticoagulation are taken into account. Furthermore, previous studies generally did 
not take (un)certainty of recurrences into account. In our study we showed incidences 
of recurrence both starting follow-up after the date of thrombosis and after the date 
of discontinuation of treatment. We chose to show the main results of only those 
with a certain recurrence, as these are most likely to truly have had a recurrent 
event. However, we also present results where uncertain diagnoses were counted as 
recurrence, and in which recurrence status of patients with an uncertain recurrence 
was imputed. By showing all possible ways of estimating incidence rates, our results 
can easily be compared with those of other studies.
Recurrent events occurred more often than expected just by chance at the same site 
as the first thrombosis, i.e., patients with a first PE were more likely to have a PE as 
recurrent event, and patients with a first DVT had more DVT as recurrence. This may be 
explained by damage to the veins or by a higher awareness of thrombotic symptoms 
at the location of the first event. However, when a patient had had a first venous 
thrombosis of the left leg with a recurrence in the leg, the side of recurrence was 
random. These results suggest that most recurrences are not due to vascular damage 
or residual thrombosis but may be the result of a more general hypercoagulable state. 
When studying the effect of treatment duration, we observed parallel running survival 
curves. The curves ran parallel because we considered for this analysis only recurrences 
that occurred after discontinuation of anticoagulation therapy. Obviously, with 
increasing duration of anticoagulation, discontinuation occurred later during follow-
up. This finding implies that the risk of recurrence is not higher after three months of 
treatment than with longer periods, which is in line with findings from a recent meta-
analysis by Boutitie et al.[23]
As has been consistently shown in other studies, we found a two-fold higher risk of 
recurrence in men than women. For women more modifiable provoked risk factors are 
known and therefore they are at lower risk of recurrence than men. These risk factors 
are not present in idiopathic patients. However, men with an idiopathic thrombosis 
were still at higher risk of recurrence (incidence: 47.6 per 100 person-years; 95%CI, 
41.7-53.5) than women with an idiopathic first event (incidence: 28.2 per 1000 person-
years; 95%CI, 20.1-36.3), indicating that men have a higher intrinsic risk of thrombosis. 
Such an intrinsic higher risk in men has also recently been demonstrated by a study of 
our group where we showed that the risk of a first event is also twice as high in men 
when hormonal risk factors are taken into account.[23] Most previous studies did not 
stratify by sex in the analysis of idiopathic versus provoked first venous thrombosis and 
the risk of recurrence.[5,9,10,13] Increasing age did not increase the risk of a recurrent 
event after adjustment for sex. Similar results were obtained from previous studies, 
including our own.[5,17,18] 
The MEGA follow-up study is the largest single study on risk of recurrent venous 
thrombosis. While varying estimates of recurrence risk have been reported in literature, 
the large number of patients and the long duration of follow-up resulting in the 
identification of almost 700 recurrences, allowed us to estimate the risk of recurrence 
with great precision, overall and in several subgroups. 
A limitation of this study is that it was based in a clinical setting. We did not perform 
CUS for all patients after the first event to better evaluate a subsequent recurrence. 
However, we tracked all possible recurrences and had access to three sources of 
information to decide on the likelihood of a true recurrence. The sensitivity analysis 
showed little difference between the minimum and maximum recurrence rate possible 
(27.9-37.0) per 1000 person-years as described in Table 1. However, an advantage of 
this clinical setting is that our study gives the optimal estimate of true effects in clinical 
practice. A second limitation is that we included only patients with a first event who 
were younger than 70 years of age. Therefore, our results are not generalizable to 
patients with a first venous thrombosis above 70 years. A third limitation is that for 
21% of patients limited follow-up was available. Some of these patients were lost to 
follow-up due to death. However, from some of them we still knew their recurrence 
status up to death through registries of the causes of death and information from 
anticoagulation clinics. Therefore, in the end we did not know the recurrence status of 
8% of patients who died, which at most would have led to a slight underestimation of 
the incidence of recurrent thrombosis. The majority of patients were lost to follow-up 
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Cancer-associated venous thrombosis is a common condition, though the reported 
incidence varies widely between studies depending on patient population, start and 
duration of follow-up and the method of detecting and reporting thrombotic events. 
Furthermore, as cancer is a heterogeneous disease, the risk of venous thrombosis 
depends on cancer types and stages, treatment measures and patient-related factors. 
In general, cancer patients with venous thrombosis do not fare well and have an 
increased mortality compared with cancer patients without. This may be explained 
by the more aggressive type of malignancies associated with this condition. It is 
hypothesized that thromboprophylaxis in cancer patients might improve prognosis 
and quality of life by preventing thrombotic events. However, anticoagulant treatment 
leads to increased bleeding, particularly in this patient group, so in case of proven 
benefit of thromboprophylaxis only patients with a high risk of venous thrombosis 
should be considered. This review describes the literature on incidence of and risk 
factors for cancer-associated venous thrombosis, with the aim to provide a basis for 
identification of high-risk patients, and for further development and refinement of 
prediction models. Furthermore, knowledge on risk factors for cancer-related venous 
thrombosis may enhance understanding of the pathophysiology of thrombosis in these 
patients. 
Introduction 
In 1865, Armand Trousseau, a French physician, was one of the first to describe an 
association between thrombosis and cancer. Not many know the association had 
already been reported earlier in 1823 by Jean Baptiste Bouillaud.[1,2] Perhaps because 
of the irony of Trousseau diagnosing the condition on himself and dying from it in 1867, 
the condition was later called Trousseau’s syndrome. Since then, many studies have 
confirmed the association between cancer and venous thrombosis and demonstrated 
that the incidence of venous thrombosis in cancer patients is high, that it has risen over 
the past decades and that cancer patients with venous thrombosis do not fare well. It 
is hypothesized that thromboprophylaxis targeted at cancer patients with a particular 
high risk of thrombosis might improve their prognosis. Therefore a need exists to 
identify such patients, which is not easy since cancer is a heterogeneous disease and 
the risk of venous thrombosis depends on the interaction between tumor cells, the 
hemostatic system and characteristics of the patient. Furthermore, identification of 
risk factors for cancer-related venous thrombosis will help to improve understanding 
of the pathophysiology of thrombosis in cancer patients. Thus, even 150 years after 
Trousseau died, there is still a need to study the epidemiology of venous thrombosis 
and cancer in detail.
Incidence of venous thrombosis in cancer patients
It is estimated consistently that about 20 to 30% of all first venous thromboembolic 
events are cancer-associated (Table 1).[3-9] In a population-based, nested case-control 
study within the Olmsted County population (Minnesota), 625 residents with an incident 
deep vein thrombosis (DVT) or pulmonary embolism (PE) were matched on age and sex 
to 625 unaffected residents. A population attributable risk (PAR; the percentage of all 
cases of a disease in a population that can be attributed to a risk factor) was calculated 
and reported to be 18% (95%CI; 13.4-22.6) for an active malignancy.[5] White and 
coworkers used the California discharge data set to identify a cohort of 21 002 patients 
hospitalized with incident venous thrombosis in 1996. Of these patients again about 
20% (4368) were reported to have cancer-associated venous thrombosis.[9] In a 
third study, medical records of residents from the Worcester metropolitan area were 
obtained for a total of 1399 subjects with a confirmed episode of venous thrombosis. 
Of these patients 29% had a recent or active malignant neoplasm.[8] In a more recent 
registry, the RIETE registry, which included over 35 000 consecutive symptomatic VT 
patients from 2001 up to 2011, active cancer was reported in 6075 patients (17%).
[4] Lastly, the Tromsø study is a population-based prospective follow-up study of over 
26 000 subjects. Participants were followed for venous thrombosis from 1994 to 2007. 
Of 462 patients with a first-ever VT event, 106 had an active cancer (23%).[3] 
Cancer patients have a several fold increased risk of venous thrombosis as compared 
with the general population or patients without cancer, with relative risks ranging from 
4 to 7 (Table 1).[10-13] Frequently cited is the Olmsted County population study. In this 
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study malignant neoplasm was shown to increase the risk of venous thrombosis four-
fold (OR 4.1 (95%CI; 1.9-8.5).[12] However patients were included between 1976 up 
to 1990, which might outdate the findings. In a Dutch population-based case-control 
study (the MEGA study), over 3000 consecutive patients with venous thrombosis 
were included between 1999 and 2004, together with over 2100 partner controls.
[10] The risk of venous thrombosis was increased seven-fold in patients with cancer 
compared with patients without (OR 6.7 (95%CI; 5.2-8.6)). By linkage of four United 
Kingdom databases Walker and coworkers estimated the relative risk of VT in cancer 
versus age-matched non-cancer controls from the general population to be 4.7 (HR 
4.7 (95%CI; 4.5-4.9)).[13] Surprisingly similar results were reported from a Danish 
population-based cohort of 57 591 incident cancer cases that were followed in time for 
venous thrombosis, together with 287 476 individuals without cancer from the general 
population. Non-cancer controls were matched on age, sex and county of residence. 
After adjustment for comorbid conditions the risk of venous thrombosis was also 4.7 
times higher in cancer patients compared with the non-cancer participants (RR 4.7 
(95%CI; 4.3-5.1)).[11] Although these relative risks demonstrate a strong association 
between cancer and venous thrombosis, absolute risks are clinically more meaningful, 
for example to communicate a patient’s risk of venous thrombosis or to decide whether 
a patient needs prophylactic treatment with anticoagulants or not, for which it needs 
to be balanced with the risk of unwanted side-effects (minor or major bleeding) of the 
anticoagulant treatment. Cohort studies are best suited for this purpose because they 
provide absolute risks. 
The reported absolute risk (cumulative incidence) of venous thrombosis in cancer 
patients varies widely (1% - 8%) depending on patient population, duration of follow-
up, calendar period and the method of detecting and reporting venous thrombotic 
events (Table 1). The heterogeneity of the studies makes it difficult to compare rates 
of venous thrombosis between these studies. Some follow-up studies include cancer 
patients with a diagnosis long before start of follow-up, in others follow-up is started at 
the beginning of cancer treatment. When comparing studies and generalizing results to 
other populations, follow-up should start at the same time, preferably at time of cancer 
diagnosis. When follow-up starts at a later time, some patients may have died and are 
therefore missing in the analyses. By linkage of the California Cancer Registry to the 
California Patient Discharge Data Set, Chew and colleagues followed 235 149 cancer 
patients from time of cancer diagnosis. Within 2 years 5032 patients developed a 
venous thrombotic event (1.6%).[14] The cumulative incidence reported in populations 
of such cancer registries or hospital discharge data is generally lower compared with 
rates reported in, for example, patients admitted to an inpatient oncology service. This 
is indeed observed in data from Sallah et al. who reported a cumulative incidence of 
venous thrombosis of 7.8% in 26 months in cancer patients referred to hematology/ 
oncology services.[15] In the CATS study, a prospective follow-up of 840 cancer patients 
admitted to the Medical University in Vienna, 8% of the cancer patients developed a 
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A recent meta-analysis by Horsted et al described incidence rates of venous 
thrombosis in cancer patients, stratified by ‘background risk’ of venous thrombosis.[17] 
Among cohorts with average-risk patients, defined as cancer patients representative of 
all patients with cancer, the incidence rate of venous thrombosis was estimated to be 
13 per 1000 person-years (95%CI; 7-23). Among cohorts with high-risk patients, defined 
as cancer patients with high-grade or metastatic disease or treated with therapeutic 
strategies that increase thromboembolic risk, the overall incidence rate was 68 per 
1000 person-years (95%CI; 48-96). In the abovementioned study with linkage of four 
United Kingdom databases, over 82 000 cancer patients and over 577 000 age-matched 
control participants were followed in time for venous thrombotic events. The incidence 
rate of VT in all cancers was 13.9 per 1000 person-years (95%CI; 13.4-14.4).[13]
Over the years the incidence of venous thrombosis in cancer patients has increased 
(Table 1).[18,19] Among patients hospitalized with cancer between 1979 and 1999 
the cumulative incidence of venous thrombosis was reported by Stein and coworkers. 
Data was obtained from the US National Hospital Discharge Survey. The cumulative 
incidence of venous thrombosis increased from the late 1980s onward (1.5% in 1989) 
and this trend continued to the late 1990s (3.5% in 1999).[19] A similar trend was seen 
in another study of hospital discharge data. In this study the cumulative incidence of 
venous thrombosis was 3.6% in 1995-1996 and 4.6% in 2002-2003 (28% increase).
[18] A similar rise in VT incidence over time in cancer patients, but not in non-cancer 
controls, is seen in the study with linkage of four United Kingdom databases by Walker 
(Figure 1).[13] In this study the rise in VT incidence is reported for different cancer 
types. Several factors could explain this finding, including a greater awareness of the 
association between cancer and venous thrombosis and improvements in diagnostic 
tests. Also, due to improved treatment strategies patients with cancer currently survive 
longer, leading to more aged patients undergoing more cancer treatments, which in 
themselves also increase thrombosis risk. For these reasons, the incidence is expected 
to rise further in the future. 
Risk factors for venous thrombosis in cancer patients
Cancer is a heterogeneous disease and its different types and stages should be taken 
into account when determining the risk of venous thrombosis. Also several patient-
associated and treatment-associated factors are known to increase the risk of 
thrombosis. 
Extensive work has been published on type of malignancy and subsequent risk 
of venous thrombosis (Table 1). Overall, pancreas, brain, lung and ovarian cancer 
are reported to induce highest risks.[11,13,17,20] In the literature high risks are 
additionally reported for lymphomas, myeloma and kidney, stomach and bone cancer.
[11,14,18,21] Relatively low risks are generally seen in patients with breast or prostate 
cancer. Horsted and colleagues summarized in their meta-analysis incidence rates 
of venous thrombosis for eight different types of malignancy (Figure 2).[17] For the 
absolute risks presented in this figure only cohort studies with start of follow-up at 
Figure 1. Absolute rates of venous thrombosis (per 1000 person years) for individual calendar 
years between 1997 and 2006. Cases are cancer patients and controls are age-matched non-
cancer controls from the general population. Figure from Walker European Journal of Cancer 
2013, with permission from Elsevier.[13]
Figure 2. Pooled incidence rates (per 1000 person years) of venous thrombosis per type of 
cancer. Only studies with start of follow-up at time of cancer diagnosis were included. Numbers 
in brackets refer to the number of studies that contributed to the pooled estimate. Figure from 
Horsted Plos Med 2012.[17]
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time of cancer diagnosis were included. It appears that especially the cancer types that 
are biologically aggressive, as evidenced by short survival time and early metastatic 
spread, are correlated with a high incidence of venous thrombosis.[22] Figure 3 shows 
VT incidence rates for different types of cancer (according to results of Horsted[17], 
Walker[13] and Cronin-Fenton[11]) grouped and plotted against the one-year relative 
mortality for each cancer type. One-year relative mortality rates were derived from 
Eurocare.it.[23] Although VT incidence per type of cancer varies for the different 
studies, a clear positive association can be observed with one-year relative mortality 
of the cancer type, as a measure of biological aggressiveness of the cancer, and an 
associated thrombogenic potential. 
Such an association between aggressiveness of cancer and thrombogenic potential can 
also be observed when taking stage of cancer into account, which is highly correlated 
with risk of venous thrombosis (Table 1).[10,11,14,17] In the Danish follow-up study, 
mentioned above, where 55 000 cancer patients and over 285 000 matched non-
cancer controls from the general population were followed in time, the risk of venous 
thrombosis in cancer patients appeared to be strongly dependent on stage of the 
cancer, with adjusted relative risks of 2.9, 2.9, 7.5 and 17.1 among patients with stage I, 
II, III, and IV disease.[11] Also in the California Cancer Registry study, increased relative 
risks of venous thromboembolic events in metastatic cancer patients compared with 
patients with localized disease were reported for 12 different types of cancer (range of 
hazard ratios 1.1-21.5).[14] In this study metastatic disease at time of cancer diagnosis 
was found to be the strongest predictor of subsequent venous thrombosis. Figure 4 
shows two-year cumulative incidence rates of venous thrombosis per type and stage 
of cancer, according to data from this California Cancer Registry.[14] For every type of 
cancer presented, VT incidence increases from localized, to regional to remote cancer. 
Lastly, in the Vienna Cancer and Thrombosis study (CATS), which included 740 patients 
with newly diagnosed (or progressed after remission) patients with solid tumors, 
tumor grade (G3+G4 vs G1+G2) was also significantly associated with risk of venous 
thrombosis (HR 2.0; 95%CI; 1.1-3.5).[24] This was after correction for age, sex, tumor 
histology, types and stage. 
The incidence of venous thrombosis is clearly highest in the first few months after 
cancer diagnosis and decreases thereafter (Table 1). In the MEGA-study, the risk of 
venous thrombosis was highest in the first three months after cancer diagnosis (OR 54 
(95%CI; 8.6-334.3)), was decreased but still high in the period between three and twelve 
months (OR 14.3 (95%CI; 5.8-35.2)) and decreased to almost no elevated risk ten years 
after cancer diagnosis.[10] In a retrospective analysis of over 68 000 colorectal cancer 
patients from the California Cancer Registry, incidence rates of symptomatic venous 
thrombosis were calculated.[25] The incidence was reported to decrease over time 
from 5.0/100 person years in the first 6 months after cancer diagnosis, 1.4/100 person 
years 6-12 months after cancer diagnosis to 0.6/100 person years 12-24 months after 
cancer diagnosis. This phenomenon has been shown for all types of cancer in the large 
Figure 3. Incidence rates of venous thrombosis (VT) (per 1000 person years) per type of cancer 
(according to Horsted[17], Walker[13] and Cronin-Fenton[11]) plotted against the one-year 
relative mortality for each cancer type . One-year relative mortality was calculated by (1 – One-
year relative survival) according to Eurocare.it.[23] For haematologic cancer VT incidence is 
exclusively shown for results of Horsted et al., since Walker et al. and Cronin-Fenton et al. did not 
present VT incidence rates for haematologic cancer as a combined group. 
Figure 4. Two-year cumulative incidence (%) of venous thrombosis per type and stage of 
cancer. Types of cancer were ordered by their respective one-year mortality rates, according to 
Eurocare.it.[23] Data from Chew Arch Intern Med 2006.[14]
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follow-up study by linkage of four United Kingdom databases.[13] This change in risk 
over time again illustrates why follow-up studies into incidence of venous thrombosis 
in cancer patients need to start at time of cancer diagnosis. If follow-up is started at a 
later point in time, the incidence will be lower and studies can not be compared directly. 
There are several possible explanations for a higher risk of venous thrombosis in the first 
few months after diagnosis compared with the period thereafter. First, several cancer 
treatment modalities increase the risk of venous thrombosis (see below), inducing a 
high risk directly after diagnosis and start of treatment. Second, a proportion of treated 
cancer patients will go into remission, leading to a reduced thrombotic risk thereafter. 
A third explanation is that over time a considerable proportion of the cancer patients 
will succumb to the disease. The occurrence of such a competing event (death) will 
prevent thrombotic events from being observed. 
In addition to type and staging of cancer, cancer treatment modalities also 
substantially increase the thrombotic potential (Table 1). Surgery, chemotherapy, 
hormonal therapy, anti-angiogenic drugs, immunomodulatory agents, erythropoiesis 
stimulating agents, blood transfusions and central venous catheters are all reported 
to be associated with an increased risk.[26,27] Surgery is a well-known risk factor 
for venous thrombosis, also in non-cancer patients. In cancer patients, risk of 90-day 
post-operative venous thrombosis is reported to be twice as high as in non-cancer 
patients.[28] Incidence rates in patients treated with chemotherapy are high, with 
an annual incidence of 11%-20%.[29] Also, other new systemic cancer treatments 
and supportive therapies are reported to predispose to venous thrombosis.[29] An 
important caveat, however, in interpreting these risks is that most studies on this topic 
are observational studies. In observational studies the decision on (type of) treatment 
is made by the treating physician, depending on several patient’s characteristics, such 
as stage of disease and prognosis. Therefore treated and untreated patients are not 
directly comparable and it cannot be discerned whether increased risk of venous 
thromboembolism is due to the treatment, the cancer or the patients’ prognosis. This 
phenomenon is called confounding by indication and plays a role in all observational 
studies. In randomized clinical trials exposure (treatment) is assigned in a random 
fashion, for which reason patients are directly comparable with respect to their 
thrombotic risk. A direct comparison of different treatment modalities is even more 
difficult when thrombosis prophylaxis is indicated for specific types of treatment. For 
example, the risk in patients who underwent surgery can not be directly compared 
with the risk in patients treated with chemotherapy as thromboprophylaxis is common 
practice after surgery, but not during chemotherapy. A disadvantage of clinical trials is 
the highly selected patient population, limiting the generalizability of the results. 
Out of the large literature on this topic, we will present some examples of randomized 
clinical trials as an illustration of increased risk induced by several types of treatment. 
Several randomized clinical trials in women with breast cancer have shown a clear 
link between chemotherapy and/or hormone therapy and venous thrombosis risk.
[30-33] In a randomized trial in postmenopausal women with node-positive primary 
operable breast cancer (with positive estrogen and progesterone receptor status), the 
cumulative incidence of thromboembolic events was assessed for women randomized 
to 2 years of tamoxifen or to tamoxifen (2 years) plus chemotherapy for 6 months.
[33] The cumulative incidence in the tamoxifen only group was 2.6% versus 13.6% 
in the combined treatment group. Similarly, results from a clinical trial in advanced 
gastro-esophageal cancer patients showed varying rates of venous thrombosis for 
either one of four epirubicin/platinum/fluoropyrimidine combination regimens during 
treatment until 30 days after the last treatment cycle. A higher cumulative incidence 
of venous thrombosis was observed in patients receiving a cisplatin-containing 
combination regimen (12.2%) as compared with oxaliplatin (6.5%).[34] A systematic 
review of randomized controlled trials demonstrated that cancer patients treated with 
erythropoiesis-stimulating agents (ESAs) in addition to red blood cell transfusions had 
an increased risk of thromboembolic events over patients not additionally treated 
with ESAs (relative risk 1.7).35 These results are supported by a systematic review from 
Bennett et al.[36] In another large meta-analysis of clinical trials, patients with cancer 
receiving the angiogenesis inhibitor bevacizumab, had a somewhat increased risk of 
venous thrombosis (relative risk 1.3 95%CI; 1.1-1.6).[37] 
Apart from cancer-related factors, patient-related factors play a role in the 
development of thrombosis in cancer patients (Table 1). Several traditional risk 
factors for thrombosis are additionally present in many cancer patients like older age, 
prolonged immobility, prior history of venous thrombosis and comorbidities. In the 
California Cancer Registry study in colorectal cancer patients, a significant predictor 
of venous thrombosis during the first year after diagnosis was the presence of three 
or more comorbid conditions (HR 2.0 (95%CI; 1.7-2.3)).[25] In a retrospective cohort 
study using discharge databases of all cancer patients admitted to US academic 
medical centers, over 1 000 000 cancer patients were followed for venous thrombosis.
[18] Variables associated with VT in a clinically significant way were ethnicity and the 
presence of comorbidities. Such comorbidities included arterial thromboembolism, 
pulmonary disease, renal disease, infection and anemia which all increased the risk 
of venous thrombosis (ORs 1.5, 1.4, 1.5, 1.8 and 1.4 respectively). Patients with black 
ethnicity seemed to be at increased risk (OR 1.2 (95%CI; 1.1-1.2)), while patients 
with Asian ethnicity had a decreased risk of venous thrombosis when compared 
with Caucasians (OR 0.7 (95%CI; 0.7-0.8)). Similarly, in colorectal cancer patients 
from the abovementioned California Cancer Registry, the risk of venous thrombosis 
was significantly reduced among Asians/Pacific Islanders (HR 0.4 (95%CI; 0.3-0.4)) 
compared with Caucasian patients.[25] This is probably explained by an overall lower 
risk of venous thrombosis in Asians/ Pacific Islanders.[9] Prothrombotic mutations are 
additionally reported to influence risk of thrombosis in cancer patients.[10,38] For 
example, the Factor V Leiden mutation seems to interact with cancer with respect to 
VT risk. Cancer patients with Factor V Leiden were reported to have a 2-fold increased 








A limited number of studies have looked at differences in the clinical presentation of 
venous thrombosis between patients with and without cancer. Bilateral DVT seems 
to be more common among cancer patients than in non-cancer patients.[39,41] A 
recent study by Imberti showed that rates of symptomatic bilateral lower limb DVT, 
symptomatic iliocaval thrombosis and upper limb DVT were higher in cancer patients 
compared with patients free from cancer (8.5% vs 4.6%), (22.6% vs 14.0%) and (9.9% 
vs 4.8%); respectively.[6] In this study rates of PE and symptomatic proximal DVT were 
similar. The relatively high incidence of upper limb DVT in cancer patients is at least 
partly explained by the frequent use of a central venous catheter.[42] Furthermore, 
cancer is reported to be common in rare forms of thrombosis such as Budd-Chiari 
syndrome, extrahepatic portal vein obstruction and mesenteric vein thrombosis.[43] 
Prognosis
In general, cancer patients with venous thrombosis do not fare well. Thrombotic events 
are reported to be the second leading cause of death in cancer patients.[44] Patients 
with cancer-associated venous thrombosis have higher risks of bleeding complications 
during anticoagulant treatment and of recurrent venous thrombosis than patients with 
venous thrombosis but without cancer.[4,45,46] In a Norwegian study of 740 patients 
with a first venous thrombotic event, the one-year case fatality rates (the proportion 
of deaths within one year after the venous thrombotic event) were 5-fold higher in 
patients with cancer-associated venous thrombosis (63.4% (95%CI; 54.5-71.8)) than in 
venous thrombosis patients without cancer (12.6% (95%CI; 10.1-15.5)).[7] In the RIETE 
registry, a large prospective cohort of over 35 000 VT patients, three month mortality 
was much higher in the patients with cancer-related VT as compared with VT patients 
without cancer (26% vs 4% respectively).[4] 
Furthermore, cancer patients who develop a venous thrombotic event have a lower 
survival rate than cancer patients without venous thrombosis.[14,47-50] In a large, 
Danish, population-based study, patients diagnosed with cancer at the time of venous 
thrombosis were matched to control cancer patients without venous thrombosis, 
based on age, sex, type of cancer and year of diagnosis.[50] The one-year survival rate 
for the group with cancer and venous thrombosis was 12%, as compared with 36% 
in the control group. Chew and colleagues investigated the survival of over 235 000 
cancer patients and compared these survival rates between cancer patients with and 
without a subsequent diagnosis of venous thrombosis.[14] In a multivariate analysis 
with adjustment for age, race and stage of cancer, a diagnosis of venous thrombosis 
was a significant predictor of decreased survival within one year for all cancer types 
(hazard ratios ranging from 1.6 to 4.2). We studied mortality rates in participants of 
the Tromsø study, a large Norwegian follow-up study in participants free of cancer and 
venous thrombosis at baseline in 1994-1995.[3] In total, 25,983 subjects were followed 
until September 1, 2007, of whom 1751 subjects developed cancer and 417 developed 
venous thrombosis (109 of which cancer-related). By means of a time-dependent 
Table 2. Crude mortality rates and age- and sex-adjusted hazard ratios of death in participants 
without cancer and without venous thrombosis, with venous thrombosis only, with cancer 
only and with cancer-related venous thrombosis, The Tromsø study 1994-2007
Exposure Person years Deaths (n) MR per 100 pyrs (95%CI) HR (95%CI)
None 277713 1750 0.63 (0.60-0.66) 1.0 (reference)
VT only 1317 67 5.1 (4.0-6.4) 2.6 (2.0-3.3)
Cancer only 5650 721 12.7 (11.9-13.7) 7.4 (6.8-8.2)
Cancer-related VT 131 72 55.0 (43.6-69.3) 31.2 (24.6-39.6)
MR denotes mortality rate; pyrs, person-years; CI, confidence interval; HR: hazard ratio; VT, 
venous thrombosis. 
Hazard ratios were calculated by means of a time-dependent Cox regression analysis. 
analysis mortality rates and hazard ratios for death were estimated for disease free 
subjects, subjects with cancer only, subjects with venous thrombosis only and subjects 
with cancer-related venous thrombosis (Table 2). Subjects with cancer-related venous 
thrombosis had a 30-fold increased risk of death during follow-up as compared with 
disease-free subjects (HR 31.2 (95%CI; 24.6-39.6)), while subjects with cancer only 
or venous thrombosis only had a 7-fold and 3-fold increased risk respectively. An 
explanation for the difference in mortality rates could be the more aggressive course 
of the malignancies associated with high thrombosis risk (Figure 3). It is unknown to 
what extent the high mortality rates in patients with cancer and venous thrombosis 
can be attributed to the thrombotic events themselves. In a study in 4466 cancer 
patients in the US starting with chemotherapy and followed for a median of 75 days, 
thrombosis (including both venous and arterial events) was the second leading cause 
of death (n=13; 9%) after cancer progression (n=100; 71%).[44] In this study causes of 
death were assigned by the treating physicians, mainly based on clinical data, rather 
than autopsies. Among patients from a large database comprised of Multiple-Cause 
Mortality Files from 1979 to 1998 in whom pulmonary embolism was reported on the 
death certificates, 23% were reported to have cancer.[51] Causes of death according 
to the treating physician or death certificate may not be that reliable and autopsy 
studies should be used to answer this question. In two autopsy studies from Sweden 
and the US, the incidence of pulmonary embolism in cancer patients was 26% and 17%, 
respectively, of which 8% and 14% were fatal pulmonary emboli.[52]
Thromboprophylaxis
It is hypothesized that anticoagulant treatment for the prevention of venous 
thrombotic events in cancer patients might improve prognosis and quality of life. 
However, such treatment comes with a disadvantage of an increased risk of bleeding, 
which is especially pronounced in cancer patients.[46,53,54] In a prospective follow-up 
of 842 DVT patients, Prandoni et al. investigated bleeding rates during anticoagulant 
treatment. The 12-month cumulative incidence of major bleeding was about two-
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fold higher in patients with active cancer (12.4% (95%CI; 6.5-18.2%)) than in patients 
without cancer (4.9% (95%CI; 2.5-7.4%)).[46] Several randomized clinical trials 
have investigated the effects of thromboprophylaxis in ambulatory cancer patients 
receiving chemotherapy. A recent Cochrane review summarized results of 9 of those 
trials.[55] Thromboprophylaxis was reported to significantly reduce the incidence 
of symptomatic VT (RR 0.62 (95%CI; 0.41-0.93). However, this treatment was also 
associated with an increase in bleeding events. The number needed to treat to 
prevent one venous thrombotic event, was 60. Thromboprophylaxis should therefore 
be targeted only at cancer patients with a high risk of venous thrombosis, which 
outweighs the risk of bleeding events. Several biomarkers have been associated with 
risk of venous thrombosis in cancer patients, like P-selectin, D-dimer, tissue factor-
bearing microparticles, pre-chemotherapy hemoglobin, platelet and leukocyte counts, 
factor VIII and C-reactive protein.[16,56-63] A recent clinical trial randomized advanced 
cancer patients with higher levels (> 3.5 x 104 microparticles/µL) of circulating tissue 
factor-bearing microparticles (TFMP) to either enoxaparin for two months (n=23) or 
observation without any treatment (n=11).[64] Advanced cancer patients with lower 
levels of TFMP were followed without treatment (n=32). Patients with higher TFMP 
levels, not randomized to enoxaparin, had a significantly higher two-month cumulative 
incidence of venous thrombosis (27%) as compared with patients with lower TFMP 
levels (7%). Patients with high TFMP levels randomized to enoxaparin had the lowest 
cumulative incidence of venous thrombosis (6%). Median survival was 17.8 months in 
patients treated with enoxaparin as compared with 11.8 months in untreated patients 
with higher levels of TFMP. 
Although this clinical trial using risk stratification based on one biomarker shows 
promising results, prediction models incorporating several risk factors, instead of one, 
are probably more useful for guiding decisions on prophylaxis in individual patients. 
Such a risk assessment model has been developed by Khorana et al.[59] In a randomly 
selected development cohort of 2701 cancer patients initiating a new chemotherapy 
regimen, baseline clinical and laboratory risk factors for venous thrombosis were 
included in a risk model, which was validated in an independent cohort of 1365 cancer 
patients from the same population. Patients were followed for symptomatic venous 
thromboembolic events for a median of 73 days. Five predictive variables present 
before initiation of chemotherapy were identified in the final multivariate analysis 
and used for a risk score model: primary site of cancer, platelet count ≥350 000/μL, 
hemoglobin less than 10 g/dL and/or use of red cell growth factors, leukocyte count 
more than 11 000/ μL and body mass index ≥35 kg/m2 (Table 3). Rates of venous 
thrombosis in the development and validation cohort were 0.8% and 0.3% in low-risk 
(score=0), 1.8% and 2% in intermediate-risk (score=1-2) and 7.1% and 6.7% in high-
risk patients (score≥3), respectively. Ay and colleagues applied this risk model to their 
prospective observational cohort study of patients with newly diagnosed cancer or 
with progression of disease after complete or partial remission who had not recently 
received chemotherapy, surgery and/or radiotherapy (CATS study).[65] Additionally, 
they expanded the model by adding two predictive biomarkers, i.e. soluble P-selectin 
(≥53.1 ng/mL) and D-dimer levels (≥1.44μg/mL) and they added additional types of 
cancer to the high and very high risk groups. In the expanded risk model the cumulative 
probabilities of VT after six months of follow-up were 35% in patients with a score ≥5, 
10.3% in patients with score 3 and 1.0% in patients with score 0. The disadvantage of 
this expanded risk model is that additional laboratory tests have to be performed since 
D-dimer and P-selectin levels are not routinely measured in the clinic. Intervention 
trials based on risk assessment models are necessary to demonstrate the effectiveness 
and safety of prophylactic anticoagulant treatment in high-risk patients. In an ongoing 
study, the use of thromboprophylaxis in patients deemed high-risk, based on the 
original prediction model by Khorana, is currently being tested (www.clinicaltrials.gov 
No. NCT00876915).
Recurrent venous thrombosis and cancer 
The overall risk of recurrent venous thrombosis in patients who suffered once from 
VT is high, with a five to ten year cumulative incidence ranging from 25% to 30%.
[66-68] Cancer patients are at an approximately two to three-fold increased risk of 
recurrent venous thrombosis compared with non-cancer patients.[46,67-69] Prandoni 
and coworkers followed 355 consecutive patients with a first episode of DVT for eight 
years and found a two-fold risk of recurrent venous thrombosis in cancer patients 
compared with non-cancer patients (hazard ratio 1.7 95%CI; 1.3-2.3).[68] The same 
group of investigators found a 12-month cumulative incidence of recurrent venous 
thrombosis of 20.7% in cancer patients on conventional anticoagulant treatment versus 
6.8% in patients without cancer on anticoagulant treatment in a prospective cohort 
study including 842 DVT patients.[46] Recurrence appeared to be related to extent of 
disease, classified according to the tumor-node-metastasis (TNM) classification, with 
highest recurrence rates in patients with extensive vs moderately or less extensive 
cancer. This again reflects the apparent relation between agressiveness of cancer and 
thrombogenic potential. In the RIETE study patients with symptomatic, acute venous 
thrombosis were enrolled and three-month outcomes of the participants were studied. 
Table 3. Predictive model for chemotherapy-associated venous thrombosis
Patient characteristic Risk score
Site of cancer
   very high risk (stomach, pancreas) 2
   high risk (lung, lymphoma, gynecologic, bladder, testicular) 1
Prechemotherapy platelet count 350 x 10^9/L or more 1
Hemoglobin level less than 100 g/L or use of red cell growth factors 1
Prechemotherapy leukocyte count more than 11 x 10^9/L 1
BMI 35 kg/m^2 or more 1
From Khorana Blood 2008.[59]
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Of 18 883 participants, 3805 had been diagnosed with active cancer. A relative risk for 
recurrent PE of 2.0 and for recurrent DVT of 2.4 was found for patients with a cancer 
diagnosis less than three months before their first venous thrombosis.[69] Not much is 
known about the risk of recurrent venous thrombosis for different types of cancer and 
results from previous studies are contradictory.[46,69] A clinical prediction rule (Ottawa 
prognostic score) has been developed for recurrent venous thrombosis during the first 
six months of anticoagulant treatment in a retrospective cohort study of 543 patients 
with a cancer-associated venous thrombotic event.[70] The final model included four 
predictors (sex, primary tumor site, stage and number of prior venous thrombotic 
events) leading to a score sum that ranged between -3 and +3 points. Patients with a 
score ≤0 had a low risk of recurrence (4%) while patients with a score ≥1 had a relatively 
high recurrence risk (16%). The prediction rule was validated by the investigators in an 
independent set of patients from two randomized clinical trials and results appeared 
to be consistent. Another group of investigators from the Netherlands assessed the 
reproducibility of the Ottawa score in an independent sample of 419 patients with 
cancer-associated venous thrombosis.[71] Their results were similar to those reported 
by Louzada and coworkers in their validation sample. Recently the Ottawa score was 
additionally validated in an independent patient population in a tertiary hospital in 
Korea.[72] In 546 patients with cancer associated-VT the model was less discriminatory 
compared with the derivation study. Of patients in the low-risk group (score<=0) 13.2% 
were identified with recurrent venous thrombosis, while 22.4% of patients in the high-
risk group (score >=1) were identified with a recurrence. Thrombosis risk as well as 
cancer predominance is known to be different in the Asian population, which may be 
an explanation for the different findings. Furthermore differences in study design, like 
different durations of follow-up or definition of recurrences may explain these findings.
Screening
Acute venous thrombosis can be the first manifestation of an occult cancer. Rates of 
occult cancer detection at the time or shortly after diagnosis of venous thrombosis 
vary in the literature, depending on patient population, duration of follow-up and 
detection methods. While some articles published in the eighties contradict each other 
as to whether there is an association between venous thrombosis and an increased 
risk of subsequent cancer diagnosis[73-75], recent articles show a clear association 
between the two. In a nationwide, retrospective cohort study in Scotland almost 
60 000 patients with DVT or PE diagnosed between 1982 and 2000 were followed for 
the occurrence of cancer until the end of 2000.[76] The ratio of the observed cases of 
cancer and the number of cases expected based on national cancer incidence rates 
was calculated, which gives a standardized incidence ratio (SIR). For all malignancies 
combined there was an excess risk of being diagnosed with cancer in VT patients which 
remained up to 2 years after diagnosis of VTE. Especially in the first one to six months 
after diagnosis of venous thrombosis the risk was high (SIR 4.2 (CI 3.9-4.5)). Two other 
follow-up studies, quite alike in design, showed similar results with respect to risks and 
types of cancer (liver, pancreas, ovary, brain and lymphoma) for which the association 
was most pronounced.[77,78] In a recent systematic review by Carrier and colleagues, 
data from 34 studies that reported prevalence of undiagnosed cancer at the time of an 
acute, first thromboembolic event were combined.[79] In 4.1% (95%CI; 3.6-4.6%) of 
the included patients, a previously undiagnosed cancer was detected within a month 
after the venous thrombotic event. Within a year after the event 6.3% (95%CI; 5.6-
6.9%) of the patients were diagnosed with cancer. 
Patients with an idiopathic venous thrombosis have a higher risk of detection of an 
occult cancer than patients with a venous thrombotic event secondary to a provoking 
risk factor.[79,80] In the abovementioned study by Carrier the period prevalence 
of previously undiagnosed cancer between baseline (venous thrombotic event) 
and 12 months was 10.0% (95%CI; 8.6-11.3%) for patients with unprovoked venous 
thrombosis versus 2.6% (95%CI; 1.6-3.6%) for patients with a secondary event. This 
raises the question whether only patients with an idiopathic venous thrombosis should 
be screened for occult cancer. Van Doormaal and colleagues prospectively followed 
630 idiopathic venous thrombosis patients who underwent either baseline cancer 
screening (consisting of history, physical examination, basic laboratory tests and chest 
X-ray) or extensive cancer screening (consisting of additional abdominal and chest CT 
scan and mammography), based on the center in which patients were treated.[81] After 
baseline screening 7 out of 288 patients (2.4%) were diagnosed with cancer versus 12 
out of 342 patients (3.5%) after extensive screening methods. Survival did not differ 
between the groups, which led the authors to conclude to not support extensive routine 
screening for cancer in patients with a first episode of idiopathic venous thrombosis. 
In one randomized clinical trial by Piccioli and colleagues,[82] acute idiopathic venous 
thrombosis patients were randomized to either an extensive screening for occult 
cancer or to no further testing. Unfortunately the trial was terminated prematurely due 
to a lower than anticipated number of participating centers and an increasing tendency 
among physicians to perform screenings tests for occult cancer in control patients. 
Extensive screening was found to be able to detect hidden malignancies and to lead to 
identification of malignancies at an earlier stage. However, due to the limited sample 
size, effects on prognosis of patients remained again unclear. Cancer related mortality 
during the 2-year follow-up period did not significantly differ between both groups 
(absolute difference 1.9% (95%CI; -5.5-10.9%)). The effect of extensive screening in 
idiopathic venous thrombosis patients on prognosis remains elusive.[83,84] Further 
studies are needed to investigate whether screening procedures are cost-effective and 
affect cancer-related mortality. 
  
Superficial venous thrombosis and cancer
Superficial vein thrombosis (SVT), or superficial thrombophlebitis, is a common 
condition of which the incidence in general has so far not been properly assessed, 
possibly because in the past SVT was considered a benign, self-limiting, disease. 
However, it is thought to occur at least as often as deep vein thrombosis. Interest in 
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the disease was renewed when more and more studies in the past decade described 
an association between SVT and deep venous thrombosis.[12,85,86] Many conditions 
have been reported to predispose to SVT, mostly also well-known risk factors for deep 
venous thrombosis. For this reason it would be reasonable to suspect an association 
between cancer and SVT.[87-90] The incidence of SVT in cancer patients has not been 
studied. Whether SVT should be seen as a marker of occult cancer is also controversial. 
In a sub-study of the Calisto trial, a trial in which ~3000 SVT patients with isolated SVT 
were randomized to either fondaparinux or placebo, Prandoni and coworkers compared 
737 SVT patients with 1438 control patients with regard to cancer diagnoses during an 
average of 26 months of follow-up.[91] They concluded that occurrence of SVT in the 
legs does not represent a risk factor for subsequent malignancies. The same conclusion 
was drawn in a small study performed in the Netherlands.[92] However, Sorensen et al. 
did find a relation between a diagnosis of SVT and a subsequent cancer diagnosis in the 
Danish population.[93] The occurrence of cancer in 7663 SVT patients was compared 
with the expected number of cancer diagnoses based on national incidence rates and 
a SIR of 2.5 (95%CI; 2.1-2.9) for the first year of follow-up was reported. A possible 
explanation for the difference in findings is that in the study by Sørensen unrecognized 
concomitant deep vein thrombosis was possibly present, which increased the risk of a 
cancer diagnosis. Prandoni and colleagues excluded cases with a concomitant venous 
thrombotic event confirmed by ultrasonography. Future epidemiologic studies are 
needed to study the strength of the relationship between SVT and cancer and the 
incidence of SVT in cancer patients.
Concluding remarks 
Despite the fact that the strong association between cancer and venous thrombosis 
has been known for more than 150 years, cancer-associated thrombosis is still a topic 
of extensive (epidemiologic) research from which there is much to gain for patients. 
Future studies need to be targeted at development and validation of prediction models 
to categorize cancer patients into high or low risk of venous thrombosis. Randomized 
trials should study the benefit of thromboprophylaxis in patients deemed at high risk 
based on these models. Furthermore, studies are needed to investigate whether cancer 
screening procedures in idiopathic venous thrombosis patients are cost-effective and 
affect cancer-related mortality.
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Cancer before and after venous thrombosis and 
the risk of recurrent venous thrombosis: Results 
from the MEGA follow-up study











The magnitude of the risk of recurrent venous thrombosis (VT) in patients with cancer 
is not well described and results for different types of cancer are not consistent. We 
aimed to evaluate the risk of recurrent VT in relation to time of diagnosis and for several 
types of cancer.
Patients and methods
Patients with a first deep vein thrombosis of the leg or pulmonary embolism were 
followed for recurrence from time of VT-diagnosis (MEGA follow-up study). Incidence 
rates (IR) of recurrence per 1000 person-years (py) were estimated for patients 
with cancer as well as (time-dependent) hazard ratios (HR) adjusted for sex and age 
comparing recurrence in patients with cancer with those without. Cancer diagnoses 
were self-reported and complemented with data from the Dutch Hospital Data Register.
Results
4643 Patients were included with a median follow-up of 5.9 years (IQR 1.7-7.8). 
Participants with a history of cancer within five years before first VT (n=423) did not 
have an increased risk of recurrence (HR 1.1; 95%CI,0.8-1.6), except for patients with 
a malignancy that was still active during follow-up. Their recurrence-risk was about 
two-fold increased (HR 2.3; 95%CI,1.5-3.6). Participants who developed cancer after 
the first thrombosis (n=161) also had an increased recurrence-risk (HR 2.2; 95%CI,1.5-
3.4), which was especially high in the first three months after cancer diagnosis (HR 
5.2; 95%CI,2.3-11.6; cumulative incidence 4%). Risk of recurrence was high for patients 
who developed non-Hodgkin lymphoma, cancer of the gastro-intestinal tract, prostate 
or testis.
Conclusion
VT patients with a history of cancer do not have an increased risk of recurrent VT 
compared with patients without cancer, except when their cancer is still active after the 
first VT. Patients who develop cancer after a first VT also have an increased recurrence-
risk, which varies for different types of cancer and for different time periods after 
cancer diagnosis.
Introduction
A strong relation between cancer and venous thrombosis has been known for a 
long time, since its first notion in the early 19th century.[1,2] Venous thrombosis, 
encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a 
multicausal disease which affects about 1-2 per 1000 persons per year.[3] A long list of 
risk factors, both genetic and acquired has arisen over the past decades, of which the 
presence of active cancer is reported to be one of the strongest.[4] About 20-30% of all 
first venous thrombotic events are related to cancer and cancer increases the risk of a 
first thrombosis about 4- to 7-fold.[5-11] 
After a first venous thrombotic event recurrence is common. The five-year cumulative 
incidence is reported to range from 12 to 25%.[12-14]Few studies have investigated 
the risk of recurrent venous thrombosis in patients with cancer.[9,13-19] Furthermore, 
most of these previous studies were small and heterogeneous with regard to duration 
of follow-up (either during anticoagulant treatment or after discontinuation), selection 
of patients (either DVT and PE or DVT only) and definition of recurrent venous 
thrombosis.[9,13-19] 
The risk of a first event depends strongly on type and stage of cancer and the time point 
after cancer diagnosis.[5,20-22] Furthermore, certain cancer treatment modalities, 
such as chemotherapy, substantially increase the thrombotic potential.[9,23,24] It is 
likely that the risk of recurrent venous thrombosis also varies between patients with 
different types and stages of cancer, different treatment strategies and for different 
time periods after diagnosis. However, results of previous studies are contradictory 
with regard to recurrence risk for different types of cancer.[19,25-27] Prandoni and 
colleagues reported increased risks of recurrence of similar magnitude for patients with 
cancer at various sites as compared with patients without cancer.[19] The exception 
was with patients with breast cancer, for whom a much lower recurrence risk was found 
than for other cancer patients. Findings from the RIETE register showed that only age 
and time since cancer diagnosis were associated with recurrent DVT and only age, time 
since cancer diagnosis and type of first event with recurrent PE.[27] Although patients 
with either recurrent PE or DVT more often had lung or pancreatic cancer than patients 
who did not develop recurrent thrombosis, on multivariate analyses no association 
was found between type of cancer and risk of recurrence. Two other studies, however, 
showed considerable variation in recurrence risk for patients with different types of 
cancer, with high recurrence rates seen in patients with lung, brain and ovarian cancer.
[25,26] 
Although cancer is a heterogeneous disease all patients with cancer and a venous 
thrombotic event are currently treated the same way and for the same duration of 
time.[28,29] Knowledge on characteristics that influence risk of recurrent venous 
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thrombosis in these patients is needed, so that targeted and prolonged therapy may 
be offered only to patients with a high recurrence risk and that such prolonged therapy 
is withheld in patients with a low recurrence risk to prevent them being exposed to an 
unnecessary risk of bleeding. 
We aimed to evaluate the risk of recurrent venous thrombosis in relation to the 
presence of cancer in a large prospective cohort of venous thrombosis patients (MEGA 
follow-up study) with a strict definition of objectively identified recurrent events, both 
during and for a prolonged period after discontinuation of anticoagulant treatment. 
Our secondary aim was to study recurrence risk according to different types of cancer 
and according to different time periods after cancer diagnosis.
Methods
Patients
This study includes patients who took part in the Multiple Environmental and Genetic 
Assessment of risk factors for venous thrombosis (MEGA) study. Details of the MEGA 
study have been described previously.[5] In brief, between March 1999 and August 
2004, 4956 consecutive patients with an objectively diagnosed first DVT of the leg 
or PE were included. Patients were aged 18-70 years and were enrolled from six 
anticoagulation clinics in the Netherlands. Anticoagulation clinics monitor all patients 
taking vitamin K antagonists in a well-defined geographical area. All patients filled in a 
detailed questionnaire (“Questionnaire CC”) on the presence of possible risk factors for 
venous thrombosis before their first venous thrombotic event. 
Of 4956 patients included in the MEGA study, 4731 gave written informed consent for 
future follow-up on recurrent venous thrombosis (MEGA follow-up study). Between 
June 2008 and July 2009 these participants were asked whether they had developed 
a recurrent venous thrombotic event by means of a short answer form with one 
yes/no question. Furthermore, all participants were asked to complete a second 
questionnaire on the presence of risk factors for venous thrombosis after their first 
event (“ Questionnaire FU”). Duration of follow-up was estimated as the time at risk 
from the date of the first thrombotic event to the end of follow-up. The end of follow-
up was defined as the date of a recurrent event and in the absence of a recurrence, 
the date of filling in the short answer form. If a patient did not fill in this form, they 
were censored at the last date we knew them to be recurrence free. This could be date 
of death (n=99), date of emigration (n=3), date of the last visit to the anticoagulation 
clinic (n=489) or the last moment known to be recurrence free from information of 
the MEGA case-control study (n=411). Details of assessment of end of follow-up have 
been described previously.[30] Data on anticoagulant treatment during follow-up, 
both starting dates and dates of discontinuation of treatment, were retrieved for all 
participants from the anticoagulation clinics where patients were treated for their 
first event. All participants gave informed consent and gave written permission to 
obtain information about their medical history. The study was approved by the ethics 
committee of the Leiden University Medical Center, the Netherlands.
Adjudication of cancer diagnoses
In Questionnaires CC and FU, participants were asked to self-report on the presence 
of cancer, either before or after the first venous thrombotic event, and if present, on 
date of diagnosis, type of cancer and presence or absence of metastases. Data from 
Questionnaire CC, i.e., cancer diagnosed before the first venous thrombosis, have 
been verified earlier by Blom et al.[5] For Questionnaire FU the response rate was 60% 
(2827/4731). Our data were linked to the Dutch hospital data register, which allowed 
us to verify the cancer diagnoses. The Dutch hospital data register covers complete, 
nationwide data on hospital admissions since 1986. The data from the follow-up were 
linked to discharge diagnosis data from 1995 up to 2010 from this register by the Dutch 
Central Bureau of Statistics (CBS). Discharge diagnosis data are collected in practically 
all general and university hospitals and most specialized clinics, such as cancer clinics. 
Diagnosis at discharge is determined by the treating physician and subsequently coded 
by trained hospital staff according to International Classification of diseases, ninth 
version clinical modification (ICD-9-CM). 92% (4350/4731) of our participants could 
be individually linked to records of the hospital data register. Furthermore, between 
2007 and 2009 the vital status of all follow-up participants was acquired from the 
Dutch population register, as has been described previously.[31] For the patients who 
died during follow-up, the cause of death was obtained from the national register of 
death certificates. The causes of death were encoded according to the International 
Classification of Diseases, tenth revision, clinical modification (ICD-10-CM).
Data on cancer diagnoses from questionnaires CC and FU, the Dutch hospital 
data register and cause of death statistics were combined. From these 4 different 
sources, a decision rule regarding certainty of the cancer diagnosis was made using 
the information collected per patient. Participants were classified as having no cancer, 
probably no cancer, a probable cancer diagnosis, a certain cancer diagnosis or as having 
missing data regarding cancer (see Supplement for decision rule).
As date of a certain or probable cancer diagnosis we used the first date reported 
in either Questionnaire CC or FU, the hospital discharge diagnoses or cause of death 
statistics. If a date of cancer diagnosis was not available from any source of information, 
we classified date of diagnosis as the date of the first thrombosis in case of a cancer 
diagnosis before the first thrombotic event (n=9) and as the date halfway between date 
of the first thrombotic event and end of follow-up in case of a cancer diagnosis during 
follow-up (n=1). In case a malignancy was reported in the cause of death statistics 
only (n=22), the date of cancer diagnosis was set at the date halfway between the first 
thrombotic event and date of death. 
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Patients could have a cancer diagnosis before or after the first thrombotic event. 
See Figure 1 for a timeline of events and overview of cancer exposure categories. We 
classified participants with a cancer diagnosis before the first thrombotic event as 
participants with a cancer diagnosis within five years before first venous thrombosis. 
Participants who reported a cancer diagnosis date of more than five years before the 
first thrombotic event and for whom no other data on subsequent cancer progression 
from any of our sources was registered (and who were therefore assumed to be relapse 
free) (n=66), were excluded from all analyses. Furthermore, we decided to exclude 
participants with a missing cancer diagnosis (n=22). This left 4643 participants to be 
included for analyses, out of 4731 participants eligible for follow-up. 
Cancer that was diagnosed after the end of follow-up was not taken into account. 
Types of skin cancer other than melanoma were not registered as a cancer diagnosis. 
Adjudication of recurrent venous thrombotic events
During the same period when participants were asked to self-report on any recurrent 
thrombotic events during follow-up, information about recurrences was additionally 
retrieved from the anticoagulation clinics where patients were initially included for their 
first event and in case they moved house, at the clinic nearest to their new address. 
Death due to venous thrombosis was also included. For recurrent events reported 
by either the patient or the clinic discharge letters from the treating physician were 
requested. A decision rule regarding certainty of the diagnosis was made according 
to the information collected per patient. Possible recurrences were classified into 
certain recurrences and uncertain recurrences, with as a main purpose to distinguish 
extensions of a first event from truly new thromboses. Details of this decision rule have 
been described previously.[30] For this study, we considered certain recurrences as 
outcome event only (n=664). In short, reported recurrences were classified into certain 
recurrences when 1) there was a discharge letter stating a diagnosis of a recurrent 
event based on clinical and radiological data, or when 2) both the anticoagulation clinic 
and the patient reported a recurrent event at either a clearly different location than 
the first event or that occurred more than one year since the first event, or when 3) 
a registered death from a recurrent event at least six months after the first event was 
found. Participants with uncertain recurrent events (n=212) were censored from this 
uncertain recurrent event onward. 
Statistical analyses
All statistical analyses were performed separately for: 1) patients with cancer diagnosed 
before the first thrombotic event and 2) patients with cancer diagnosed after the first 
thrombotic event. This was done since selection into the study was different for both 
patient groups. Patients with a cancer diagnosis before first venous thrombosis only 
represent subjects who survived long enough to develop venous thrombosis, while we 
identified all participants with a cancer diagnosis after the first thrombosis.
Incidence rates of recurrent venous thrombosis were first estimated separately 
for participants without cancer, with probably no cancer, with probable cancer and 
with certain cancer. Next, we further classified the probable groups based on the 
recurrence rates we found in these groups (Supplementary Table 1). For analyses on 
cancer diagnosed before the first thrombotic event, patients with a probable diagnosis 
of cancer were further excluded, considering their low recurrence rate. For analyses on 
cancer diagnosed after the first thrombotic event participants with a probable cancer 
diagnosis were grouped with the certain cancers. Participants with probably no cancer 
were reclassified in the group without cancer. 
After these classifications, incidence rates of recurrent venous thrombosis were 
estimated as the number of events over the accumulated follow-up time with person 
time split and divided over persons with and without cancer. The Cox-proportional 
hazards model was used to evaluate risks of recurrent venous thrombosis between 
groups. Hazard ratios and corresponding 95% confidence intervals were estimated by 
means of a time-dependent Cox regression analysis using anticoagulant treatment and 
cancer diagnosis as time-dependent variables. Hazard ratios were adjusted for age, sex 
and anticoagulant treatment. 
Analyses for cancer before the first thrombotic event 
Incidence rates of recurrence for patients with a diagnosis of cancer before the first 
thrombotic event and for participants without cancer were estimated. Incidences 
were further split for participants with and without cancer during and after the initial 
anticoagulant treatment period. Participants with a cancer diagnosis within five years 
before the first thrombosis probably represent a mix of patients who have gone into 
remission and patients whose cancer continued to be active after the first event. For 
this reason, in a subgroup analysis, we classified patients separately as active during 
follow-up and not active. In the ‘active’ group we entered subjects with metastases at 












Figure 1. Timeline of exposure to cancer and outcome. Some of the patients had two diagnoses 
of cancer, which could be either; 1) both before the first thrombotic event or 2) both after the 
first thrombotic event or 3) one before and one after the first thrombotic event.
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Data on whether cancer was metastasized or not came from either Questionnaire CC 
or FU and the hospital discharge data.
Analyses for cancer after the first thrombotic event 
Incidence rates of recurrence and corresponding hazard ratios for patients with a 
cancer diagnosis after the first thrombotic event and for participants without cancer 
were estimated. This was additionally done for different time periods after cancer 
diagnosis (three months, one year, two years and five years). Furthermore cumulative 
incidences were estimated for the different time frames. These were corrected for 
competing events, since cumulative incidences derived from standard life-table 
methods are biased in studies on cancer-associated venous thrombosis in which 
patients with cancer are both at risk for venous thrombosis and death.[32] For this 
competing risk approach, cumulative incidence functions were generated using Stata’s 
user-contributed stcompet suite. Risks of recurrence were additionally estimated for 
different types of cancer.
All statistical analyses were performed using Statistical Package for the Social Sciences 




4643 Patients with a first episode of venous thrombosis were followed for recurrent 
events. Mean age of participants was 48 years and 46% were men. Most of the first 
events were deep vein thrombosis (67%). Median duration of follow-up was 5.9 years 
(IQR 1.7-7.8). During 23 650 person-years of follow-up 664 certain recurrent venous 
thrombotic events were identified for a total incidence rate of 28.1 per 1000 person-
years (95%CI 26.0-30.3). We identified 575 patients with certain cancer and 81 patients 
with probable cancer. 
Analyses for cancer diagnosed BEFORE the first thrombotic event:
423 Patients with a cancer diagnosis before the first thrombotic event were identified. 
The mean time between cancer diagnosis and thrombosis diagnosis was 2.8 years and 
most of the diagnoses were cancer of the colon (18%), breast (15%), lung (12%), prostate 
(9%) or a gynaecological type of cancer (8%). 25 Patients were identified with both a 
cancer diagnosis before and after the first thrombotic event, at different sites. Table 1 
shows incidence rates and hazard ratios of recurrence for participants with or without 
cancer. Participants with cancer did not have a clearly increased risk of recurrence as 
compared with participants without cancer, with an incidence rate of recurrence of 
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(95%CI; 0.8-1.6) after correction for age and sex. Participants with a diagnosis of cancer 
both before and after the first thrombotic event had a recurrence rate of 59.7 per 1000 
person-years (95%CI; 24.8-143.3). Additional correction for anticoagulant treatment 
(as a time-dependent variable) in the abovementioned analyses did not materially 
affect results (data not shown).
Incidence of recurrent venous thrombosis during and after the initial anticoagulant 
treatment period 
Overall, in the current study population 33 recurrent thrombotic events were identified 
during anticoagulant treatment, for an incidence rate of 8.8 per 1000 person-years 
(95%CI; 6.3-12.4). Recurrence rate after discontinuation of anticoagulant treatment 
was much higher (31.3 per 1000 person-years (95%CI; 28.9-33.9)). During anticoagulant 
treatment participants with a cancer diagnosis before the first thrombotic event had 
an approximately four-fold higher recurrence risk than patients without cancer (HR 4.2 
(95%CI; 1.8-9.7)) (Table 2). However, after discontinuation of anticoagulant treatment 
recurrence risk in this group of patients with cancer was not increased compared with 
patients without cancer (HR 1.0 (95%CI; 0.7-1.5)).
Incidence of recurrent venous thrombosis, according to activity of cancer 
Participants with a cancer diagnosis within five years before the first thrombosis 
probably represent a mix of patients who have gone into remission and patients whose 
cancer was still active during follow-up after the first thrombotic event. The risk of 
recurrence for participants with cancer which we considered active during follow-up 
was two-fold increased as compared with participants without cancer (HR 2.3; 95%CI, 
1.5-3.6 for participants who died of cancer and HR 1.7; 95%CI, 1.0-2.7 for participants 
with metastasized cancer (Table 3)). Participants with cancer without metastases, 
which might have gone into remission before thrombosis, did not seem to have an 
increased risk of recurrent thrombosis compared with participants without cancer (HR 
0.8; 95%CI, 0.5-1.2). After additional correction for anticoagulant treatment (as a time-
dependent variable) results remained similar (data not shown).
Analyses for cancer diagnosed AFTER the first thrombotic event:
161 Patients were identified who developed cancer after the first thrombotic event. The 
mean time between cancer diagnosis and thrombosis date was 2.9 years for these 161 
patients and most of the diagnoses were cancer of the lung (16%), breast (15%), colon 
(14%) or prostate (11%). Table 4 shows incidence rates and hazard ratios of recurrence 
for participants with and without cancer. Participants with cancer had an increased 
risk of recurrence compared with participants without cancer, with an incidence rate 
of recurrence of 64.5 per 1000 person-years (95%CI; 43.9-94.7) and a corresponding 
adjusted hazard ratio of 2.2 (95%CI; 1.5-3.4). Additional correction for anticoagulant 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of recurrent venous thrombosis according to time after cancer diagnosis 
For participants with a cancer diagnosis during follow-up, i.e. after their first thrombosis, 
recurrence rates and corresponding hazard ratios were estimated for different time 
periods after their cancer diagnosis (Table 5). The risk of recurrent venous thrombosis 
was especially high in the first three months after cancer diagnosis, with an incidence 
rate of 164.5 per 1000 person-years (95%CI; 74.0-366.5), and a five-fold increased risk 
of recurrence compared with participants without cancer (HR 5.2 (95%CI; 2.3-11.6)). 
Recurrence risks steadily decreased after the first three months up until the first year 
after diagnosis, and was about 40 per 1000 person-years in the years thereafter. After 
correction for anticoagulant treatment results remained similar (data not shown).
Cumulative incidences of recurrence, corrected for the competing risk of death, were 
4% (95%CI; 2-8) in the first three months after diagnosis, 10% (95%CI; 4-15) in the first 
year, 13% (95%CI; 8-19) in the first two years and 20% (95%CI; 13-28) in the five years 
following cancer diagnosis. 
Incidence of recurrent venous thrombosis for different types of cancer
Table 6 shows incidence rates and corresponding hazard ratios of recurrent venous 
thrombosis for participants with different types of cancer diagnosed during follow-
up. High recurrence risks were seen for patients with lung cancer, certain types of 
gastrointestinal cancer, prostate cancer, urinary tract cancer, non-Hodgkin lymphoma 
and testicular cancer.
Discussion
In this follow-up study with over 4500 participants with a first venous thrombosis we 
studied risk of recurrent thrombosis for participants with and without cancer. In a 
time-dependent analysis we found participants with cancer diagnosed after the first 
thrombotic event, to have a two-fold increased risk of recurrence (HR 2.2; 95%CI, 1.5-
3.4). We found a high rate of recurrence in the first three months after these cancer 
diagnoses (IR 165 per 1000 pyrs; 95%CI, 74-367 and cumulative incidence 4%), which 
corresponds with a five-fold increased risk compared with participants without cancer. 
Recurrence risks were different for different types of cancer, with high rates observed 
in participants with gastrointestinal cancer, lung cancer, prostate and urinary tract 
cancer, non-Hodgkin lymphoma and testicular cancer. For participants with a cancer 
diagnosis before the first venous thrombosis the risk of recurrence was not increased 
compared with patients without cancer (HR 1.1; 95%CI, 0.8-1.6). However, in a selection 
of these participants, i.e. with cancer which was active during follow-up, we did find an 
increased recurrence risk, which was of similar size as in those patients who developed 
cancer after venous thrombosis (doubled). 
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The few studies that have so far investigated the risk of recurrent venous thrombosis 
in patients with cancer described a two- to nine-fold increased risk compared with 
patients without.[9,13-19] However, these studies differed substantially with regard to 
patient characteristics, duration of follow-up, type of analysis and data collection. Two 
studies, which included DVT patients only, with long duration of follow-up (3-9 years), 
reported similar hazard ratios of 1.97 (95%CI; 1.20-3.23) and 1.72 (95%CI; 1.31-2.25) 
for recurrence in patients with known cancer at time of the first thrombosis compared 
with patients without cancer.[13,14] One study, based on data from the Olmsted 
County population, with a similarly long duration of follow-up, that included both 
patients with DVT and PE, reported hazard ratios of 2.2 and 4.2 for patients treated 
with and without chemotherapy, respectively.[9] Another study reported a high relative 
risk of 9.2 (HR 9.2 (95%CI; 2.0-41.7)).[15] This result might be explained by a small 
number of recurrent events or the design of the study in which thrombotic events 
were identified by hospital discharge records only. Four studies reported relative risks 
of recurrence during anticoagulant treatment.[16-19] They all reported that patients 
with active cancer at time of thrombosis had an approximately three-fold increased 
risk of recurrent venous thrombosis as compared with patients without cancer during 
anticoagulant treatment (OR 2.7; HR 2.6; RR 3.0; HR 3.2). Some of the abovementioned 
relative risks were adjusted for potential confounders, while others were not. 
In this large follow-up study with long duration of follow-up we were able to study the 
risk of recurrent venous thrombosis for patients with different cancer characteristics, 
such as type of cancer or metastasized cancer and to study recurrence risk for different 
time points after cancer diagnosis. The risk of recurrence in patients who developed 
cancer after the first thrombotic event has not been studied before, since all of 
abovementioned previous studies were in patients with cancer known or active at time 
of the first venous thrombotic event only. We included diagnoses of cancer both before 
and after the first thrombotic event. Additionally, we were able to study the risk of 
recurrent venous thrombosis both during and after discontinuation of anticoagulant 
treatment and to show results with and without adjustments for age and sex. This 
increases comparability with other studies. Recurrent events reported in this study 
were objectively defined and only certain recurrent events were taken into account. 
Diagnoses of cancer were considered based on four different sources of information 
and we took care to use only those in whom we were certain of a correct diagnosis.
We did not find an increased risk of recurrent venous thrombosis in participants with 
a cancer diagnosis before the first thrombotic event. This finding is probably explained 
by participants with a cancer diagnosis within five years before the first thrombosis 
representing a mix of patients who had gone into remission and patients whose cancer 
was still active. Additionally, we could have had a selection of patients with cancer 
with a relatively good prognosis, because patients with a worse prognosis may not 
have wanted to participate in our MEGA study. When we stratified results for patients 








HR (95% CI) HR* (95% CI)
No cancer 3987 21797 588 27.0 (24.9-29.2) 1 (reference) 1 (reference)
Lung 26 28 2 71.0 (17.8-283.9) 2.8 (0.7-11.3) 2.1 ( 0.5-8.3)
Gastrointestinal 33 94 4 42.3 (15.9-112.8) 1.8 (0.7-4.7) 1.2 (0.4-3.2)
   Esophagus <10 6 1 180.4 (25.4-1280.5) 8.9 (1.2-63.8) 5.6 (0.8-40.3)
   Stomach <10 8 1 132.0 (18.6-937.1) 5.6 (0.8-39.6) 3.6 (0.5-25.4)
   Colon 23 81 1 12.4 (1.7-88.1) 0.5 (0.1-3.7) 0.3 (0.0-2.5)
   Pancreas <10 1 1 1250.9 (176.2-8879.9) 39.7 (5.5-285.3) 25.2 (3.5-181.6)
Breast 24 72 2 28.0 (7.0-111.8) 1.2 (0.3-4.9) 1.6 (0.4-6.6)
Gynaecological 13 45 1 22.0 (3.1-156.3) 0.9 (0.1-6.2) 1.3 (0.2-9.4)
Prostate 18 43 6 140.0 (62.9-311.7) 5.4 (2.4-12.0) 3.4 (1.5-7.7)
Urinary 17 53 4 75.7 (28.4-201.7) 2.9 (1.1-7.7) 2.4 (0.9-6.4)
Brain <10 1 0 0 (0-3689.9) NA NA
Hematological 10 30 3 100.4 (32.4-311.4) 3.6 (1.1-11.1) 3.0 (1.0-9.3)
   Leukemia <10 12 0 0 (0-307.4) NA NA
   Hodgkin 0 0 0 NA NA NA
   Non-hodgkin <10 16 3 183.3 (59.1-568.3) 6.6 (2.1-20.6) 5.2 (1.7-16.3)
   Kahler <10 1 0 0 (0-3689.9) NA NA
Testis <10 2 2 976.6 (244.2-3904.9) 25.3 (6.3-102.0) 18.2 (4.5-73.8)
Melanoma <10 12 0 0 (0-307.4) NA NA
Other‡ 15 31 2 64.3 (16.1-257.0) 2.8 (0.7-11.4) 2.4 (0.6-9.5)
IR denotes incidence rate; pyrs, person-years; CI, confidence interval; HR, hazard ratio; NA, not applicable.
*Hazard ratio adjusted for age and sex.
†Number of patients per type of cancer do not add up to 161, since patients with several types of cancer were 
counted more than once.
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whose cancer was still active during follow-up and patients who might have gone into 
remission we found increased recurrence risks for these participants with active cancer. 
During anticoagulant treatment of the first venous thrombosis we found participants 
with a cancer diagnosis before this event to have an almost four-fold increased 
recurrence risk compared with participants without cancer. After discontinuation of 
anticoagulant treatment, however, recurrence risk was similar between participants 
with and without cancer. This finding is largely explained by the much increased 
recurrence rate in participants without cancer after discontinuation of treatment (31.1 
vs 6.9 per 1000 person-years during treatment). Patients with cancer had a less strong 
increase in absolute risk (38.5 vs 26.2 per 1000 py after discontinuation of anticoagulant 
treatment). Possibly, the risk of recurrent venous thrombosis in patients with cancer is 
increased to such an extent that it outweighs the anticoagulant effect of treatment. 
An additional explanation might be that anticoagulant treatment in patients with 
cancer is usually provided as long as the cancer is active or as long as patients receive 
antineoplastic treatment. If a patient is in remission, and anticoagulant treatment 
is discontinued, these patients may not have an increased risk of recurrent venous 
thrombosis anymore as compared with participants without cancer. 
Currently, guidelines provide treatment recommendations for the group of patients with 
cancer-associated venous thrombosis as a whole and recommend long-term treatment 
with low molecular weight heparins (LMWHs) for as long as cancer is active.[28,29] 
However, the risk of recurrent venous thrombosis in these patients may well vary and 
be influenced by tumour characteristics, such as tumour site, histology and stage. If this 
is the case it might be worthwhile to adjust treatment regimens accordingly. Obviously, 
risk of bleeding should additionally be taken into account. 
It was suggested in a recent meta-analysis that metastatic malignancy, 
adenocarcinoma or lung malignancy confers a higher risk of recurrence than localized 
malignancy, non-adenocarcinoma or breast cancer.[33] The main finding according 
to the authors was, however, that “no definitive conclusions can be drawn from the 
published literature because reporting of malignancy characteristics in patients with 
cancer and recurrent venous thrombosis during the anticoagulation period is scarce”.
A large register study recently reported on an increased recurrence risk for patients with 
brain, lung and ovarian cancer, for patients with myeloproliferative or myelodysplastic 
disorders and for patients with advanced stage of cancer.[25] In the Ottawa prognostic 
score lung cancer was reported to increase recurrence risk, while patients with breast 
cancer or localized disease were reported to have lower risks of recurrent venous 
thrombosis.[26] 
Our study supports current thought that risk of recurrent venous thrombosis is not 
the same for all patients with cancer and that stratification of patients with cancer-
associated venous thrombosis according to their recurrence risk is of relevance to offer 
these patients a better tailored treatment approach. Our results show that patients 
with advanced cancer have a higher risk than patients with more localized or less 
active disease. Our results for different types of cancer diagnosed after a first event 
are based on small numbers, but we could still observe differences in recurrence risk 
for the different types of cancer. We also show an increased risk of recurrent venous 
thrombosis in patients diagnosed with cancer after a first thrombotic event. The risk was 
especially high in the first three months after cancer diagnosis and steadily decreased 
thereafter. Physicians should be aware of this in case a diagnosis with cancer is made 
in a patient with a history of venous thrombosis. To give definite answers to which 
patients would benefit from long-term anticoagulant treatment and which patients 
should not, larger studies are required. For this, meta-analyses of individual patient 
data could prove useful. 
Some limitations of this study warrant comment. First, 8% of all MEGA study participants 
could not be individually linked to the Dutch hospital data register. Furthermore some 
diagnoses of cancer from the hospital data register might have been missed because of 
incomplete recording. This possible underreporting of cancer diagnoses might have led 
to a slight underestimation of our incidence rates. However, since data from the hospital 
data register were combined with two questionnaires filled in by the participants at 
two points in time and with causes of death, underreporting of cancer diagnoses was 
probably limited. Second, before a cancer diagnosis is made the malignancy has been 
present for some time. This implies that person-time may occasionally have been 
misclassified as unexposed in participants with a malignancy that was present but not 
yet diagnosed. The recurrence rate for patients without cancer may therefore have been 
somewhat overestimated and the hazard ratios therefore somewhat underestimated. 
Third, our classification of patients with a history of cancer within five years before 
the first thrombotic event into patients whose cancer was still active during follow-
up and patients whose cancer had gone into remission, may have been somewhat 
crude. However, our finding of similarly increased recurrence risks in patients we 
classified as still active during follow-up, and patients with a cancer diagnosis after 
venous thrombosis suggests that misclassification has been limited. The same applies 
to the patients we classified as having cancer that had gone into remission, as we found 
a similar recurrence risk in this group of patients as in participants without cancer. 
Fourth, we had information on anticoagulant treatment from the anticoagulation 
clinics, that register outpatient use only. Participants (with cancer) may have received 
anticoagulant treatment in the hospital. Data on this use of anticoagulant treatment 
lack in our study, possibly inducing an additional underestimation of the recurrence risk. 
However, after adjustment for anticoagulant treatment hazard ratios did not change, 
which suggests that this did not play a major role. Fifth, we had not enough data to 
take cancer treatment regimens into account in our study. Cancer treatment regimens 
affect cancer activity and risk of venous thrombosis and it would have been interesting 
to study recurrence risks during and after treatment. However, we found increased 
recurrence rates in patients with a cancer diagnosis after their first thrombotic event, 
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especially during the first three months after diagnosis. Cancer treatment might have 
played a role in this highly increased recurrence risk we found shortly after diagnosis.
To conclude, patients with venous thrombosis and cancer had an increased risk of 
recurrent venous thrombosis compared with patients without cancer. Participants with 
a cancer diagnosis before the first venous thrombotic event whose malignancy was still 
active after thrombosis had a two- to three-fold increased risk of recurrence compared 
with patients without cancer. Participants who developed cancer after the first 
thrombosis had an increased recurrence risk, which was especially high in the first three 
months after cancer diagnosis (about five-fold compared with patients without cancer, 
cumulative incidence 4%). Risk of recurrent venous thrombosis varied for different 
types, stages and for different time periods after cancer diagnosis. Stratification of 
patients with cancer-associated venous thrombosis according to their recurrence risk 
is of relevance to offer these patients a better tailored treatment approach. 
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Decision rule regarding certainty of cancer diagnosis
Participants were classified as having a certain cancer diagnosis either when their 
cause of death listed cancer, when any hospital discharge diagnose contained a cancer 
diagnosis or when a cancer diagnosis was mentioned at both questionnaires CC and 
FU (n=575). Participants were classified as having a probable cancer diagnosis when 
they responded on either questionnaire CC or questionnaire FU that they had cancer 
and when hospital discharge register data did not report a cancer diagnosis or were 
missing (n=81). Participants were classified as having no cancer diagnosis when, in 
questionnaire FU, they responded, “No, I have never had a cancer diagnosis” and 
when hospital discharge register data did not contain a cancer diagnosis or were 
missing (n=2504). Participants who responded in questionnaire CC “No, I did not have 
a cancer diagnosis before my 1st thrombotic event”, who did not fill in questionnaire 
FU, and for whom hospital discharge registry data did not contain a cancer diagnosis 
or were missing were classified as ‘probably no cancer diagnosis’ (n=1483). When 
no information was obtained from either questionnaire regarding cancer and when 
hospital discharge register and cause of death statistics data did not report a cancer 
diagnosis, data regarding cancer diagnoses were considered to be missing (n=22).
Classification of types of cancer
All cancer diagnoses were classified into one the following types; lung, gastrointestinal 
(esophagus, stomach, colon, pancreas), breast, gynaecological, prostate, urinary 
(bladder, kidney, urinary tract), brain, hematological (leukaemia, Hodgkin, non-hodgkin, 
Kahler), testis, melanoma, thyroid or other. When patients with a certain or probable 
cancer diagnosis appeared to have been diagnosed with several types of cancer (n=244) 
we checked for every patient individually, whether the second diagnosis with cancer 
was most probably a metastasized tumour of the first cancer type or a new malignancy. 
When this was the case only the first type of cancer was taken into account. For (n=43) 
patients we decided that the second reported cancer type was probably a second 








































































































































































































































































































































































































































































































































Coagulation factor levels in relation to venous 
thrombosis and cancer: 
Results from the MEGA study
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The pathophysiology underlying the association between cancer and subsequent 
venous thrombosis (VT) is not well known. Furthermore, it is not known in what way 
patients with cancer who develop VT are different from those who do not. 
We aimed to study plasma coagulation factor levels (procoagulant, anticoagulant, 
fibrinolytic) in four groups of individuals with and without cancer and with and without 
VT. 
From the MEGA case-control study (n=11253) four groups of participants with 
or without cancer (CA+ or CA-) and with or without VT (VT+ or VT-) were included, 
and plasma coagulation factors measured after the initial anticoagulant treatment 
for the thrombotic event. Cancer diagnoses were objectively verified. Median levels 
of coagulation factors, with 95% confidence intervals, were estimated, as well as 
geometric mean differences in factor levels over the groups of participants with the 
VT-CA- group as the reference. 
Median levels of coagulation factors were generally lowest in the VT-CA- group 
(n=2825). Compared with this group, levels of fibrinogen, factor VIII, von Willebrand 
factor and factor XI were increased in the VT+CA- participants (n=2166) and highest in 
the VT+CA+ participants (n=147). Results were most pronounced for factor VIII and von 
Willebrand factor. Levels of factor V, IX, total and free protein S and TFPI were increased 
only in the VT+CA+ participants. 
To conclude, increased levels of procoagulant coagulation factors in participants 
with both VT and cancer suggest a generalized role of procoagulant pathways in 
patients with cancer and suggest the importance of a procoagulant state in cancer-
associated VT.
Introduction
An association between cancer and venous thrombosis was first described by Bouillaud 
and Trousseau in the 19th century already.[1,2] Since then, the strong relation between 
cancer and venous thrombosis has been confirmed in various studies. It is estimated 
that a fifth of all venous thrombotic events are cancer associated.[3-5] Cancer is 
reported to increase the risk of venous thrombosis about four- to seven-fold[3,6], and 
venous thrombotic events are a major cause of morbidity and mortality in patients 
with cancer.[7] 
The pathophysiology underlying the association between cancer and venous 
thrombosis is largely unknown. It is likely to be multifaceted and to involve interactions 
of tumor cells, the hemostatic system, cancer treatment measures and characteristics 
of the patient. General procoagulant effects are exerted by the host response to 
cancer (acute-phase reaction, paraprotein production, inflammation, necrosis and 
hemodynamic disorders) and by anticancer therapies.[8] In addition, several substances 
released by and activities directly associated with tumor cells (including tissue factor, 
tumor derived cytokines, inhibitors of fibrinolysis and cell adhesion molecules) play a 
prominent role.[8-10] 
Progression of cancer is accompanied by the development of a hypercoagulable 
state. It is cited in literature that about 50% of all patients with cancer and up to 90% 
of patients with metastasised cancer exhibit abnormalities in one or more routine 
coagulation parameters.[11-16] The most commonly described hemostatic changes in 
patients with cancer are an increase in plasma levels of clotting factors I (fibrinogen), 
V, VIII, IX and XI as well as in fibrinogen degradation products and platelet count.[17] 
Most of these studies were, however, conducted a long time ago. 
Cancer treatment strategies, and therefore the prognosis of patients, have changed 
considerably. Furthermore, it is not well known how patients with cancer who develop 
venous thrombotic events differ from those patients with cancer without thrombosis. 
Few studies have linked the coagulation profile in patients with cancer with the clinical 
occurrence of venous thrombosis.[18-20] Neither has this, as far as we know, been 
done for a wide range of procoagulant and anticoagulant factors.
We aimed to study several plasma coagulation factor levels (procoagulant, anticoagulant 
and fibrinolytic) in four groups of individuals with and without cancer and with and 
without venous thrombosis to determine to what extent the coagulation profile differs 
between these groups. For this purpose, we used data from the MEGA case-control 
study (n>10 000) in which for more than half of the participants blood was sampled 
and factors of the hemostatic system were measured. 
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This study was performed within the MEGA- (Multiple Environmental and Genetic 
Assessment of risk factors for venous thrombosis) study, which is a large case-control 
study aimed at identifying risk factors for venous thrombosis. Details of this study 
have been described previously.[6] In brief, from March 1999 until September 2004, 
4956 consecutive patients with a first objectively diagnosed venous thrombotic event 
were included from six anticoagulation clinics in the Netherlands. Anticoagulation 
clinics monitor all patients taking vitamin K antagonists in a well-defined geographical 
area. Detailed diagnostic information was obtained from hospital discharge reports 
and general practitioners. 3297 Partner controls of the patients, who had no history 
of venous thrombosis, were included in the study. Additionally from January 2002 to 
September 2004, 3000 random-digit-dialing controls (RDD), with no history of venous 
thrombosis, were included. All participants were 18 to 70 years of age. All participants 
completed the informed consent process prior to enrolment, and the study was 
approved by the ethics committee of the Leiden University Medical Center.
Between 2007 and 2009 the vital status of all MEGA participants was acquired from 
the Dutch population register, as has been described previously.[21] For the participants 
who died, a cause of death (encoded according to International Classification of 
Diseases ICD-10-CM) was obtained from the national register of death certificates. 
Cancer diagnosis
All participants were asked to complete a detailed questionnaire on acquired risk 
factors for venous thrombosis. All items in the questionnaire referred to the period 
before the index date. We used the date of diagnosis of venous thrombosis as the 
index date for patients as well as their partner controls. For the RDD controls the 
index date was the date of completing the questionnaire. Participants were asked to 
report on the presence of acquired risk factors, amongst others any type of diagnosed 
malignancy, date of diagnosis and type of malignancy diagnosed. Approximately three 
months after discontinuation of anticoagulant treatment, or one year after the event 
in case anticoagulant treatment was continued for more than a year, cases and their 
partner controls were interviewed. The RDD group was invited for the interview at 
time of returning the questionnaire. In the interview, participants were again asked to 
report on any malignancies diagnosed after inclusion in the study, date of diagnosis and 
type of cancer diagnosed. Self-reported cancer diagnoses were verified by means of 
discharge letters from the primary physician or hospital where patients were treated. 
Details of this verification process were described previously.[6] For the current study, 
participants with a cancer diagnosis within five years before the index date, or a cancer 
diagnosis within six months after the index date, were included. Participants with a 
cancer diagnosis outside this period were excluded from analyses. 
Blood collection and laboratory analyses
At the time of the interview blood was sampled from both cases and controls. Details of 
collection and processing of blood samples have been described previously.[22,23] For 
logistic reasons, blood sampling for measurement of coagulation proteins was done in 
patients diagnosed with venous thrombosis before June 1, 2002. Blood samples were 
drawn at least three months after discontinuation of oral anticoagulant therapy, or 
during anticoagulant therapy in patients who continued this therapy for more than 
one year. Partner controls visited the anticoagulation clinic for blood sampling at the 
same time as their partner and therefore blood samples were available only for partner 
controls recruited before June 2002. The additional group of controls recruited via RDD 
were invited for a blood sample irrespective of their time of enrolment. Participants 
who were unable or unwilling to provide blood samples or were patients and partner 
controls recruited after June 1, 2002, were sent buccal swabs to collect DNA for genetic 
profiling. 
The levels of natural anticoagulants (antithrombin, protein S, protein C levels and 
TFPI), procoagulant factors (fibrinogen, factor II, factor V, factor VII, factor VIII, von 
Willebrand factor, factor IX, factor X, and factor XI), and the fibrinolytic marker D-dimer 
were assessed in the blood samples. All assays were performed in automated machines 
by laboratory technicians who were unaware of the case–control status of the samples. 
For details on the measurements of coagulation factors, see the Supplement. 
Statistical analyses
Blood samples were available for 2377 participants with venous thrombosis (48% 
(2377/4956)) and 2939 controls (47% (2939/6297)). 123 Participants (64 cases, 59 
controls) were excluded from analyses because of a cancer diagnosis more than five 
years before inclusion in the study, because of a cancer diagnosis more than six months 
after the index date or because information regarding a possible cancer diagnosis or 
cancer diagnosis date was missing. In total, 2313 participants with venous thrombosis 
and 2880 controls without venous thrombosis were included for the current analyses. 
Median coagulation factor levels with corresponding 95% confidence intervals were 
estimated for participants with neither venous thrombosis nor cancer (VT-CA- ; n=2825), 
participants with cancer but without venous thrombosis (VT-CA+ ; n=55), participants 
with venous thrombosis but no cancer (VT+CA- ; n=2166) and for participants with 
both cancer and venous thrombosis (VT+CA+ group; n=147). Boxplots with medians 
and corresponding 95% confidence intervals were constructed for every coagulation 
factor separately to visually show the spread of coagulation factor levels over the 
groups of participants (Supplementary Figure 1). Levels of D-dimer were plotted on the 
10log scale, because of the wide range of D-dimer measurements. 
Mean differences in coagulation factor levels (and corresponding 95% confidence 
intervals) were estimated between the groups of participants, with the VT-CA- group 
as the reference category. Mean differences were adjusted for age and sex by means 
of multivariate linear regression analysis. Mean differences between the groups 
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of participants were estimated with a natural logarithmic transformation, thus 
providing geometric mean differences, since mean differences without a logarithmic 
transformation are substantially influenced by extremely high or low values of 
coagulation factors for some of the participants. The interpretation of a geometric 
mean difference is different from the interpretation of a mean difference. Instead of an 
absolute difference in factor levels it represents a relative difference with in our case 
the VT-CA- group as the reference. For example, a geometric mean difference for factor 
VIII of 1.10 in the VT+CA+ group means that on average factor VIII levels are 1.10 times 
higher (10% higher) in the VT+CA+ group than in the VT-CA- group. We chose a cut-off 
of five percent to define levels of coagulation factors as increased. 
Participants with a cancer diagnosis within five years before their thrombotic event 
could have gone into remission in the meantime and might have a different coagulation 
profile than participants whose malignancy was still active at time of blood sampling. 
For this reason, we estimated median coagulation factor levels in the VT+CA+ group 
separately for participants who died of cancer in the years after the index date (as 
registered by the national register of death certificates) and for participants who 
survived the years following the index event. The first group of participants was 
classified as having ‘active cancer’ while the second group of participants was classified 
as ‘unknown activity’. Geometric mean differences, adjusted for age and sex, in 
coagulation factor levels between the two groups of participants with cancer (active 
cancer vs activity unknown) were estimated. 
At the time of blood collection 304 participants (275 individuals with venous 
thrombosis; 29 controls without venous thrombosis) were on anticoagulant treatment. 
These participants were excluded from all analyses concerning vitamin K dependent 
coagulation factors (factor II, VII, IX and X, protein C activity, total protein S antigen, free 
protein S antigen) and factors that are otherwise affected by anticoagulant treatment 
(D-dimer).
Results 
The clinical characteristics of the participants are shown in Table 1, for all participants 
included and for the four groups of participants separately. Mean age of all participants 
was 48 years. Mean age was higher in participants with cancer, i.e. 55 years in the 
VT+CA+ group and 58 years in the VT-CA+ group. The most common types of cancer 
were breast, prostate, colorectal and a hematological type of cancer. 
Median levels of coagulation factors differed considerably across the four groups 
of participants and were generally lowest in the group of participants without venous 
thrombosis and without cancer (VT-CA-) (Table 2). Differences in median levels over 
the groups of participants were most pronounced for levels of factor VIII (activity and 
antigen), von Willebrand factor and D-dimer. Levels were lowest in the VT-CA- group, 
higher in the other groups of participants and highest in the VT+CA+ group. Levels 
of factor V, factor VII, protein C activity and total protein S antigen were increased in 
both cancer groups (VT-CA+ and VT+CA+) as compared with the groups of participants 
without cancer (VT-CA- and (VT+CA-).
Geometric mean differences in coagulation factor levels, adjusted for age and sex, 
between the VT-CA- group and the VT-CA+, VT+CA- and VT+CA+ groups are presented in 
Table 3. The VT-CA- group was used as the reference category and the geometric mean 
differences for the other groups of participants represent the relative increase in levels 
of the coagulation factors. Following a cut-off of five percent to define an increase in 
coagulation factor level, we identified four patterns for the coagulation factors over the 
four groups. For the first pattern, levels were increased by at least 5% for the VT+CA+ 
participants only, and not for the other groups. We identified pattern 1 for factor V, 
factor IX, total and free protein S and TFPI. Fibrinogen, factor VIII activity and antigen, 
von Willebrand factor, factor XI and D-dimer levels were increased by at least 5% in the 
VT+CA- group and highest in the VT+CA+ group (pattern 2). Only D-dimer levels were 
increased to the same extent both in the VT+CA- and VT+CA+ groups (by aproximately 
40%). Levels of factor VII were increased to about the same extent in both groups of 
participants with cancer (VT-CA+ and VT+CA+) (pattern 3). The fourth pattern showed 
no clear difference in factor levels over the groups of participants, which was the case 
for factor II, factor X, antithrombin and protein C. In all of abovementioned analyses 
adjustment for age had a larger effect on mean differences in coagulation factor levels 
than adjustment for sex (results not shown).
In Table 4, the median coagulation factor levels are shown for participants who 
died of cancer in the years following their thrombotic event (n=39) and for participants 
who survived in the years following thrombosis (n=97) (‘active cancer’ vs ‘unknown 
activity’). The geometric mean differences in coagulation factor levels, adjusted for age 
and sex, between the two groups are additionally shown. After adjustments, levels of 
factor VIII activity, factor VIII antigen and von Willebrand factor were increased by at 
least 20% in the active cancer group as compared with the group of participants with 
cancer with unknown activity. Levels of both TFPI and D-dimer were increased in the 
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Table 1. Clinical characteristics of the study population
VT* - Cancer - VT – Cancer + VT + Cancer - VT + Cancer + Total
General characteristics
Number of participants 2825 55 2166 147 5193
Male sex n, (%) 1351 (48%) 26 (47%) 986 (46%) 72 (49%) 2435 (47%)
Mean age (range) 48 (18-70) 58 (31-70) 47 (18-70) 55 (18-70) 48 (18-70)
Types of cancer
   Breast n, (%) 0 12 (22%) 0 23 (16%) 35 (1%)
   Prostate n, (%) 0 15 (27%) 0 15 (10%) 30 (1%)
   Colorectal n, (%) 0 3 (5%) 0 21 (14%) 24 (0%)
   Haematologic n, (%) 0 3 (5%) 0 20 (14%) 23 (0%)
   Lung n, (%) 0 1 (2%) 0 7 (5%) 8 (0%)
   Other n, (%) 0 21 (38%) 0 61 (42%) 82 (2%)
*VT denotes: venous thrombosis
Table 2. Median coagulation factor levels for participants with or without cancer and with or without 
venous thrombosis
Coagulation factor VT* - Cancer -
median (95%CI)
VT - Cancer +
median (95%CI)
VT + Cancer -
median (95%CI)
VT + Cancer +
median (95%CI)
Procoagulant     
Fibrinogen activity (g/L) 3.2 (3.2-3.3) 3.5 (3.2-3.7) 3.4 (3.4-3.4) 3.7 (3.5-3.8)
Factor II activity (IU/dL)† 109 (109-110) 113 (107-119) 112 (111-112) 111 (109-115)
Factor V (IU/dL) 92 (91-93) 97 (91-103) 93 (92-94) 101 (96-104)
Factor VII acitivity (IU/dL)† 109 (108-110) 124 (109-130) 112 (110-113) 119 (116-128)
Factor VIII activity (IU/dL) 106 (104-107) 110 (103-132) 134 (131-136) 148 (139-152)
Factor VIII antigen (IU/dL) 108 (107-110) 123 (115-132) 146 (143-148) 162 (152-175)
Von Willebrand factor antigen 
(IU/dL) 105 (103-105) 110 (102-123) 138 (136-140) 158 (148-164)
Factor IX antigen (IU/dL)† 103 (102-104) 109 (101-117) 107 (106-109) 113 (109-117)
Factor X activity (IU/dL)† 116 (115-117) 126 (115-129) 118 (117-119) 116 (111-120)
Factor XI activity (IU/dL) 98 (97-99) 106 (101-112) 104 (102-105) 105 (103-111)
Anticoagulant     
Antithrombin (IU/dL) 105 (105-106) 105 (101-109) 105 (105-106) 107 (105-109)
Protein C activity (IU/dL)† 116 (115-117) 124 (115-131) 115 (113-116) 122 (117-127)
Total protein S antigen (IU/dL)† 101 (100-102) 113 (100-117) 102 (101-103) 109 (105-112)
Free protein S antigen (IU/dL)† 90 (89-91) 88 (82-105) 92 (91-94) 97 (92-102)
TFPI (U/mL) 1.7 (1.7-1.7) 1.9 (1.7-2.0) 1.7 (1.7-1.7) 1.9 (1.9-2.0)
Fibrinolytic     
D-dimer (ng/mL)† 236 (230-240) 263 (230-312) 327 (315-339) 347 (303-400)
*VT denotes: venous thrombosis, CI: confidence interval
†Participants on anticoagulant treatment during blood sampling were excluded
Table 3. Geometric mean differences in coagulation factor levels between groups of participants 
with and without cancer and with and without venous thrombosis
 
Coagulation factor
VT - Cancer -
 
VT - Cancer +
GMD (95%CI)†
VT + Cancer -
GMD (95%CI)†
VT + Cancer +
GMD (95%CI)†
Procoagulant     
Fibrinogen activity (g/L) reference 1.00 (0.95-1.06) 1.05 (1.04-1.06) 1.11 (1.07-1.14)
Factor II activity (IU/dL)‡ reference 1.01 (0.97-1.05) 1.01 (1.00-1.02) 1.03 (1.00-1.05)
Factor V (IU/dL) reference 1.02 (0.97-1.07) 1.02 (1.01-1.03) 1.06 (1.03-1.09)
Factor VII activity (IU/dL)‡ reference 1.05 (0.99-1.12) 1.02 (1.01-1.04) 1.08 (1.04-1.13)
Factor VIII activity (IU/dL) reference 1.04 (0.95-1.13) 1.25 (1.23-1.27) 1.30 (1.23-1.37)
Factor VIII antigen (IU/dL) reference 1.04 (0.95-1.14) 1.34 (1.32-1.37) 1.42 (1.34-1.50)
Von Willebrand Factor antigen 
(IU/dL) reference 1.02 (0.93-1.12) 1.33 (1.30-1.36) 1.43 (1.35-1.52)
Factor IX antigen (IU/dL)‡ reference 1.03 (0.98-1.08) 1.04 (1.03-1.05) 1.09 (1.06-1.12)
Factor X activity (IU/dL)‡ reference 1.04 (0.99-1.09) 1.02 (1.01-1.03) 1.01 (0.98-1.04)
Factor XI activity (IU/dL) reference 1.00 (0.05-1.06) 1.05 (1.04-1.06) 1.09 (1.05-1.12)
Anticoagulant     
Antithrombin (IU/dL) reference 1.00 (0.97-1.03) 1.00 (0.99-1.00) 1.03 (1.01-1.05)
Protein C activity (IU/dL)‡ reference 1.02 (0.97-1.07) 0.99 (0.98-1.01) 1.03 (1.00-1.07)
Total protein S antigen (IU/dL)‡ reference 1.04 (0.99-1.09) 1.01 (1.00-1.02) 1.05 (1.01-1.08)
Free protein S antigen (IU/dL)‡ reference 1.01 (0.93-1.10) 1.04 (1.03-1.06) 1.05 (1.01-1.10)
TFPI (U/mL) reference 1.03 (0.95-1.10) 1.00 (0.99-1.02) 1.08 (1.03-1.13)
Fibrinolytic     
D-dimer (ng/mL)‡ reference 0.97 (0.81-1.15) 1.42 (1.37-1.47) 1.41 (1.25-1.58)
*VT denotes: venous thrombosis, GMD: geometric mean difference, CI: confidence interval
†Adjusted for age and sex
‡Participants on anticoagulant treatment during blood sampling were excluded 
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Median (95%CI) GMD (95%CI)
Adjusted†
 
VT patients with cancer 
with unknown activity (n=97)
VT patients with 
active cancer (n=39)
Procoagulant    
Fibrinogen activity (g/L) 3.7 (3.5-3.8) 3.7 (3.4-3.9) 1.03 (0.95-1.12)
Factor II activity (IU/dL)‡ 111 (107-116) 112 (109-116) 1.02 (0.97-1.07)
factor V (IU/dL) 97 (93-102) 106 (97-111) 1.05 (0.98-1.14)
Factor VII acitivity (IU/dL)‡ 120 (116-128) 119 (107-138) 0.98 (0.90-1.07)
Factor VIII activity (IU/dL) 141 (132-152) 151 (147-195) 1.23 (1.03-1.46)
Factor VIII antigen (IU/dL) 155 (143-166) 198 (157-222) 1.22 (1.07-1.38)
Von Willebrand factor antigen 
(IU/dL) 152 (136-162) 192 (154-226) 1.27 (1.09-1.48)
Factor IX antigen (IU/dL)‡ 113 (108-120) 112 (102-123) 0.99 (0.92-1.07)
Factor X activity (IU/dL)‡ 115 (110-121) 120 (110-128) 1.05 (0.99-1.11)
Factor XI activity (IU/dL) 107 (103-112) 105 (94-115) 0.98 (0.91-1.05)
Anticoagulant    
Antithrombin (IU/dL) 106 (105-110) 108 (103-110) 1.00 (0.96-1.05)
Protein C activity (IU/dL)‡ 123 (117-127) 116 (111-137) 1.00 (0.94-1.07)
Total protein S antigen (IU/
dL)‡ 108 (103-113) 110 (105-120) 1.01 (0.94-1.08)
Free protein S antigen (IU/dL)‡ 97 (92-102) 103 (92-107) 1.03 (0.94-1.12)
TFPI (U/mL) 1.9 (1.7-2.0) 2.2 (1.9-2.3) 1.14 (1.03-1.27)
Fibrinolytic    
D-dimer (ng/mL)‡ 345 (297-400) 317 (275-536) 1.15 (0.81-1.64)
*CI denotes: confidence interval, VT: venous thrombosis, GMD: geometric mean difference, for which 
the patients with cancer with unknown activity were set as reference.
†Adjusted for age and sex
‡Participants on anticoagulant treatment during blood sampling excluded
Discussion
In this study, in which we studied plasma coagulation factor levels in participants 
with and without cancer and with and without venous thrombosis, we found that all 
coagulation factor levels (procoagulant, anticoagulant and fibrinolytic) were lowest in 
individuals without venous thrombosis and without cancer. Compared with this group 
of participants, levels of fibrinogen, factor VIII activity and antigen, von Willebrand 
factor and factor XI were increased in participants with venous thrombosis without 
cancer and were highest in participants with both venous thrombosis ánd cancer. 
These findings were most pronounced for factor VIII and von Willebrand factor (30-
40% increase). Levels of factor V, factor IX, total and free protein S and TFPI were 
increased only in the group of participants with both venous thrombosis and cancer. 
Levels of factor VII were increased in participants with cancer and were unaffected by 
the presence or absence of venous thrombosis. 
Our findings of increased levels of procoagulant coagulation factors in participants 
with venous thrombosis without cancer and even higher levels of these factors in 
participants with both venous thrombosis and cancer support prior observations of 
a generalized role of procoagulant pathways in patients with cancer and thrombosis 
and emphazise the importance of the coagulation system in cancer-associated venous 
thrombosis. These findings were most pronounced for levels of factor VIII and von 
Willebrand factor. Our finding of slightly increased levels of anticoagulant proteins, free 
protein S and TFPI, in participants with cancer and venous thrombosis is suggestive of 
an additional effect of cancer on anticoagulant pathways. 
Although previous studies have compared coagulation profiles for individuals with 
and without cancer[11,16,19,24], few studies have linked these profiles with venous 
thrombotic events in patients with cancer.[18,19] Johnson et al compared coagulation 
profiles between 98 (hospice) patients with advanced cancer either with or without 
deep vein thrombosis (identified on screening) with a group of control participants 
without cancer.[19] Goldenberg et al studied coagulation factor levels in 36 patients 
with cancer-only, 58 patients with venous thrombosis-only and 32 patients with both 
cancer and venous thrombosis.[18] Some of our findings are in accordance with 
these studies, while others are not. Similar to our observations, Johnson et al found 
increased levels of fibrinogen, factor VIII and D-dimer in cancer patients as compared 
with healthy controls. However, cancer patients with DVT had somewhat lower levels 
of fibrinogen and factor VIII than cancer patients without DVT, which is contrary to 
our findings. Goldenberg et al reported an increased level of von Willebrand factor in 
the group of cancer patients with DVT as compared with the group of patients with 
cancer or DVT alone. This is in line with our findings. These studies were, however, not 
comparable with ours with respect to patient selection and study design. For example, 
Johnson et al only included hospice-in patients with advanced cancer. Furthermore, 
none of the results were adjusted for age and sex.
We found somewhat increased levels of the anticoagulant proteins total and free 
protein S and TFPI in the group of participants with cancer and venous thrombosis. In 
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general, levels of anticoagulant proteins, such as antithrombin, protein C and protein 
S are assumed to be lower in patients with cancer than in non-cancer individuals due 
to a decreased hepatic synthesis of such anticoagulant proteins.[17] Decreased levels 
of both protein C and protein S in patients with cancer as compared with healthy 
controls have indeed been shown in several studies.[25-27] A possible explanation for 
these conflicting results is that previous studies included patients with more advanced 
disease. In patients with advanced disease, consumption of these proteins (as seen in 
sepsis)[28] or active liver disease may have led to decreased levels of these proteins.
We found increased levels of factor VII in patients with cancer, independent of the 
presence of VT, which is in line with a study by Kakkar et al.[29] In this study in over 100 
patients with solid tumors and a comparison group of healthy volunteers, plasma levels 
of factor VII were found to be 46% higher in patients with cancer. These results were, 
however, not corrected for age and sex.
In our study, factor VIII, von Willebrand factor and D-dimer showed the highest rise 
in levels in participants with cancer. High factor VIII and von Willebrand factor levels 
have been described before in different types of cancer patients.[30-32] Levels of these 
factors were largely determined by age in our study, which is in accordance with studies 
showing progressive increase in plasma coagulation factors with age.[33] Levels of 
factor VIII (activity and antigen) and von Willebrand factor were substantially increased 
in participants with both cancer and venous thrombosis but were not increased in VT-
CA+ participants after adjustment for age and sex. An explanation for these findings 
could be that the more aggressive types of cancer and advanced stages of cancer are 
associated with venous thrombosis.[6,34-37] Perhaps these types and advanced stages 
of cancer induce higher levels of coagulation factors, which subsequently induce a 
higher risk of venous thrombosis than other types of cancer. Indeed, Vormittag and 
colleagues observed a significant difference in factor VIII levels according to tumor 
site,[38] which were highest in patients with tumor sites associated with a high risk of 
venous thrombosis. Auwerda et al. reported an association between factor VIII and von 
Willebrand factor levels and disease stage, with highest levels in patients with stage III 
disease (vs stage I or stage II disease).[30] The same can be concluded from our analysis 
in which we found that venous thrombosis patients who died from cancer had much 
higher factor VIII and von Willebrand factor levels than VT patients with cancer who 
survived. 
Strengths of our study are that we studied coagulation factor levels (procoagulant, 
anticoagulant and fibrinolytic) in four groups of participants: participants without 
venous thrombosis and without a cancer diagnosis, a cancer-only group, a venous 
thrombosis-only group and a group with both venous thrombosis and cancer. 
Furthermore, the plasma levels of a wide range of procoagulant and anticoagulant 
factors that are essential to the coagulation system were measured at the same time 
and with the same standardized assays for each factor. In addition, the levels were 
adjusted for age and sex. 
Some limitations of this study have to be mentioned as well. First of all, blood was 
sampled at least three months after inclusion in the study. For this reason some of 
the MEGA-study participants who died after inclusion into the study but before the 
moment of blood collection are missing in our analyses. Also, participants with an 
advanced stage of disease and who were therefore unable to visit the hospital for 
blood sampling or participants who were not willing to visit the hospital for other 
reasons are not included in our analyses. Of 3227 cases in the MEGA study eligible for 
blood sampling, 851 (26%) did not provide a blood sample. For the partner controls 
this was 32% and for the RDD controls this was 51%. For abovementioned reasons, 
participants with cancer included in our analyses may have been less ill than those who 
did not participate, which can have diluted our results. Secondly, a drawback of this 
study is the relatively small sample size for some groups of participants, which did not 
allow us to study coagulation factor levels for different types of cancer. Furthermore, 
we missed some clinical details on the cancers diagnosed, such as stage of cancer and 
information on cancer treatment. However, a recent longitudinal study from Austria 
(n=112) in which hemostatic factors were measured in patients with various types of 
cancer at multiple time points showed that several coagulant factors were increased 
in patients with malignancy, at diagnosis, but also during the course of antineoplastic 
treatment with little difference in coagulation factor concentrations before and during 
antineoplastic treatment.[20] 
Overall, we found increased levels of procoagulant coagulation factors in individuals 
with venous thrombosis without cancer and even higher levels of these factors in 
individuals with both venous thrombosis and cancer, suggesting a generalized role of 
procoagulant pathways in patients with cancer. These findings were most pronounced 
for levels of factor VIII and von Willebrand factor. Our finding of slightly increased levels 
of anticoagulant proteins, free protein S and TFPI in participants with cancer and venous 
thrombosis is suggestive of an additional role of anticoagulant pathways in cancer. For 
further studies it would be useful to study coagulation factor levels in relation to cancer 
and venous thrombosis for different types and stages of cancer and in patients with 
different cancer treatments in large enough numbers and sufficient follow-up. 
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Prothrombin (factor II) activity, factor VII activity and factor VIII activity were measured 
with a mechanical clot detection method on a STA-R coagulation analyser following the 
instructions of the manufacturer (Diagnostica Stago, Asnieres, France). Levels of factor 
IX antigen, factor X antigen, factor VIII antigen, factor V antigen, factor XI antigen and 
total protein S levels were determined by enzyme-linked immunosorbent assay (ELISA). 
Fibrinogen activity was measured on the STA-R analyzer according to methods of Clauss. 
Von Willebrand factor (VWF) antigen was measured with the immunoturbidimetric 
method, using the STA Liatest kit (rabbit anti-hum VWF antibodies), following the 
instructions of the manufacturer. Measurement of antithrombin and protein C levels 
was performed with a chromogenic assay on the STA-R analyser. Free protein S was 
measured by an immune-turbidimetric method (Diagnostica Stago) accordingly to the 
manufacturer instructions. TFPI activity in plasma was measured by a chromogenic 
assay using the ACTICHROME TFPI activity assay (Sekisui Diagnostics, Stamford, 
Connecticut, USA) following the instructions of the manufacturer. TFPI activity was 
measured by inhibition of cleavage of a chromogenic substrate (spectrozyme Xa, 
Sekisui diagnostics) by factor Xa, after initiation of coagulation with an excess of factor 
X and Tissue Factor-Factor VIIa complex. D-dimer was assayed using the D-dimer 
HemosIL assay (Instrumentation Laboratory). The HemosIL D-Dimer HS is an automated 
latex enhanced immunoassay performed on the ACL TOP 700CTS (Instrumentation 
Laboratory, Warrington, UK).
Supplementary Figure 1. Boxplots of factor levels for groups of participants.
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Prediction of recurrent venous thrombosis remains a challenge in the clinic.
Objective
To investigate the predictive value of coagulation factor VIII (FVIII) levels for recurrent 
venous thrombosis.
Patients/methods
Patients, aged 18-70 years with a first venous thrombosis were followed from 
discontinuation of anticoagulant treatment (1999-2010 MEGA follow-up study). Levels 
of FVIII activity, FVIII antigen and von Willebrand factor antigen (VWF) were measured 
at least 3 months after cessation of anticoagulant treatment.
Results
Out of 2242 patients followed for a median of 6.9 years, 343 developed recurrent 
thrombosis (incidence rate 2.7/100 patient-years (95%CI, 2.5-3.1)). Recurrence rates 
steadily increased with higher FVIII activity levels from 1.4 (95%CI, 1.0-1.9), 2.3 (95%CI, 
1.8-2.9), 3.0 (95%CI, 2.4-3.7), 3.2 (95%CI, 2.5-4.1), 3.9 (95%CI, 2.8-5.3), to 5.1 (95%CI, 
3.8-6.8) per 100 patient-years, for levels ranging from <100 IU/dL to >200 IU/dL. 
Patients in the highest category of FVIII (>200 IU/dL) had a three-fold higher recurrence 
rate than patients in the lowest category (≤100 IU/dL) (HR 3.4 (95%CI, 2.2-5.3)). Results 
were similar for FVIII antigen and VWF levels, in several sensitivity analyses and FVIII 
predicted recurrence rates over a long time period. Within subgroups of patients 
currently assumed to have low recurrence risks, a high level of FVIII was still predictive 
for recurrences. Adding FVIII to an existing prediction model (DASH-score) improved 
its predictive value, and after replacing D-dimer by FVIII, the model performed equally 
well if not better.
Conclusions
FVIII predicted recurrence in a dose-response fashion, overall and in several subgroups, 
and is a strong candidate component of recurrence prediction tools. 
Introduction
The annual incidence of venous thrombosis (deep vein thrombosis (DVT) and 
pulmonary embolism (PE)) is 1-2 per 1000 inhabitants.[1] The five-year cumulative 
incidence of recurrent venous thrombosis, a condition with considerable comorbidity 
and mortality, is 12-25%.[2-4] Secondary prevention of recurrent venous thrombosis by 
prolonged anticoagulant treatment should, considering the risk of major haemorrhage 
(1-2% per year) [5,6], be targeted at high risk patients.[7] According to the latest ACCP 
guidelines, primary factors determining the risk of recurrence are the presence of a 
transient provoking risk factor (associated with a decreased incidence of recurrence) 
and the presence of active cancer at the time of the first event (associated with an 
increased incidence of recurrence).[7] Yet, only 50% of patients can be classified in 
either of these two categories. For the other 50% of patients prediction of recurrent 
venous thrombosis remains a challenge in the clinic and knowledge of good predictors 
is crucial.[8]
Factor VIII (FVIII) levels have been consistently reported as a potent predictor for 
first venous thrombosis.[9] These levels are fairly constant over time[10,11], and since 
FVIII levels are not affected by anticoagulant use, it is an interesting candidate for a 
prediction tool for recurrence. However, none of the existing guidelines or prediction 
models for recurrent thrombosis include levels of FVIII.[12-14] This is probably because 
research on this topic is scarce and results are not as consistent as in studies on first 
events.[10,15,16] 
We aimed to investigate the predictive value of FVIII levels on recurrent venous 
thrombosis, both on its own as in combination with other variables in a prognostic 
model, in a large group of patients (n=2242) with a first venous thrombotic event. Since 
the aim of this study is to investigate the potential of FVIII as a predictor of recurrent 
venous thrombosis, and not to study the underlying mechanism, we will not take into 
account potential confounding factors.
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Between March 1999 and August 2004, 4956 patients aged 18-70 with an objectively 
diagnosed first DVT of the leg or PE were included in a population-based case-control 
study (MEGA study). All patients filled in an extensive questionnaire on putative 
risk factors for venous thrombosis. Details of the MEGA study have been described 
previously.[17] Of the MEGA case-control study, only the cases were further followed 
for recurrence (MEGA follow-up study). For this, 225 of the 4956 patients did not 
consent, leaving 4731 patients (Supporting Fig1). Approximately three months after 
discontinuation of oral anticoagulant therapy, patients were invited for collection of a 
blood sample, unless they were still on anticoagulant therapy one year after their event, 
in which case blood was drawn during anticoagulant therapy.[18] Blood sampling was 
requested until June 2002, which included 3122 patients. 734 of these 3122 patients 
did not provide a blood sample, because of unwillingness or death, leaving 2388 
patients for analyses on laboratory measurements. 
Between 2007 and 2009 the vital status of all patients was acquired from the central 
Dutch population register.[19] For the patients who died, a cause of death (ICD-10-CM) 
was obtained from the national register of death certificates at the Central Bureau 
of Statistics. Questionnaires concerning recurrent venous thrombosis were sent by 
mail to all survivors and consenting individuals between June 2008 and July 2009, and 
supplemented by telephone interviews. Additional information was acquired from the 
regional anticoagulation clinics and from hospitals. Deaths due to recurrent venous 
thrombosis were counted as fatal recurrent events. Based on hospital discharge letters, 
the information from the anticoagulation clinic, questionnaires filled in by the patients 
and causes of death, possible recurrences were classified into certain and uncertain 
recurrences, following a decision rule (Supporting Methods). 
This study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center, and all participants gave written informed consent.
Current analyses
For the current analyses, follow-up was started at the moment of discontinuation of 
anticoagulant treatment because clinically it is more relevant to know recurrence rates 
and risks after discontinuation of treatment. Furthermore, because levels of FVIII were 
measured some time after the thrombotic event and some patients did not survive 
until blood collection, immortal time bias might play a role when follow-up is started 
before.[20] For these analyses 117 patients were excluded because their follow-up 
ended before discontinuation of anticoagulant treatment. An additional 29 patients 
were excluded because FVIII levels could not be accurately measured, leaving 2242 
patients. MEGA follow-up patients included or excluded from the current analyses did 
not differ substantially on clinical characteristics, except for the proportion of patients 
with malignancy (Supporting Table1).
Laboratory measurements
Blood samples were drawn into vacuum tubes containing 0.1-volume 0.106- mol/L 
trisodium citrate and centrifuged for 10 minutes at 4ºC, after which plasma was 
aliquoted, frozen and stored at -80 ºC. FVIII activity (FVIII:C), FVIII antigen (FVIII:Ag) 
and von Willebrand factor antigen (VWF:Ag) levels were determined at a later point in 
time in series with the same method. The levels of these three measures are strongly 
correlated, since FVIII is stabilized when bound to VWF.[21] FVIII:C was measured with 
a mechanical clot detection method on a STA-R analyzer (Diagnostica Stago, Asnieres, 
France). FVIII:Ag was determined by enzyme-linked immunosorbent assay (ELISA). 
VWF:Ag was measured with a immunoturbidimetric method, using the STA Liatest kit 
(rabbit anti-human VWF antibodies). In this study, we focused on FVIII activity levels 
as this is the fastest test and the most commonly used in the clinic. 197 patients who 
were still on anticoagulant treatment at the time of blood collection were included 
for analyses, since FVIII is not vitamin K dependent and its levels are not affected by 
treatment with vitamin-K-antagonists.
ABO Blood group was determined by polymerase chain reactions using the TaqMan 
assay.[17] D-dimer was assayed using the D-dimer HemosIL assay (Instrumentation 
Laboratory). The HemosIL D-Dimer HS is an automated latex enhanced immunoassay 
for the quantitative determination of D-dimer performed on the ACL TOP 700 
(Instrumentation Laboratory, Warrington, UK).
Statistical analysis
Duration of follow-up was counted from date of discontinuation of anticoagulant 
treatment to end of follow-up, which was defined as the date of a recurrence or, in its 
absence, the date of returning the follow-up questionnaire. The last questionnaire was 
returned on April 8, 2010. If patients did not complete the questionnaire, they were 
censored at the last date we knew them to be recurrence free (date of death (n=26), 
date of emigration (n=1), date last seen by the anticoagulation clinic or for research 
purposes (n=285)). Here we limit the analyses to certain recurrent events (n=343), and 
censored patients with uncertain recurrent events (n=84) at that time.
We used fixed cut-off levels of FVIII activity (100 IU/dL, 125 IU/dL, 150 IU/dL, 175 
IU/dL and 200 IU/dL). Incidence rates of recurrent venous thrombosis were estimated 
as number of events over the accumulated follow-up time. Cox-proportional hazards 
models were used to evaluate rates between groups. Hazard ratios for recurrence were 
estimated for increasing levels of FVIII, using levels below 100 IU/dL as reference. The 
cumulative incidences of recurrence were estimated, treating death as competing 
risk using Stata’s user-contributed stcompet suite. Survival curves were constructed 
to visualize the cumulative incidence of recurrent events over the years. By means 
of adding an interaction term between log(time) as a time-dependent variable and 
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To quantify potential misclassification of outcomes, several sensitivity analyses were 
performed (see Supporting Methods). 
We stratified patients by those with first provoked and first unprovoked events, by sex 
(as unprovoked events and male sex are associated with higher recurrence risks)[22,23] 
and by blood group O and non-O (since VWF and FVIII levels are strongly determined 
by ABO blood group).[24,25] Stratified analyses with two age categories (cut-off 45 
years) and two BMI categories (cut-off BMI 25 kg/m2) were additionally performed. 
For a definition of both provoked and unprovoked venous thrombotic events see the 
Supporting Methods. 
In a separate analysis we assessed both the predictive value of FVIII antigen levels 
and of VWF antigen levels on incidence of recurrent venous thrombosis. 
Lastly, we studied how FVIII:C levels perform in an existing prediction model for 
recurrent venous thrombosis, i.e. the DASH-score.[14] For this, we first validated the 
DASH-score in our data. The DASH-score identifies patients with unprovoked first 
thrombosis at high or low recurrence risk by using the following risk variables: 1) 
abnormal D-dimer (cut-off 500 ng/mL; 2 points); 2) age (cut-off≤50 years at time of first 
event; 1 point); 3) sex (1 point for male); 4) hormone use at first event (-2 points if yes). 
We restricted our patient group according to the criteria that were used for derivation of 
the DASH-score, i.e. patients in whom the first event occurred in the absence of surgery, 
trauma, cancer, immobility or pregnancy/puerperium (n=1271; 57%) and in whom all 
items of the DASH-score were available. Furthermore, we excluded patients still taking 
anticoagulant therapy at time of blood sampling, finally leaving 1082 patients. Follow-
up was started after discontinuation of anticoagulant treatment, similar as for the 
DASH-score. Next, we assessed the model accuracy for various versions of the model 
by means of the c-statistic.[27] This included models adding FVIII:C levels to the DASH-
model and replacing D-Dimer by FVIII levels (‘FASH’-model). We performed similar 
analyses for levels of VWF. Statistical analyses were performed using SPSS, version 20.0 
(IBM Corp., Armonk, NY) and Stata, version 12 (Stata Corp., College Station, Texas).
Results
Clinical characteristics
2242 patients with a first episode of venous thrombosis were followed for recurrent 
events for a median of 6.9 years (interquartile range 2.7-8.0 years, total follow-up 
12,499 years). Mean age at enrollment was 48 years and 1010 (45%) patients were men. 
Of the first events, 1578 (72%) were provoked, with trauma, surgery or immobilization 
accounting for most of these events (n=895; 57%) (Table 1). Most (n=1322; 59%) first 
events were DVTs. Median time between first event and blood collection was 10.0 
months (interquartile range, 8.3-12.2 months). 
Incidence of recurrent venous thrombosis related to levels of FVIII activity
343 patients developed recurrent thrombosis during follow-up, for an overall incidence 
rate of 2.7/100 person-years (95%CI, 2.5-3.1). Of these events 54 occurred before blood 
collection. Median FVIII activity level for all participants was 134 IU/dL (interquartile 
range 107-165 IU/dL). When FVIII was included as a continuous variable in the Cox 
model, the hazard ratio of recurrent venous thrombosis was 1.06 (95%CI, 1.04-1.08) 
Table 1. Clinical characteristics
General characteristics MEGA follow-up cohort Included for analyses
Total 4731 (100) 2242 100
Men 2164 (46) 1010 (45)
Age at enrollment, y 48 (18-70) 48 (18-70)
Classical venous thrombosis risk factors
Provoked by* 3301 (72) 1578 (72)
Malignancy 426 (13) 127 (8)
Trauma/surgery/immobilization 1902 (58) 895 (57)
Plaster cast 219 (7) 109 (7)
Estrogen use (women) 1350 (41) 709 (45)
Pregnancy/puerperium (women) 173 (5) 92 (6)
Travel >4 hrs 717 (22) 374 (24)
Unprovoked 1299 (28) 621 (28)
Prothrombotic factor
Blood group non-O 2913 (71) 1591 (71)
Type of index event
Deep vein thrombosis only 2747 (58) 1322 (59)
Pulmonary embolism only 1549 (33) 702 (31)
Pulmonary embolism + deep vein thrombosis 435 (9) 218 (10)
Continuous variables denoted as mean (range), categorical variables as number (%). 
Some data were missing for some variables.




Factor VIII and recurrent venous thrombosis
121 
6 6
Table 2. Incidence rates (a) and cumulative incidences (b) of recurrent venous thrombosis for 
strata of factor VIII














Main analysis*      
FVIII:C (≤ 100 IU/dL) 438 2686 38 1.4 (1.0-1.9) 1 (reference)
FVIII:C (101-125 IU/dL) 516 3005 68 2.3 (1.8-2.9) 1.6 (1.1-2.4)
FVIII:C (126-150 IU/dL) 493 2775 83 3.0 (2.4-3.7) 2.1 (1.4-3.1)
FVIII:C (151-175 IU/dL) 382 2088 67 3.2 (2.5-4.1) 2.2 (1.5-3.3)
FVIII:C (176-200 IU/dL) 205 1028 40 3.9 (2.8-5.3) 2.7 (1.7-4.1)
FVIII:C (>200 IU/dL) 208 917 47 5.1 (3.8-6.8) 3.4 (2.2-5.3)
First DVT (n=1322)
FVIII:C (≤ 100 IU/dL) 243 1522 22 1.4 (0.9-2.2) 1 (reference)
FVIII:C (101-125 IU/dL) 301 1744 44 2.5 (1.8-3.4) 1.7 (1.0-2.9)
FVIII:C (126-150 IU/dL) 303 1750 56 3.2 (2.4-4.2) 2.2 (1.3-3.6)
FVIII:C (151-175 IU/dL) 233 1312 42 3.2 (2.3-4.3) 2.2 (1.3-3.6)
FVIII:C (176-200 IU/dL) 117 622 20 3.2 (2.0-5.0) 2.2 (1.2-4.0)
FVIII:C (>200 IU/dL) 125 577 28 4.9 (3.2-7.0) 3.2 (1.8-5.5)
First PE (with or without DVT) (n=920)
FVIII:C (≤ 100 IU/dL) 195 1164 16 1.4 (0.8-2.2) 1 (reference)
FVIII:C (101-125 IU/dL) 215 1260 24 1.9 (1.2-2.8) 1.4 (0.7-2.6)
FVIII:C (126-150 IU/dL) 190 1025 27 2.6 (1.7-3.8) 1.9 (1.0-3.5)
FVIII:C (151-175 IU/dL) 149 776 25 3.2 (2.1-4.8) 2.3 (1.2-4.3)
FVIII:C (176-200 IU/dL) 88 406 20 4.9 (3.0-7.6) 3.5 (1.8-6.7)
FVIII:C (>200 IU/dL) 83 340 19 5.6 (3.4-8.7) 3.9 (2.0-7.5)
CI denotes confidence interval; py, person-years; FVIII:C, factor VIII activity level 
* Sensitivity analyses presented in the supplementary material (Supporting Table 2)
2b. Cumulative incidences of recurrent venous thrombosis
Unprovoked first event (n=659) Provoked first event (n=1652)
Factor VIII category 1-year (95%CI) 5-years (95%CI) 1-year (95%CI) 5-years (95%CI)
FVIII:C (≤100 IU/dL)  4.9 (0.7-9.1) 16.3 (8.7-23.9) 2.0 (0.4-3.6) 5.9 (3.2-8.7)
FVIII:C (101-125 IU/dL)  5.8 (1.6-10.1) 17.7 (10.6-24.7) 4.2 (2.1-6.3) 8.8 (5.8-11.9)
FVIII:C (126-150 IU/dL)  9.2 (4.0-14.3) 21.9 (14.2-29.5) 3.6 (1.6-5.6) 11.1 (7.6-14.6)
FVIII:C (151-175 IU/dL)  8.2 (3.3-13.1) 20.9 (13.4-28.3) 6.1 (3.0-9.2) 13.4 (8.8-17.9)
FVIII:C (176-200 IU/dL) 15.0 (5.9-24.1) 32.5 (20.0-45.0) 3.1 (0.1-6.1) 12.6 (6.4-18.8)
FVIII:C (>200 IU/dL) 9.5 (2.2-16.8) 30.8 (18.9-42.7) 4.4 (0.6-8.3) 18.9 (11.1-26.7)
Total 8.2 (6.0-10.4) 21.9 (18.4-25.3) 3.8 (2.8-4.8) 10.5 (8.9-12.1)
DVT (n=1322) PE (with or without DVT) (n=920)
Factor VIII category 1-year (95%CI) 5-years (95%CI) 1-year (95%CI) 5-years (95%CI)
FVIII:C (≤100 IU/dL) 3.9 (1.9-6.0) 8.6 (5.4-12.8) 1.1 (0.2-3.6) 7.8 (4.4-12.5)
FVIII:C (101-125 IU/dL) 3.9 (2.1-6.6) 11.0 (7.6-15.2) 5.5 (2.9-9.2) 10.9 (7.0-15.7)
FVIII:C (126-150 IU/dL) 6.3 (3.9-9.5) 15.6 (11.6-20.2) 2.9 (1.1-6.2) 10.7 (6.5-16.2)
FVIII:C (151-175 IU/dL) 6.2 (3.6-9.9) 14.7 (10.3-19.9) 7.4 (3.8-12.6) 17.3 (11.3-24.3)
FVIII:C (176-200 IU/dL) 5.3 (2.2-10.5) 18.6 (11.7-26.7) 8.9 (4.0-16.5) 19.9 (11.5-30.1)
FVIII:C (>200 IU/dL) 6.5 (2.9-12.2) 24.6 (16.5-33.6) 5.4 (1.7-12.2) 20.3 (11.4-31.0)
Total 5.2 (6.5-4.1) 14.1 (26.2-12.2) 4.6 (3.3-6.2) 12.8 (10.5-15.2)
CI denotes confidence interval; py, person-years; FVIII:C, factor VIII activity level 
for each increase of 10 IU/dL. Incidence rates of recurrence clearly increased with 
categories of FVIII activity levels, from 1.4 (95%CI, 1.0-1.9) per 100 patient-years for 
levels below 100 IU/dL to 5.1 (95%CI, 3.8-6.8) above 200 IU/dL (Table 2a). Corresponding 
hazard ratios are additionally presented in Table 2a. The p-value for the interaction 
term between log(time) and categories of FVIII was non-significant (p=0.62), which 
means that hazards were found to be proportional over time.
All sensitivity analyses (Supporting Table2), in which we, amongst others excluded 
patients who donated blood during their anticoagulant treatment period, showed 
similar results, i.e., a graded increase in the incidence of recurrence for higher levels 
of FVIII activity. Results were similar for patients with a first DVT and patients with a 
first PE. 
The cumulative incidence of recurrent venous thrombosis in patients with FVIII 
levels below 100 IU/dL was 5% after 2 years, 7% after 4 years and 10% after 8 years 
of follow-up (Fig1). For patients with FVIII levels above 200 IU/dL, these risks were 
13%, 21%, and 31%, respectively. Cumulative incidences were higher for unprovoked 
than for provoked first events, and invariably peaked for high FVIII levels (Table 2b). 
Five-year cumulative incidences of recurrence for patients with a first unprovoked 
event were 16.3% (95%CI, 8.7-23.9) and 30.8% (95%CI,18.9-42.7) for levels ≤100 IU/
dL and for levels >200 IU/dL, respectively. For patients with a provoked first event 
these cumulative incidences were 5.9% (95%CI, 3.2-8.7) and 18.9% (95%CI, 11.1-26.7), 
respectively.
Figure 1. Survival curves of recurrent venous thrombosis for strata of factor VIII levels. FVIII:C 
denotes factor VIII activity.
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Incidence of recurrent venous thrombosis related to FVIII antigen and VWF antigen 
levels
Median FVIII antigen level was 146 IU/dL (interquartile range 115-185 IU/dL) and median 
VWF antigen was 138 IU/dL (interquartile range 109-174 IU/dL). The recurrence rate 
was 1.1 per 100 person-years (95%CI, 0.7-1.6) for patients with factor VIII antigen levels 
≤100 IU/dL, while it was 5.3 per 100 person-years (95%CI, 4.1-6.9) for patients with 
levels >225. For VWF these rates were 1.3 per 100 person-years (95%CI, 0.9-1.8) and 
5.6 per 100 person-years (95%CI, 4.1-7.5), respectively. Incidence rates of recurrence 
increased gradually for increasing levels of FVIII antigen and VWF antigen, in a similar 
fashion as the FVIII activity levels (Table 3). 
Subgroup analyses
We stratified patients into those with first provoked or unprovoked first events, by sex, 
by age and by BMI (Table 4). Mean FVIII levels were slightly higher in unprovoked than 
provoked thrombosis, and older and overweight patients (Table 4). Rates of recurrence 
were highest in men and after an unprovoked first event.[2-4,26] Within all subgroups 
there was a dose-dependent increase in recurrence incidence for increasing levels of 
FVIII. Excluding patients with a malignancy did not materially affect the results. Blood 
group non-O was associated with an increase in risk of recurrence of 30% (HR 1.3 
(95%CI, 1.0-1.7) compared with blood group O. Both for blood group O and non-O 
a graded increase in recurrence risk was observed for increasing FVIII activity levels 
(Table 5). 
Table 3. Incidence rates of recurrent venous thrombosis for strata of factor VIII antigen and von 
Willebrand factor




Incidence rate, per 
100 py (95% CI)
Hazard ratio 
(95% CI)
FVIIIag (≤ 100 IU/dL) 347 2111 23 1.1 (0.7-1.6) 1 (reference)
FVIIIag (101-125 IU/dL) 383 2283 47 2.1 (1.5-2.7) 1.9 (1.1-3.1)
FVIIIag (126-150 IU/dL) 465 2673 64 2.4 (1.8-3.1) 2.2 (1.4-3.5)
FVIIIag (151-175 IU/dL) 366 1967 68 3.5 (2.7-4.4) 3.1 (1.9-5.0)
FVIIIag (176-200 IU/dL) 253 1422 47 3.3 (2.4-4.4) 3.0 (1.8-4.9)
FVIIIag (201-225 IU/dL) 182 943 36 3.8 (2.7-5.3) 3.4 (2.0-5.8)
FVIIIag (>225 IU/dL) 244 1087 58 5.3 (4.1-6.9) 4.6 (2.9-7.5)
VWFag (≤ 100 IU/dL) 424 2598 33 1.3 (0.9-1.8) 1 (reference)
VWFag (101-125 IU/dL) 446 2520 67 2.7 (2.1-3.4) 2.1 (1.4-3.1)
VWFag (126-150 IU/dL) 505 2957 62 2.4 (1.8-3.1) 1.6 (1.1-2.5)
VWFag (151-175 IU/dL) 320 1757 63 3.6 (2.8-4.6) 2.8 (1.8-4.2)
VWFag (176-200 IU/dL) 252 1320 47 3.6 (2.6-4.7) 2.7 (1.8-4.3)
VWFag (201-225 IU/dL) 109 563 27 4.8 (3.2-7.0) 3.7 (2.2-6.1)
VWFag (>225 IU/dL) 186 784 44 5.6 (4.1-7.5) 4.1 (2.6-6.5)
CI denotes confidence interval; py, person-years; FVIIIag, factor VIII antigen level; VWFAg, von 
Willebrand factor antigen


































 Men (n=1010)  Women (n=1232)  Unprovoked* (n=621)
 
Mean FVIII:C 141 
(95%CI, 138-144)  
Mean FVIII:C 139 
(95%CI, 136-141)  
Mean FVIII:C 146 
(95%CI, 142-150)
FVIII:C (≤ 100 IU/dL) 2.2 (1.4-3.2) 1 (reference)  0.9 (0.5-1.5) 1 (reference)  2.5 (1.4-4.2) 1 (reference)
FVIII:C (101-125 IU/dL) 3.1 (2.2-4.3) 1.4 (0.9-2.4)  1.6 (1.1-2.3) 1.8 (1.0-3.5)  3.3 (2.1-4.9) 1.3 (0.7-2.5)
FVIII:C (126-150 IU/dL) 4.8 (3.6-6.3) 2.1 (1.3-3.5)  1.9 (1.3-2.6) 2.1 (1.1-4.0)  4.9 (3.4-6.9) 1.9 (1.0-3.5)
FVIII:C (151-175 IU/dL) 4.8 (3.5-6.3) 2.1 (1.3-3.5)  1.7 (1.0-2.7) 1.9 (0.9-3.8)  4.9 (3.4-6.9) 1.9 (1.0-3.5|)
FVIII:C (176-200 IU/dL) 6.0 (3.9-9.0) 2.6 (1.5-4.6)  2.5 (1.4-4.1) 2.8 (1.4-5.8)  6.8 (4.2-10.5) 2.6 (1.3-5.0)
FVIII:C (>200 IU/dL) 5.8 (3.8-8.6) 2.5 (1.4-4.4)  4.5 (2.8-6.9) 4.9 (2.5-9.6)  7.1 (4.4-10.7) 2.6 (1.4-5.1)
         
 Provoked (n=1578)  Provoked minus malignancy 
(n=1451)
 Age <45 years (n=884)
 
Mean FVIII:C 137
 (95%CI, 135-140)  
Mean FVIII:C 136 
(95%CI, 134-138)  
Mean FVIII:C 130 
(95%CI, 127-133)
FVIII:C (≤ 100 IU/dL) 1.1 (0.7-1.6) 1 (reference)  1.1 (0.7-1.6) 1 (reference)  1.0 (0.6-1.7) 1 (reference)
FVIII:C (101-125 IU/dL) 2.0 (1.4-2.6) 1.8 (1.1-3.0)  1.9 (1.4-2.6) 1.8 (1.0-3.0)  2.8 (2.0-3.9) 2.7 (1.5-5.0)
FVIII:C (126-150 IU/dL) 2.4 (1.8-3.2) 2.2 (1.3-3.6)  2.3 (1.7-3.1) 2.1 (1.3-3.6)  2.3 (1.5-3.5) 2.2 (1.2-4.3)
FVIII:C (151-175 IU/dL) 2.4 (1.7-3.4) 2.2 (1.3-3.8)  2.5 (1.7-3.5) 2.2 (1.3-3.9)  2.4 (1.4-4.0) 2.3 (1.1-4.7)
FVIII:C (176-200 IU/dL) 2.7 (1.6-4.2) 2.5 (1.3-4.6)  2.9 (1.7-4.5) 2.6 (1.4-4.9)  2.0 (0.7-4.4) 1.9 (0.7-4.9)
FVIII:C (>200 IU/dL) 4.2 (2.7-6.3) 3.7 (2.1-6.6)  3.6 (2.2-5.6) 3.2 (1.7-5.9)  4.2 (2.0-7.7) 3.8 (1.7-8.6)
         
 Age>45 years (n=1358)  BMI<25 kg/m2 (n=805)  BMI>25 kg/m2 (n=1335)
 
Mean FVIII:C 146 
(95%CI, 144-149)  
Mean FVIII:C 136 
(95%CI, 132-139)  
Mean FVIII:C 142 
(95%CI, 139-144)
FVIII:C (≤ 100 IU/dL) 1.9 (1.2-2.9) 1 (reference)  1.2 (0.6-1.9) 1 (reference)  1.7 (1.1-2.5) 1 (reference)
FVIII:C (101-125 IU/dL) 1.8 (1.2-2.6) 1.0 (0.6-1.7)  2.3 (1.4-3.3) 1.9 (1.0-3.7)  2.3 (1.6-3.1) 1.4 (0.8-2.3)
FVIII:C (126-150 IU/dL) 3.4 (2.6-4.4) 1.8 (1.1-2.8)  3.2 (2.1-4.5) 2.7 (1.4-5.0)  3.0 (2.3-4.0) 1.8 (1.1-2.9)
FVIII:C (151-175 IU/dL) 3.6 (2.6-4.7) 1.8 (1.1-3.0)  3.4 (2.2-5.0) 2.8 (1.5-5.4)  2.9 (2.1-4.0) 1.7 (1.0-2.9)
FVIII:C (176-200 IU/dL) 4.7 (3.2-6.5) 2.4 (1.4-4.0)  2.8 (1.3-5.3) 2.3 (1.0-5.3)  4.2 (2.8-6.2) 2.5 (1.4-4.3)
FVIII:C (>200 IU/dL) 5.4 (3.8-7.5) 2.7 (1.6-4.6)  5.1 (2.9-8.4) 4.1 (2.0-8.4)  5.5 (3.7-7.7) 3.1 (1.8-5.4)
CI denotes confidence interval; py, person years; FVIII:C, factor VIII activity level
* Numbers of unprovoked and provoked do not add up to a total of 2242 because some data were missing for some variables 
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Performance of FVIII in a prognostic model
We first validated the DASH-score in our study. The annual rates of recurrent venous 
thrombosis increased with every point increase of the DASH-score, although less 
pronounced than in the original article (Supporting Table3). The discriminative ability 
of different models, including FVIII, the DASH-score, the DASH-score + FVIII and the 
‘FASH’-score (replacing D-Dimer with FVIII) is shown in Table 6. The c-statistic was 0.64 
(95%CI, 0.61-0.68) for the DASH-model, which became slightly higher when FVIII levels 
were added, i.e., 0.68 (difference 0.032, 95%CI, 0.004-0.061, p= 0.026). For the ‘FASH’-
score, the c-statistic became 0.67 (difference 0.022, 95%CI, -0.016; 0.059, p-value 
0.264). When we added levels of VWF to the DASH-model the C-statistic was 0.67 
(95%CI, 0.63-0.70), while it was 0.65 (95%CI, 0.61-0.69) in case D-dimer levels were 
replaced by levels of VWF.















O FVIII:C (≤ 100 IU/dL) 236 1431 15 1.0 (0.6-1.7) 1 (reference)
O FVIII:C (101-200 IU/dL) 378 2094 61 2.9 (2.2-3.7) 2.2 (1.4-3.6)
O FVIII:C (>200 IU/dL) 31 129 7 5.4 (2.2-11.2) 4.5 (2.1-9.8)
Non-O FVIII:C (≤ 100 IU/dL) 202 1255 23 1.8 (1.2-2.7) 1 (reference)
Non-O FVIII:C (101-200 IU/dL) 1214 6784 197 2.9 (2.5-3.3) 1.8 (1.2-2.7)
Non-O FVIII:C (>200 IU/dL) 175 783 40 5.1 (3.6-7.0) 3.3 (2.0-5.3)
CI denotes confidence interval; py, person-years
Table 6. Discriminative ability of different models within 
MEGA follow-up study 
Model  C-statistic (95%CI)
Factor VIII (continuous)  0.60 (0.56-0.64)
Factor VIII (categorical)  0.60 (0.56-0.64)
DASH  0.64 (0.61-0.68)
DASH + factor VIII (continuous)  0.67 (0.64-0.71)
DASH + factor VIII (categorical)  0.68 (0.64-0.71)
‘FASH’  0.67 (0.63-0.70)
CI denotes confidence interval
Discussion 
We followed 2242 patients with a first venous thrombosis for a median of 6.9 years 
and observed steadily increasing incidence rates of recurrent venous thrombosis with 
increasing FVIII levels, with a three-fold higher risk in those with FVIII levels over 200 
IU/dL vs the lowest category (≤100 IU/dL). The assumption of proportional hazards over 
time held, which implies that levels of FVIII were able to predict recurrent thrombosis 
over long periods of time. We found higher incidence rates of recurrence for increasing 
levels of FVIII both in patients with unprovoked as in patients with provoked first events 
but the rate was maximum in patients with a high FVIII level who had a first unprovoked 
event. Lastly, we found that adding FVIII levels to an existing prediction model improved 
its performance. 
Results from previous smaller studies have been contradictory.[10,15,26,27] In a study 
in our center (n=474), we did not find a relation between high FVIII activity levels and 
recurrent venous thrombosis (HR 1.1; 95%CI, 0.7-1.8),[26] possibly due to a low FVIII 
cut-off level (>166 IU/dL) to dichotomize patients.[28] Similar to Kyrle et al[15], we 
found the highest incidences of recurrence for patients with highest FVIII, although 
they reported an increased risk of recurrence only for patients with FVIII>234 IU/dL. 
We found recurrence rates to increase in a dose-response fashion with increasing 
levels of factor VIII. Cristina et al. found no relationship in patients with a provoked 
first event[27], which may be explained by a small group size (14 recurrences in 255 
patients). We found an association between levels of factor VIII and recurrent venous 
thrombosis both in patients with a first unprovoked, as well as a first provoked event. 
Within exposures that are currently thought to be associated with a low recurrence risk 
(provoked first event, women), high FVIII was still predictive for recurrent events. This 
implies that a more refined risk estimation is possible at an individual level. However, 
venous thrombosis is a multicausal disease and prediction of recurrence based on one 
factor is not sufficient to guide treatment duration.[29,30] Therefore we assessed the 
performance of FVIII in a prognostic model, in several combinations. When we added 
FVIII to the DASH-score, the model performed somewhat better. When we replaced 
D-dimer levels in the DASH-score by FVIII levels, the model performed equally well 
if not better. This may have considerable implications for the clinic since FVIII levels 
can be measured without error both during as well as after anticoagulant treatment 
with vitamin-K antagonists. Results of our sensitivity analysis in which we excluded 
patients who donated blood during their anticoagulant treatment period showed 
similar results as our main analysis. This would offer an important clinical advantage of 
FVIII over D-dimer measurement, which is affected by anticoagulant treatment.[31-33] 
Of note, measurement of factor VIII activity is also influenced by the new anticoagulant 
treatments (DOACs) that became recently available.[34,35]
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In patients with a first venous thrombosis the average risk of recurrence is not high 
enough to outbalance the bleeding risk associated with continued anticoagulant 
treatment. Refinement of the size of the risk for subgroups is one way to aid in the 
decision to continue or not. For this, the results in Tables 2b and 4 can be of use. 
Furthermore, case-fatality rates of recurrent venous thrombosis and major bleeding 
events can be helpful in balancing the risks and benefits of different anticoagulant 
treatment strategies.[36] For example, the risk of recurrent venous thrombosis is 8.2% 
in the year after discontinuing anticoagulants in patients with an unprovoked first 
event and a FVIII level between 150 and 175 IU/dL (Table 2b). Should anticoagulant 
treatment be continued if this risk then drops to 0.5% at the cost of a 2.0% risk of a 
major bleeding event? In this example the additional mortality risk for bleeding would 
not outweigh the mortality benefit of reduced thrombosis (8.2% risk x 3.6% case-fatality 
rate of recurrent venous thrombosis[36] = 0.30% fatal events without continuation of 
anticoagulant treatment vs. 2.0% risk x 11.0% case-fatality rate of major bleeding[36] 
= 0.22% fatal bleeding events + 0.5% risk x 3.6% case-fatality rate of recurrent venous 
thrombosis = 0.24% fatal events with continued anticoagulant treatment). 
Important strengths of our study are that this is the largest study till date on this issue 
in which patients were followed for a long period of time after their first event (median 
7 years) and in which recurrent events were objectively confirmed and strictly classified 
as such. Furthermore, because of the large size several sensitivity analyses as well as 
subgroup analyses could be performed showing detailed and precise risk estimates. 
We are the first to externally validate the performance of the DASH-score and have 
shown the performance of the score with inclusion of factor VIII into the model. 
Limitations of our study should also be mentioned. First, factor VIII can be increased 
in patients due to an acute phase reaction at the time of the first event. To avoid this 
problem, blood was drawn at least three months after the first event, in an outpatient 
setting. In a similar setting Tichelaar et al showed that factor VIII levels are fairly 
constant over time.[37] Second, FVIII levels were measured only once during follow-
up. However, serial measurements of FVIII over time after venous thrombosis have 
shown that they remain reasonably constant and that high FVIII levels are a persistent 
phenomenon, which is in line with the predictive strength we found to be present over 
a prolonged period.[10,11,37] Third, FVIII levels were not measured in all patients, 
mainly because of logistic reasons. However, some may have been additionally missing 
in patients who were sickest. While this does not compromise the internal validity of 
our results, as we did not pose a causal question, it may imply that our results are 
generalizable only to those patients well enough to provide a blood sample. Fourth, 
since we used a strict definition of recurrent venous thrombosis and included only 
certain recurrences in our study, incidence rates and cumulative incidences may have 
been slightly underestimated. Fifth, our study consisted for 90% of Caucasians and 
hence our results may not be generalizable to other ethnic groups. Sixth, because our 
aim was to study whether levels of FVIII predict future recurrent events we did not 
adjust for potential confounding factors. Therefore, this study provides no information 
on whether FVIII is causally related to recurrent thrombosis. Finally, although high FVIII 
levels predicted increased risks of recurrent venous thrombosis in both patients in 
whom the first event was either provoked or unprovoked, we cannot currently provide 
sufficient information whether the recurrent episodes were unprovoked or provoked 
in nature.
In summary, this study presents detailed evidence for a strong predictive value of 
FVIII levels for the risk of recurrent venous thrombosis in a large unselected group 
of patients with long follow-up. FVIII levels predicted recurrences in a dose-response 
fashion in various subgroups of patients over a long period of time. Addition of FVIII to 
an existing prognostic model, the DASH-score, improved the model’s performance and 
D-Dimer could be replaced by FVIII levels without loss of predictive accuracy. 
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Supporting Table 1. Clinical characteristics of participants included and excluded from 
analyses
General characteristics Included in 
current analyses
 Excluded from 
current analyses
Total 2242 (100)  2489 (100)
Men 1010 (45)  1154 (46)
Age at enrollment, y 48 (18-70)  49 (18-70)
BMI 27 (16-58)  27 (14-63)
Chronic disease at baseline* 328 (15)  403 (16)
Classical venous thrombosis risk factors  
Provoked by† 1578 (72)  1723 (72)
Malignancy 127 (8)  299 (17)
Trauma/surgery/immobilization 895 (57)  1007 (58)
Plaster cast 109 (7)  110 (6)
Estrogen use (in women) 92 (45)  641 (37)
Pregnancy/puerperium (in women) 374 (6)  81 (5)
Travel >4 hrs 374 (24)  343 (20)
Unprovoked 621 (28)  678 (28)
Prothrombotic factor  
Blood group non-O 1591 (71)  1322 (71)
Type of index event  
Deep vein thrombosis only 1322 (59)  1425 (57)
Pulmonary embolism only 702 (31)  847 (34)
Pulmonary embolism + deep vein thrombosis 218 (10)  217 (9)
Continuous variables denoted as mean (range), categorical variables as number (%).   
Some data were missing for some variables. 
* Chronic disease defined as diabetes, liver disease, kidney disease, rheumatoid arthritis, 
multiple sclerosis, paralysis, hyperthyroidism, hypothyroidism, chronic bronchitis, 
eymphysema.
† As concomitance of provoked risk factors occurred frequently, patients could be 
counted twice or more. 
Supporting Methods
To be classified as a certain recurrence, a reported recurrence should fulfil one of the 
following criteria. 
1. A discharge letter was present concluding a diagnosis of recurrence, based on 
available clinical and radiological data. This recurrence should be in a different vein 
or in a different part of the body than the first event. The discharge letter had to 
contain information about instrumental diagnostic procedures. If location of either 
first or second thrombosis was not known or was similar to the first event, an event 
was still classified as certain if at least three months had passed since the first 
thrombosis. 
2. A discharge letter was not available (e.g. when treating physician was unknown) but 
both the anticoagulation clinic and the patient reported a recurrence at a clearly 
different location than the first event (contralateral leg, DVT after PE or vice versa) 
or a time period of more than a year had passed between the two events.
3. A registered cause of death from PE or DVT at least six months after the first event. 
Uncertain recurrences were defined by four criteria, one of which had to apply: 
1. A diagnosis of a possible recurrence in the discharge letter, where clinical and 
radiological data could not distinguish between an extension of the first and a new 
thrombotic event. 
2. A discharge letter was not available but both the patient and the anticoagulation 
clinic reported a recurrence within a year after the first event. 
3. Information was only available from either the patient or the anticoagulation clinic.
4. A registered cause of death from PE or DVT within six months after the first event.
To quantify potential misclassification of outcomes, several sensitivity analyses were 
performed; one in which hazard ratios were corrected for time between the first 
thrombotic event and blood collection (n=2242), one in which all patients lost to follow-
up were considered to have developed a recurrent event at the end of the study (for 
which the date of the recurrent event was set at the date on which the vital status was 
checked) (n=2242), one with start of follow-up from first thrombotic event (n=2357), 
one with patients with an active malignancy at time of the index date excluded from 
analysis (n=2115 included, n=127 excluded), one in which both certain and uncertain 
recurrent events are taken into account (n=2242, 427 recurrent events) and lastly, 
one with participants on anticoagulant treatment at the moment of blood collection 
excluded (n=2045 included, n=197 excluded). 
Unprovoked first venous thrombosis was defined as venous thrombosis without surgery, 
trauma, plaster cast, pregnancy or immobilization in the first three months before the 
event, prolonged travel in the first two months before the event, active malignancies 
in the first five years before the event or hormone use (oral contraceptives or hormone 
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replacement therapy) at the time of the event. Patients who had one or more of these 
risk factors at time of their first event were classified as having a first provoked venous 
thrombosis.












FVIII:C (≤ 100 IU/dL) 438 2686 38 1.4 (1.0-1.9) 1 (reference)
FVIII:C (101-125 IU/dL) 516 3005 68 2.3 (1.8-2.9) 1.6 (1.1-2.4)
FVIII:C (126-150 IU/dL) 493 2775 83 3.0 (2.4-3.7) 2.1 (1.4-3.0)
FVIII:C (151-175 IU/dL) 382 2088 67 3.2 (2.5-4.1) 2.3 (1.5-3.4)
FVIII:C (176-200 IU/dL) 205 1028 40 3.9 (2.8-5.3) 2.7 (1.7-4.1)
FVIII:C (>200 IU/dL) 208 917 47 5.1 (3.8-6.8) 3.5 (2.3-5.3)
Sensitivity analysis 2†   
FVIII:C (≤ 100 IU/dL) 438 2973 95 3.2 (2.6-3.9) 1 (reference)
FVIII:C (101-125 IU/dL) 516 3270 133 4.1 (3.4-4.8) 1.3 (1.0-1.7)
FVIII:C (126-150 IU/dL) 493 3063 154 5.0 (4.3-5.9) 1.6 (1.2-2.1)
FVIII:C (151-175 IU/dL) 382 2277 111 4.9 (4.0-5.9) 1.6 (1.2-2.0)
FVIII:C (176-200 IU/dL) 205 1172 72 6.1 (4.8-7.7) 2.0 (1.4-2.7)
FVIII:C (>200 IU/dL) 208 1066 90 8.4 (6.8-10.4) 2.7 (2.0-3.6)
Sensitivity analysis 3‡   
FVIII:C (≤ 100 IU/dL) 451 2978 39 1.3 (0.9-1.8) 1 (reference)
FVIII:C (101-125 IU/dL) 531 3359 72 2.1 (1.7-2.7) 1.6 (1.1-2.4)
FVIII:C (126-150 IU/dL) 522 3232 86 2.7 (2.1-3.3) 2.0 (1.4-2.9)
FVIII:C (151-175 IU/dL) 402 2439 72 3.0 (2.3-3.7) 2.2 (1.5-3.3)
FVIII:C (176-200 IU/dL) 219 1209 41 3.4 (2.4-4.6) 2.5 (1.6-3.9)
FVIII:C (>200 IU/dL) 232 1151 51 4.4 (3.3-5.8) 3.3 (2.2-5.0)
Sensitivity analysis 5§   
FVIII:C (≤ 100 IU/dL) 422 2591 37 1.4 (1.0-2.0) 1 (reference)
FVIII:C (101-125 IU/dL) 492 2898 65 2.2 (1.7-2.9) 1.6 (1.0-2.3)
FVIII:C (126-150 IU/dL) 464 2636 79 3.0 (2.4-3.7) 2.1 (1.4-3.1)
FVIII:C (151-175 IU/dL) 360 1992 65 3.3 (2.5-4.2) 2.2 (1.5-3.4)
FVIII:C (176-200 IU/dL) 191 955 39 4.0 (2.9-5.6) 2.8 (1.8-4.3)
FVIII:C (>200 IU/dL) 186 856 41 4.8 (3.4-6.5) 3.2 (2.0-5.0)
Sensitivity analysis 6¶   
FVIII:C (≤ 100 IU/dL) 438 2686 46 1.7 (1.3-2.3) 1 (reference)
FVIII:C (101-125 IU/dL) 516 3005 82 2.7 (2.2-3.4) 1.6 (1.1-2.3)
FVIII:C (126-150 IU/dL) 493 2775 95 3.4 (2.8-4.2) 2.0 (1.4-2.8)
FVIII:C (151-175 IU/dL) 382 2088 87 4.2 (3.3-5.1) 2.4 (1.7-3.4)
FVIII:C (176-200 IU/dL) 205 1028 53 5.2 (3.9-6.7) 2.9 (2.0-4.3)
FVIII:C (>200 IU/dL) 208 917 64 7.0 (5.4-8.9) 3.8 (2.6-5.6)
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Sensitivity analysis 7**   
FVIII:C (≤ 100 IU/dL) 415 2605 28 1.1 (0.7-1.6) 1 (reference)
FVIII:C (101-125 IU/dL) 477 3118 53 1.7 (1.3-2.2) 1.7 (1.1-2.7)
FVIII:C (126-150 IU/dL) 454 2882 67 2.3 (1.8-3.0) 2.3 (1.5-3.6)
FVIII:C (151-175 IU/dL) 345 2156 52 2.4 (1.8-3.2) 2.4 (1.5-3.8)
FVIII:C (176-200 IU/dL) 182 1063 33 3.1 (2.1-4.4) 3.2 (1.9-5.2)
FVIII:C (>200 IU/dL) 172 886 35 3.9 (2.8-5.5) 4.0 (2.5-6.6)
Supporting Table 2. Incidence rates of recurrent venous thrombosis for strata of factor VIII; 
sensitivity analyses (continued)
CI denotes confidence interval; py, person-years; FVIII:C, factor VIII activity level
* Hazard ratios corrected for time between first thrombotic event and blood collection
† Patients lost to follow-up all considered as having developed a recurrent event at end of the 
study
‡ Start of follow-up from first thrombotic event
§ Malignancy patients excluded
¶ Certain and uncertain recurrent events taken into account
** Participants on anticoagulant treatment at moment of blood collection excluded
Supporting Table 3. Validation of the DASH score in the MEGA follow-up study
DASH score
 
Recurrence/total  Incidence rate, 
per 100 py
(95% CI)
-2 1/69  0.23 (0.03-1.63)
-1 19/250  1.22 (0.78-1.92)
0 18/95  3.08 (1.94-4.90)
+1 50/285  2.96 (2.24-3.91)
+2 36/191  3.27 (2.36-4.53)
+3 44/162  4.95 (3.69-6.66)
+4 11/30  8.23 (4.56-14.85)
py denotes: person-years
Supporting Figure 1. Flowchart of patients included and excluded from analyses










No consent for follow-up
N=225
Not eligible for blood sampling because of 
thrombosis date after June 2002
N=1609
End of follow-up before discontinuation of 
anticoagulant treatment
N=117
Levels of factor VIII were not 
accurately measured
N=29
Included in final 
analyses
N=2242
No blood sample available because patients died before 
moment of blood collection, patients were unable to visit 
hospital or patients were unwilling to provide blood sample
N=734
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premenopausal women: effect of continuing 
or starting hormonal contraceptive use
Bernardine H. Stegeman, Jasmijn F. Timp, Linda E. Flinterman, Frans M. Helmerhorst, 









There is a large body of literature available on hormonal contraceptive use and the risk 
of a first venous thrombotic event. Despite guideline recommendations to discontinue, 
a sizeable proportion of women continue or start using hormonal contraceptives after 
a venous thrombosis. The aim of this study was to evaluate the effect of this use on the 
risk of recurrence in premenopausal women. 
Methods
Premenopausal female patients with a first venous thrombosis, included in the MEGA 
case-control study between 1999 and 2004, were followed for a recurrent venous 
thrombotic event up to 2010. Data on hormonal contraceptive use were available 
through a prescription database (from Dutch Foundation for Pharmaceutical Statistics). 
Time-dependent Cox-proportional hazards models were used to estimate hazard ratios 
(HR) with 95% confidence intervals (CI), adjusted for age and BMI at baseline and 
anticoagulation use. 
Results
650 women were linked to the prescription database and followed for a total of 
3537 person-years (median 6.1 years; range, 41 days to 9.7 years). 57 women had a 
recurrence, of which 14 were during hormonal contraceptive use. Irrespective of 
contraceptive use at the first event, any type of hormonal contraceptive use increased 
the risk of recurrence about two-fold (HR 1.8, 95%CI: 0.9 to 3.3). Using combined oral 
contraceptives after the first event increased the risk almost three-fold (HR 2.6, 95%CI: 
1.3 to 5.2). The recurrence rate among IUD users was found to be similar to the rate 
among non-users (HR 0.9, 95%CI: 0.3-3.1). 
Conclusion
Hormonal contraceptive use after a first venous thrombosis increases the risk of a 
recurrent venous thrombotic event. A levonorgestrel-releasing intra-uterine device 
may be a safe alternative.
Introduction
A large body of literature is available about combined oral contraceptive use and the 
increased risk of a first venous thrombosis.[1-4] National[5,6] and international[7] 
guidelines state to discontinue hormonal contraceptive use after a venous thrombotic 
event, in particular combined preparations (oral contraceptive, transdermal patch 
and vaginal ring) with the idea of preventing recurrences. Despite these guidelines, 
a large proportion of women either continues or starts hormonal contraceptive use 
after a first venous thrombosis. One study found that 39% of women using hormonal 
contraceptives at the first event either continued or restarted afterwards.[8] In the 
present study about three months after stopping anticoagulation therapy, 21% of 
combined oral contraceptive users continued their contraceptive use.[9] 
Discontinuation of hormonal contraceptives could be a small intervention on a 
woman’s lifestyle, with potentially large preventive effects with regard to the risk of 
recurrent venous thrombosis. Nevertheless, not much is known about the association 
between hormonal contraceptive use and recurrent venous thrombosis, except for 
one report by Christiansen et al.[10] In this study, the risk of recurrence was fourfold 
increased in users of hormonal contraceptives compared with non-users. The number 
of recurrences was too few to allow meaningful conclusions about the type of 
contraceptive. 
The aim of the present study was to evaluate the effect of hormonal contraceptive 
use, administration route and type of combined oral contraceptive (dose of 
ethinylestradiol and type of progestagen) on the risk of recurrent venous thrombosis in 
premenopausal women with a first venous thrombosis. 
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Participants were cases from a population-based case-control study; the Multiple 
Environmental and Genetic Assessment of venous thrombosis (MEGA) study. Details 
of the study have been described elsewhere.[11] In short, between 1 March 1999 and 
31 August 2004, 4956 consecutive patients with an objectively diagnosed first deep 
vein thrombosis of the leg or pulmonary embolism were included. Patients were aged 
18-70 years and were enrolled from six anticoagulation clinics in the Netherlands. 
Anticoagulation clinics monitor all patients taking vitamin K antagonists in a well-
defined geographical area. All patients filled in a questionnaire on risk factors for venous 
thrombosis. About three months after discontinuation of the anticoagulation therapy, 
patients were invited to the anticoagulation clinic for a blood sample. During this visit 
participants were interviewed regarding the period from the venous thrombotic event 
until venepuncture. This interview included items on possible change of hormonal 
contraceptive methods since the diagnosis of venous thrombosis. 
Of 4956 eligible patients, 4731 gave informed consent for follow-up. Short answer 
forms, regarding recurrent venous thrombosis, were sent by mail to patients between 
January 2008 and December 2009. Questions were asked by telephone interview 
when answer forms were not returned. During the same period information about 
recurrences was retrieved from the anticoagulation clinics where patients were initially 
included for their first event and, in case they moved house, at the clinic nearest to 
their new address. Deaths due to recurrent venous thrombosis were obtained at the 
Central Bureau of Statistics (CBS). To obtain information on diagnostic procedures, 
discharge letters were requested from the clinician who diagnosed the recurrence 
according to the patient or the anticoagulation clinic. A detailed questionnaire on risk 
factors for venous thrombosis during follow-up was sent to participants after they gave 
permission for this in the short answer form. Details of the follow-up study have been 
described elsewhere.[12] This study was approved by the Medial Ethics Committee of 
the Leiden University Medical Center. 
For the current analyses, we focussed on premenopausal women with venous 
thrombosis before age 50 (N=1584). Women who had cancer in the five years before 
the first venous thrombosis or undergoing chemo- or radiotherapy were excluded 
(N=60). Women who were unlikely to use contraceptives due to various reasons were 
excluded, i.e., pregnant or postpartum women (N=35), current HRT users (N=53), self-
reported peri- or postmenopausal women (N=52), underweight women (N=1) and 
32 women who had undergone a hysterectomy or oophorectomy. The population of 
interest consisted of 1351 premenopausal women. 
Hormonal contraceptives
Hormonal contraceptive use was defined as use of a contraceptive that contains steroid 
hormones, administered orally, transdermally or vaginally. Users of a copper-IUD were 
considered non-users. Hormonal contraceptive use was categorised according to the 
route of administration into oral and non-oral preparations. Oral preparations were 
stratified into combined and progestagen-only preparations. Because many different 
preparations of combined oral contraceptives are available, these contraceptives were 
categorised according to the dose of ethinylestradiol and type of progestagen. Non-
oral preparations were further stratified according to the specific application (vaginal 
ring, transdermal patch, implant, injectable, and levonorgestrel-releasing intrauterine 
device (IUD)). 
Data on hormonal contraceptive use were available through two sources; a 
prescription database (the Dutch Foundation for Pharmaceutical Statistics (SFK) registry)
[13] and the detailed questionnaire filled in at the end of follow-up. Participants in the 
MEGA follow-up study were linked to the prescription database via age, sex, 4 digits 
postal code and vitamin K antagonist use within the first month after the initial venous 
thrombosis. The national ID number was not available for linkage and abovementioned 
factors were not unique for every participant. Therefore, 650 (48%) of premenopausal 
women could be successfully linked to the prescription database. Linkage was a random 
process since being unique on the variables according to which linkage was performed 
is not associated with either recurrent venous thrombosis or use of contraceptives. 
The following information was available from SFK; date of prescription, name of the 
contraceptive and the amount and defined daily dosage (DDD) of the prescription. 
Periods of contraceptive use were defined as continuous use of contraceptive based 
on the normal duration of use. For instance, a prescription for 126 oral contraceptive 
pills was assumed to be taken for 24 weeks (three weeks of taking a contraceptive pill 
a day and a stopweek). An IUD was assumed to be used for five years. Women with a 
prescription for hormonal contraceptives just before the first venous thrombotic event, 
with enough contraceptive pills prescribed to continue áfter venous thrombosis, were 
considered exposed for these days after the event. This is because women are mostly 
advised to continue using contraceptives during the anticoagulant treatment period.
[14] A prothrombotic effect of hormonal contraceptives is likely to be suppressed by 
anticoagulation, while the risk of menorrhagia associated with stopping hormonal 
therapy could be increased by anticoagulants.
The detailed questionnaire contained questions about hormonal contraceptive 
use after the first venous thrombosis; name of contraceptive used and starting date 
and date of discontinuation. Data on hormonal contraceptive use provided in the 
questionnaire was crosschecked with data retrieved at the time of the first venous 
thrombosis and at the time of venepuncture in the MEGA case-control study. 787 (58%) 
of premenopausal women filled in the detailed questionnaire and self-reported on 
their use of hormonal contraceptives after the first thrombotic event.
Recurrent venous thrombosis
A recurrent event was defined by information provided by patients through the 
questionnaire, anticoagulation clinics, discharge letters or causes of death. A decision 
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rule regarding certainty of the diagnosis was made according to the information 
collected per patient. Details of this decision rule have been described previously.[12] 
In short, reported recurrences were classified into certain recurrences when there 
was a discharge letter stating a diagnosis of a recurrent event based on clinical and 
radiological data, or when both the anticoagulation clinic and the patient reported a 
recurrent event at either a clearly different location than the first event or more than 
one year had passed since the first event, or when a registered death from a recurrent 
event at least six months after the first event was found. In the current analysis, certain 
recurrences were used as endpoint and patients with an uncertain recurrence were 
censored at time of their uncertain recurrence. 
Statistical Analysis
Premenopausal women with information on hormonal contraceptive use after a first 
venous thrombosis were included. The start of follow-up was defined as the date of the 
first venous thrombosis. The end of follow-up was defined as the date of the recurrent 
event or when no recurrent event occurred, the date of returning the short answer 
form, or the last date until we knew patients to be recurrence free (last visit to the 
anticoagulation clinic, date of death, or emigration), whichever came first. Observation 
time was calculated as the time at risk from the first thrombotic event to the end of 
follow-up. 
Hormonal contraceptive use was taken as a time-dependent exposure to allow 
women switching from use to non-use and vice versa during follow-up. Consequently, 
one woman could contribute follow-up time for hormonal contraceptive use as well 
as for non-use. Although anticoagulation use was not considered to be a confounder 
in the analysis, the risk of a recurrence is lower during a period of anticoagulation 
use. Therefore, analyses were adjusted for anticoagulation use (time-dependently) to 
obtain estimates of the incidence rate of a recurrence irrespective of anticoagulation 
use. 
The relative risk of recurrent venous thrombosis was estimated separately for 
women using hormonal contraceptives at the first event and for women using hormonal 
contraceptives during follow-up. The effect of oral and non-oral preparations on the 
risk of recurrent venous thrombosis was assessed and compared with non-use. Data 
were analysed separately by data source (prescription database or questionnaire). 
Recurrence rates were calculated for combined oral contraceptives by dose of 
ethinylestradiol and progestagen. 
All analyses were adjusted for the confounders age and BMI (at baseline) and for 
anticoagulation use. Time-dependent Cox-proportional hazards models were used to 
calculate hazard ratios (HR) with corresponding 95% confidence intervals. All statistical 
analyses were performed with STATA, version 13.0 (Statacorp LP, College Station, TX, 
USA).
Results
Of 1351 premenopausal women with a first venous thrombotic event, 650 were linked 
to the prescription database and followed for a total of 3537 person-years (median 
6.1 years; range, 41 days to 9.7 years). 787 women filled in the detailed questionnaire 
and had a total follow-up of 5155 person-years (median 6.8 years; range 120 days to 
9.9 years). Baseline characteristics of the study population by data source are given in 
Table 1. Characteristics were similar for the women linked to the prescription database 
and women who filled in the detailed questionnaire.
For 412 women data were available from both sources, and so could be checked 
for consistence. Based on the prescription data, 148 women (36%) did not use a 
contraceptive at any given time after the event and 109 women (26%) discontinued 
use some time after the event, for a total of 257 women (62%) who did not continue 
to use hormonal contraceptives after the first venous thrombosis. Data from the 
questionnaire are consistent with this, given that according to the questionnaire 241 
of these 257 women (94%) did not continue to use hormonal contraceptives after 
the event. However, the rest of the periods and types of hormonal contraceptive use 
reported by the prescription database and the questionnaire are not consistent. Out 
of the 155 women who continued or started using hormonal contraceptives according 
to the prescription database, 111 women (72%) did not self-report on such use in the 
detailed questionnaire. Because of this discrepancy and because we assumed data to 
be more accurate from the prescription database (women may not precisely remember 
their contraceptive use over the past few years), we focussed our analyses on data 
from the prescription database. Results based on the questionnaire data can be found 
in Supplementary Table 1.
Prescription database
Among the 650 women linked to the prescription database, 57 recurrences occurred, 
of which 14 were during hormonal contraceptive use. The overall rate of recurrent 
venous thrombosis among premenopausal women was 16.1 (95%CI: 12.4 to 20.9) per 
Table 1. Baseline characteristics of premenopausal women with venous thrombosis
Prescription Questionnaire
Variables N=650 N=787
Age at 1st event, mean(range), yrs 37 (18-49) 36 (18-49)
BMI at 1st event
   <25 kg/m2 246 (42) 334 (44)
   25-30 kg/m2 187 (32) 231 (31)
   >30 kg/m2 156 (26) 190 (25)
HC use at 1st event 455 (70) 590 (75)
BMI denotes: body mass index, HC: hormonal contraceptive
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1000 person-years. The recurrence rate in hormonal contraceptive users at the first 
event was similar (16.1, 95%CI: 11.8-22.0 per 1000 person-years) as in non-users at 
the first event (16.1, 95%CI: 10.0-25.9) (Table 2). This was also evident from the hazard 
ratio for users at the first event compared with non-users (HR 0.9, 95%CI: 0.5 to 1.5, 
adjusted for age, BMI and anticoagulation) (Table 2). 
Among women using hormonal contraceptives during follow-up, we observed a 
recurrence rate of 22.3 (95%CI: 13.2-37.7) per 1000 person-years and among non-
users during follow-up a rate of 14.8 (95%CI: 11.0-19.9) per 1000 person-years. This 
implied that hormonal contraceptive use after a first venous thrombosis increased 
the risk of recurrent thrombosis two-fold after adjustment for anticoagulation, age 
and BMI (HR 1.8, 95%CI: 0.9 to 3.3) (Table 2). Restriction to women who were using 
hormonal contraceptives at the first event, yielded a similar increased risk in women 
who continued to use hormonal contraceptives compared with those who stopped (HR 
2.0, 95%CI: 1.0-4.0) (Table 2).
11 recurrences occurred during combined oral contraceptive use. The recurrence 
rate for combined oral contraceptive use during follow-up was 33.7 (95%CI: 18.7-60.9) 
per 1000 person-years, almost three-fold higher than for non-use during follow-up 
(HR 2.6, 95%CI: 1.3 to 5.2, adjusted for anticoagulation; HR 2.6 after adjustment for 
age, BMI and anticoagulation, 95%CI: 1.3 to 5.2). Notable was that out of 64 women 
using a levonorgestrel-releasing IUD (250 person-years of follow-up), only three had 
a recurrence (recurrence rate 12.0, 95%CI: 3.9-37.1 per 1000 person-years). The 
recurrence rate was similar for IUD users and non-users (HR 0.9, 95%CI: 0.3-3.1). 
Recurrence rates were calculated by type of combined oral contraceptive. Numbers 
per type of combined oral contraceptive were, however, small. Incidence rates of 
recurrence were similar for the types of contraceptive mostly used in the Netherlands: 
IR 39.2 (95%CI, 17.6-87.1) for 30μg of ethinylestradiol and levonorgestrel, IR 33.4 
(95%CI, 8.3-133.4) for 30μg of ethinylestradiol and desogestrel and IR 42.7 (95%CI, 6.0-
303.5) for 30μg of ethinylestradiol and gestodene. 
Questionnaire data
Among the 787 women who filled in a questionnaire during follow-up, 80 recurrences 
occurred resulting in a rate of recurrent venous thrombosis among premenopausal 
women of 15.5 (95%CI: 12.5 to 19.3) per 1000 person-years. All results for the analyses 
based on the questionnaire data were similar to results for analyses based on the 
prescription database (Supplementary Table 1). 
In women who used hormonal contraceptives after the first venous thrombosis the 
risk of recurrence was almost three-fold increased (HR 2.8, 95%CI: 1.7 to 4.8, adjusted 
for anticoagulation, age and BMI) as compared with women who did not use hormonal 
contraceptives during follow-up. Restricting to women who were using hormonal 
contraceptives at the first event, a similarly increased risk was found with those who 
discontinued use as reference group (HR 2.9, 95%CI: 1.6-5.1). The risk of recurrent 
venous thrombosis was almost three-fold higher for combined oral contraceptive users 
than for non-users (HR 2.8, 95%CI: 1.6 to 5.0). 
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Despite guideline recommendations, a large proportion of women either continues or 
starts hormonal contraceptive use after a first venous thrombotic event. This study 
assessed the association between the risk of recurrent venous thrombosis and hormonal 
contraceptive use after a first event. Information on hormonal contraceptive use was 
available from a large prescription database as well as from a detailed questionnaire 
filled in by premenopausal women from the MEGA follow-up study. Women using 
hormonal contraceptives, in particular combined oral contraceptives, after a first 
venous thrombosis had a two- to three-fold higher risk of recurrence than non-users. 
Use or non-use of hormonal contraceptives at the first event did not affect the risk of 
recurrent venous thrombosis. The use of a levonorgestrel-releasing intrauterine device 
appeared not associated with an increased risk of recurrent venous thrombosis.
To date, only one other study (LETS) evaluated the risk of recurrent venous 
thrombosis among women using hormonal contraceptives after their first event in 
a prospective follow-up study.[10] That analysis was restricted to women who used 
hormonal contraceptives at the first event. The authors observed a recurrence rate 
of 48.8 per 1000 person-years (95%CI: 24.3-87.2) among hormonal contraceptive 
users during follow-up and a recurrence rate of 10.5 per 1000 person-years (95%CI: 
4.5-20.7) among those who had discontinued use. The recurrence rate among these 
non-users was similar as reported in the current study (14.8 per 1000 person-years); 
however, the recurrence rate in hormonal contraceptive users was higher (48.8 per 
1000 person-years versus 22.3 per 1000 person-years). This difference may be due to 
differences in the distribution of types of contraceptives in the LETS and the MEGA 
study, between which a decade elapsed. The proportion of women using a second 
generation contraceptive had increased over time (MEGA study 55% vs LETS 25%), while 
the proportion of women using a third generation contraceptive and the proportion of 
women using triphasic preparations had decreased (35% vs LETS 49% and 5% vs LETS 
11%). However, because of small numbers the difference in recurrence rates could be 
a chance finding as well. 
Several limitations of this study should be mentioned. First, we aimed to combine 
data on hormonal contraceptive use from both the prescription database and the 
detailed questionnaires. 650 Women were linked to the prescription database and 787 
women filled in the detailed questionnaire, with an overlap of 412 women. Combining 
both sources of information would have increased our power considerably. However, 
the lack of consistency between the two sources suggested that a substantial number 
of women had not correctly remembered periods of contraceptive use over the past 
years. Alternatively, as hormone use is actively advised against, women may have been 
reluctant to admit such use. We focussed our analyses on the objective data from the 
prescription database, where no misclassification is expected. Nevertheless, results for 
both data sources were similar. 
A second limitation of our study is that only 48% of our population of interest could 
be uniquely linked to the prescription database. As a consequence, numbers were too 
small to assess reliably the risk of recurrence by type of contraceptive. The recurrence 
rate among women linked to the prescription database was similar (16.1, 95%CI: 12.4 
to 20.9 per 1000 person-years) to the rate among women who could not be linked 
(17.9, 95%CI: 14.1-22.6), suggesting that bias due to the limited proportion that could 
be linked is unlikely. 
A strength of our study is its size. Furthermore, as far as we know, we are the first 
to compare the risk of recurrent venous thrombosis between women using hormonal 
contraceptives versus those who did not throughout a long period of time after a first 
event, separately for those who used or not used hormones at the first event. Also 
we were the first to study the association for different administration routes of the 
contraceptive (oral vs non-oral). Furthermore, we used a decision rule to ascertain 
recurrence status by which we ensured that only certain recurrences were included 
in our analyses. Lastly, detailed information on participants hormonal contraceptive 
use during follow-up made it possible to perform a time-dependent survival analysis, 
allowing switches from exposed to non-exposed during follow-up and vice versa. 
After a first venous thrombotic event recurrent venous thrombosis is common, with 
a five-year cumulative incidence of about 25%.[15,16,17] A large patient level meta-
analysis has shown a one-year cumulative incidence of recurrence of 5% and a three-year 
cumulative incidence of 9% in women.[18] Recurrences are associated with considerable 
comorbidity (post-thrombotic syndrome, chronic pulmonary hypertension), mortality 
and health-care costs. Despite progress in identifying determinants of recurrence risk, 
its prediction and prevention in an individual patient remains a challenge. Prevention of 
recurrent venous thrombosis by extending anticoagulant treatment is dependent on a 
delicate balance between risk of thrombosis and bleeding. Discontinuation of hormonal 
contraceptives could be a small intervention on a woman’s lifestyle, with potentially 
large preventive effects with regard to the risk of recurrent venous thrombosis. 
Current guidelines[5,6,7] recommend women to discontinue hormonal 
contraceptive use after a first venous thrombotic event. These guidelines however, are 
based on the assumption that risk factors for a first event also increase the risk of a 
recurrence. Not much was known on the risk of recurrences in women who continued 
their contraceptive use. Our study supports current guidelines which advise women to 
refrain from the use of hormonal contraceptives after a venous thrombotic event. We 
found that the risk of recurrent venous thrombosis is two- to threefold increased during 
periods of use of, particularly combined, hormonal contraceptives. Women should be 
urged to discontinue the use of hormonal contraceptives, since there are alternatives, 
e.g. a copper-IUD, available. This study suggests that the use of a levonorgestrel-
releasing IUD may also be a safe option after a venous thrombotic event. 
Given that out of 53 women who continue or restart using a combined oral 
contraceptive after a first venous thrombotic event one woman develops recurrent 
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venous thrombosis (Number Needed to Harm: 1/ risk difference = 1/ (0.0337-
0.0148)) and given that currently 20-40% of women continue or start using hormonal 
contraceptives after a first event[8,9], the overall burden of recurrent venous 
thrombosis in women could be significantly reduced by adherence to the guidelines.
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Seated immobility, either through long-haul 
travel, seated work or confinement to a 
wheelchair, and the risk of recurrent venous 
thrombosis










Several studies have shown an increased risk of venous thrombosis (VT) in otherwise 
healthy individuals during seated immobility. Temporary thromboprophylaxis during 
periods of immobility is not justified because of a low risk in absolute terms. This may 
be different for recurrent VT. 
Objectives
To study whether seated immobility, either through exposure to long-haul travel or 
through prolonged immobility in daily life, increases the risk of recurrent VT. 
Patients/ Methods 
This study is a case-control study nested within a cohort of 4731 patients with a first 
VT who were followed for recurrence (MEGA follow-up study). Participants reported 
via a questionnaire on periods of seated immobility: 1) prolonged travel >4h or seated 
work >4h/day during a 3 month-period before the recurrence for the cases or a random 
period for the controls 2) confinement to a wheelchair anytime during the follow-up 
period. 2723 participants (58%) returned the questionnaire. For the first exposure, odds 
ratios (OR), adjusted for age, sex, comorbidity at baseline and anticoagulant treatment 
were estimated to compare risk of recurrence between groups with and without recent 
immobility. For the second, adjusted hazard ratios (HR) were estimated by means of 
time-dependent Cox regression analysis to compare risk of recurrence between groups 
with and without use of a wheelchair.
Results 
No association was found between long-haul travel and recurrent VT (adjusted OR 0.8; 
95%CI, 0.6-1.1) or daily seated work and recurrent VT (adjusted OR 0.8; 95%CI, 0.6-
1.2). Within subgroups of different types and duration of travel or subgroups of days 
per week of work-related immobility results were similar. Five out of 47 patients who 
reported to use a wheelchair developed recurrent VT, but did not have an increased 
recurrence risk as compared with patients without a wheelchair (adjusted HR 1.1; 
95%CI, 0.4-2.6). 
Conclusions
For several seated immobility exposure categories, i.e. prolonged travel, seated work 
or confinement to a wheelchair, no association was found with recurrent VT. 
Introduction
In 1856, Rudolf Virchow described three broad categories of factors contributing to 
venous thrombosis; endothelial injury, hypercoagulability and stasis. Stasis as a risk 
factor for thrombosis has been described predominantly in the context of plaster casts, 
prolonged bed rest and immobilisation after surgery. However, in these instances other 
factors like damaged tissue or comorbidities that contribute to hypercoagulability also 
play a role. 
Immobilization per se as a risk factor for venous thrombosis, in otherwise healthy 
people, has been described for the first time in 1940, during the second World War, 
when an increase in number of deaths from pulmonary embolism was attributed to 
prolonged sitting in shelters during the bombardments of London.[1] 
More recently, several studies have been published in which seated immobility, 
such as during work, travel or long haul flights, was found to be a risk factor for a first 
venous thrombotic event.[2-4] In a study by Healy and colleagues prolonged work- and 
computer-related seated immobility was associated with an almost three-fold increased 
risk of a first venous thrombotic event (OR 2.8; 95%CI, 1.2-6.1).[3] A meta-analysis by 
Chandra and colleagues reports on a three-fold increased risk (pooled RR 2.8; 95%CI, 
2.2-3.7) for travellers as compared with non-travellers.[2] Prolonged immobility in a 
supine position however, has not been related to activation of coagulation.[5]
Although reported relative risks of a first venous thrombotic event during or after 
seated immobility are moderately high, the absolute risk of a first venous thrombotic 
event is low (1-2 per 1000 persons per year).[6] This is why clinical interventions such as 
temporary thromboprophylaxis (for example during long-haul flights) are not justified. 
This may be different for recurrent venous thrombosis, for which the absolute risk is 
high. The five-year cumulative incidence of recurrent venous thrombosis is reported 
to be around 12-25%.[7-9] However, the relation between seated immobility and 
recurrent venous thrombosis has not been studied before. Knowledge is needed to 
provide travellers, as well as individuals who are otherwise immobilised in the absence 
of morbidity, with solid advice regarding their actual risk and to evaluate the utility of 
prophylactic measures.
We aimed to study whether seated immobility, either through exposure to long-









Between March 1999 and August 2004, 4956 patients aged 18-70 with an objectively 
diagnosed first deep vein thrombosis (DVT) of the leg or pulmonary embolism (PE) were 
included in a population-based case-control study (MEGA study). All patients filled in 
an extensive questionnaire on putative risk factors for venous thrombosis. Details of 
the MEGA study have been described previously.[10] Of the MEGA case-control study, 
only the cases were further followed for recurrence until 2008-2009 (MEGA follow-up 
study). For this, 225 of the 4956 patients did not consent, leaving 4731 patients. Of 
these patients 134 participated in the MEGA follow-up pilot study for which follow-
up ended in 2005. The MEGA follow-up study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center, and all participants gave written 
informed consent.
Adjudication of immobility status
Data on periods of seated immobility of participants during follow-up came from a 
detailed questionnaire, filled in by the patients at the end of follow-up. We studied the 
following self-reported factors regarding seated immobility during follow-up: 1) Long-
haul travel for >4 hours; 2) seated work for >4 hours per day, categorized as either 
seated work or work-related seated travel, and 3) confinement to a wheelchair. 
Questions regarding long-haul travel or seated work were asked with regard to a 
3 months period before the date of recurrence for the participants with a recurrent 
venous thrombotic event and a randomly picked three months period during follow-up 
for the participants without a recurrent venous thrombotic event (Figure 1). 
The period of exposure to seated immobility is much longer for patients who are 
confined to a wheelchair than for patients who took e.g. a long-haul flight. Questions 
regarding the use of a wheelchair were therefore asked with regard to the complete 
















Figure 1. Three-months exposure period for cases and controls.
Adjudication of recurrent events
Between 2007 and 2009 the vital status of all patients was acquired from the central 
Dutch population register.[11] For the patients who died, a cause of death (ICD-10-CM) 
was obtained from the national register of death certificates at the Central Bureau 
of Statistics. Short answer forms concerning recurrent venous thrombosis were sent 
by mail to all survivors and consenting individuals between June 2008 and July 2009, 
and supplemented by telephone interviews. Additional information was acquired 
from the regional anticoagulation clinics and from hospitals. Deaths due to recurrent 
venous thrombosis were counted as fatal recurrent events. Based on hospital discharge 
letters, the information from the anticoagulation clinics, forms filled in by the patients 
and causes of death, possible recurrences were classified into certain and uncertain 
recurrences, following a decision rule published previously.[12] In short, reported 
recurrences were classified into certain recurrences when there was a discharge letter 
stating a diagnosis of a recurrent event based on clinical and radiological data, or when 
both the anticoagulation clinic and the patient reported a recurrent event at either a 
clearly different location than the first event or more than one year has passed since 
the first event, or when a registered death from a recurrent event at least six months 
after the first event was found. 
Adjudication of use of prophylactic anticoagulant treatment 
Information on the use of anticoagulant treatment during the three months exposure 
period, both for long-haul travel and seated work, was obtained from the SFK register. 
SFK stands for the Dutch Foundation for Pharmaceutical Statistics and is a register in 
which over 95% of the community pharmacies in the Netherlands are represented.
[13] SFK data contain information about patient specific drugs dispensed; the generic 
name of a drug, the Anatomical Therapeutic Chemical (ATC) classification, the date of 
prescription, and the number of days for which a drug was prescribed. Information 
from this register was available for the years 1999 to 2009. Linkage was based on a 
combination of age, sex, 4-digit postal code and vitamin K antagonist use within the 
first month after the initial venous thrombosis. In total 2547 (54%) patients of the 
MEGA follow-up study could be individually linked with SFK. In analyses on the use of a 
wheelchair relative risks were time-dependently corrected for anticoagulant treatment 
during follow-up. Information on this use of anticoagulant treatment was derived from 
the anticoagulation clinics.
Statistical analyses
Patients reported on long-haul travel or seated work with regard to a three months 
exposure period. To study whether long-haul travel and daily seated work after a first 
thrombotic event were associated with recurrent venous thrombosis we used a nested 
case-control design, within the MEGA follow-up study. Cases were the participants 
with recurrent venous thrombosis and controls participants without recurrent venous 
thrombosis. Patients reported on the use of a wheelchair during follow-up and the 
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first date of use. To study whether confinement to a wheelchair was associated with 
recurrent venous thrombosis we used a traditional follow-up design.
1 Analyses on long-haul travel 
For the analyses on long-haul travel participants of the MEGA follow-up pilot study 
(n=134), participants who did not return the follow-up questionnaire (n=1874), 
participants who did not fill in the question regarding long-haul travel (n=287) and 
participants with an uncertain recurrent event (n=50) were excluded. In total, 2386 
participants were eligible for analyses. This group contained 402 cases, i.e. participants 
with a recurrent event and 1984 controls, i.e. participants without a recurrent event.
The cases were 1:1 matched on time since the first thrombotic event until the three 
months exposure period to take into account that the risk of recurrence decreases over 
time. After this matching procedure 804 participants were included for analyses, i.e. 
all 402 cases and 402 controls. Odds ratios (OR) with 95% confidence intervals were 
estimated with conditional logistic regression analysis to compare the risk of recurrence 
between groups with and without recent travel.[14] Odds ratios were estimated for 
long-haul travel for >4 hours yes or no, stratified by type of transport (airplane, bus, car 
or train), number of travels and duration of travel. Odds ratios were adjusted for age, 
sex and comorbidity at baseline. Comorbidity at baseline could be diagnoses of cancer, 
diabetes, liver failure, kidney failure, rheumatoid arthritis, multiple sclerosis, chronic 
bronchitis or emphysema. Additionally, adjustment for (prophylactic) anticoagulant 
use during the three months exposure period was performed. 
2) Analyses on daily seated work
For the analyses on seated work participants of the MEGA follow-up pilot study (n=134), 
participants who did not return the follow-up questionnaire (n=1874), participants 
who did not fill in the question regarding seated work either because they were not 
employed at the time or because they did not want to answer the question (=1216) 
and participants with an uncertain recurrent event (n=31) were excluded, leaving 1476 
participants eligible for analyses. This group contained 254 cases and 1222 controls. 
After the matching procedure 506 participants were included for analyses, of which 
253 cases (out of 254) and 253 controls. Odds ratios were estimated for seated work for 
>4 hours per day, either through seated work or work-related seated travel, stratified 
by number of days per week. Odds ratios were adjusted for age, sex, comorbidities 
at baseline and anticoagulant treatment during the 3 months exposure period (as 
described above).
3) Analysis on use of a wheelchair
For the analyses on the use of a wheelchair participants of the MEGA follow-up pilot 
study (n=134), participants who did not return the follow-up questionnaire (n=1874), 
participants who responded with “Yes, I use a wheelchair’, but who did not fill in a 
starting date (n=7) and participants who did not answer the question regarding use 
of a wheelchair (n=89), 2627 participants could be included for analyses. Duration of 
follow-up was counted from date of first thrombotic event to end of follow-up, defined 
as the date of a recurrence or, in its absence, the date of returning the short answer 
form. The last form in the current study population was returned on December 31, 
2009. Here we limit the analyses to certain recurrent events (n=465) and participants 
with an uncertain recurrent event (n=86) were censored from the date of the uncertain 
recurrence onward. Incidence rates of recurrent venous thrombosis were estimated as 
the number of events over the accumulated follow-up time and with person time split 
and divided over participants with or without the need for a wheelchair during follow-
up. The association between the use of a wheelchair and recurrent venous thrombosis 
was estimated by means of time-dependent Cox regression analysis with the use of 
a wheelchair as a time-dependent variable. Hazard ratios with corresponding 95% 
confidence intervals (CI) were estimated and corrected for age, sex and comorbidity 
at baseline. Additional adjustments for anticoagulant treatment during follow-up were 
performed with anticoagulant treatment as a time-dependent variable. Hazard ratios 
were estimated for confinement to a wheelchair yes or no and stratified for the duration 
of wheelchair use. As a sensitivity analysis we included patients who responded in 
the questionnaire “Yes, I use a wheelchair”, but who did not fill in a date (n=7) and 
considered them exposed over the full follow-up period. 
Results
In the MEGA follow-up study 4731 patients with a first episode of venous thrombosis 
were followed for recurrent events for a median of 5.9 years (interquartile range 1.6-
7.8 years, total follow-up 24 064 years). Mean age at enrolment was 48 years and 2164 
(46%) patients were men. In 987 (21%) patients comorbidity at baseline was reported, 
with cancer (9%) accounting for most of the comorbidities. Baseline characteristics 
for patients who returned the follow-up questionnaire (n=2723) were similar to those 
of the total group of patients (mean age 48, 45% men) except for the proportion of 
patients with comorbidities at baseline (15% comorbidities) (Table 1). 
Relation between long-haul travel and recurrent venous thrombosis
Of 402 cases with recurrent venous thrombosis, 127 (32%) reported long-haul travel 
of more than four hours, during the three months period prior to their recurrence. 
Of the matched 402 controls 148 (37%) reported long-haul travel during the 3 
months exposure period. Long-haul travel appeared not related to recurrent venous 
thrombosis, shown by both the crude and adjusted odds ratios of 0.8 (95%CI, 0.6-
1.1) and 0.8 (95%CI, 0.6-1.1) (Table 2). When results were split for either long-haul 
air travel or long-haul non-air travel, results did not change with adjusted odds ratios 
of 0.8 (95%CI, 0.5-1.2) and 0.8 (95%CI, 0.5-1.1). Results for number of travels and 
duration of travel were additionally similar and did not show an association between 
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travel and recurrent venous thrombosis. Only for patients with long-haul air travel for 
>12 hours we found a possibly increased risk of recurrence (OR 2.0; 95%CI 0.7-6.2), 
as compared with patients without long-haul air travel. When we stratified long-haul 
non-air travel for the type of transport we did not see elevated risks for any means 
of transport, with an adjusted odds ratio of 0.7 (95%CI; 0.5-1.1) for a trip by car, 0.4 
(95%CI; 0.1-2.4) for a trip by train and of 0.9 (95%CI; 0.3-2.7) for travel by bus. In all 
of abovementioned analyses additional adjustment for (prophylactic) anticoagulant 
treatment did not change results (Table 2). We had data on other types of prophylactic 
measures, such as compression stockings or exercise, only for participants who took a 
long-haul flight. Of 56 cases who took a long-haul flight 17 (30%) reported not to have 
taken any prophylactic measures, while 21 (38%) reported to have exercised or moved 
during the flight and 28 (50%) reported to have worn compression stockings. For the 
69 controls who took a long-haul flight, these numbers were 30 (43%), 27 (39%) and 
24 (35%), respectively. 
Relation between seated work and recurrent venous thrombosis
Of 253 cases with recurrent venous thrombosis, 147 (58%) reported to perform 
seated work of more than four hours, during the three months period prior to their 
recurrence. Of the matched 253 controls 155 (61%) reported to perform seated work 
during this period (Table 3). Work-related daily immobility was not associated with 
recurrent thrombosis, shown by an adjusted odds ratio of 0.8 (95%CI; 0.6-1.2). Also after 






General characteristics Cases Controls Total  Cases Controls Total
N 466* 2171 2723  673† 3839 4731
Age, mean (sd) 50 (12.7) 48 (12.4) 48 (12.5)  50 (12.9) 48 (13.1) 48 (13.1)
Sex, male (%) 300 (64%) 877 (40%) 1222 (45%)  427 (63%) 1618 (42%) 2164 (46%)
Baseline characteristics       
Comorbidity 64 (14%) 327 (15%) 411 (15%)  110 (16%) 791 (21%) 962 (20%)
   Cancer 14 (3%) 94 (4%) 113 (4%)  41 (6%) 354 (9%) 421 (9%)
   Diabetes 12 (3%) 67 (3%) 84 (3%)  21 (4%) 140 (4%) 171 (4%)
   Liver failure 3 (1%) 5 (0%) 8 (0%)  3 (1%) 23 (1%) 27 (1%)
   Kidney failure 3 (1%) 23 (1%) 26 (1%)  7 (1%) 43 (1%) 53 (1%)
   Rheumatoid arthritis 20 (5%) 63 (3%) 87 (4%)  21 (4%) 104 (3%) 137 (3%)
   Multiple sclerosis 0 (0%) 10 (1%) 12 (1%)  2 (0%) 22 (1%) 28 (1%)
   Chronic bronchitis 18 (4%) 88 (4%) 113 (5%)  30 (5%) 191 (6%) 238 (6%)
   Emphysema 5 (1%) 18 (1%) 24 (1%)  6 (1%) 49 (2%) 58 (1%)
*86 uncertain recurrent events not counted
†219 uncertain recurrent events not counted
Table 2. Odds ratios for risk of recurrent venous thrombosis according to long-haul travel
Exposure Cases Controls OR (95%CI) OR* (95%CI) OR† (95%CI)
Long-haul travel >4 hours
   No 275 254 reference reference reference
   Yes 127 148 0.8 (0.6-1.1) 0.8 (0.6-1.1) 0.8 (0.6-1.1)
Number of travels
≤2 67 74 0.8 (0.5-1.2) 0.8 (0.5-1.2) 0.8 (0.5-1.2)
>2 60 74 0.8 (0.5-1.2) 0.8 (0.5-1.2) 0.8 (0.5-1.2)
Duration of travel
≤12 hours 104 111 0.8 (0.6-1.2) 0.9 (0.6-1.2) 0.9 (0.6-1.3)
>12 hours 17 25 0.8 (0.4-1.6) 0.8 (0.4-1.6) 0.7 (0.3-1.5)
Long-haul air travel >4 hours
   No 345 331 reference reference reference
   Yes 56 69 0.8 (0.5-1.1) 0.8 (0.5-1.2) 0.8 (0.5-1.3)
Number of flights
≤2 41 43 0.9 (0.6-1.5) 1.0 (0.6-1.6) 1.0 (0.6-1.7)
>2 15 26 0.6 (0.3-1.1) 0.5 (0.3-1.1) 0.5 (0.2-1.0)
Duration of flight
≤12 hours 42 60 0.7 (0.5-1.1) 0.7 (0.5-1.1) 0.7 (0.4-1.2)
>12 hours 9 5 1.8 (0.6-5.4) 2.0 (0.7-6.2) 2.0 (0.6-6.2)
Long-haul non-air travel >4 hours
   No 312 293 reference reference reference
   Yes 86 106 0.7 (0.5-1.0) 0.8 (0.5-1.1) 0.8 (0.5-1.1)
Type of non-air travel
Car 64 77 0.7 (0.5-1.1) 0.7 (0.5-1.1) 0.7 (0.5-1.1)
Train 2 7 0.3 (0.1-1.7) 0.4 (0.1-2.4) 0.5 (0.1-2.5)
Bus 12 10 1.0 (0.4-2.9) 0.9 (0.3-2.7) 0.8 (0.3-2.5)
Number of travels
≤2 32 39 0.7 (0.4-1.2) 0.7 (0.4-1.3) 0.7 (0.4-1.3)
>2 54 67 0.8 (0.5-1.2) 0.8 (0.5-1.3) 0.8 (0.5-1.3)
Duration of travel
≤12 hours 74 73 1.0 (0.7-1.4) 1.0 (0.7-1.6) 1.0 (0.7-1.6)
>12 hours 12 33 0.3 (0.1-0.7) 0.3 (0.1-0.7) 0.3 (0.1-0.7)
*Adjusted for age, sex, comorbidity
†Adjusted for age, sex, comorbidity and (prophylactic) anticoagulant treatment
Data on anticoagulant treatment was not available for all participants (linkage successful 54%)
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stratification for daily seated work and daily work-related seated travel no association 
was found (adjusted OR 1.0 (95%CI; 0.7-1.5) and 0.7 (95%CI; 0.4-1.3), respectively). 
Within subgroups of days per week of work-related immobility results were similar 
and no association was found between seated immobility and recurrences. In all of 
abovementioned analyses additional adjustment for (prophylactic) anticoagulant 
treatment did not change results (Table 3).
Relation between confinement to wheelchair and recurrent venous thrombosis
In the follow-up questionnaire 47 patients reported to have a condition for which they 
were confined to a wheelchair. Five of these patients developed a recurrent venous 
thrombotic event for an incidence rate of 22.5 per 1000 person-years (95%CI; 9.5-
54.0) while it was 26.9 per 1000 person-years (95%CI; 24.5-29.5) for patients without a 
wheelchair. Corresponding hazard ratio after adjustments for age, sex and comorbidity 
Table 3. Odds ratios for risk of recurrent venous thrombosis according to immobility in daily 
life through work 
Exposure Cases Controls OR (95%CI) OR* (95%CI) OR† (95%CI)
Work-related daily immobility      
   No 106 98 reference reference reference
   Yes 147 155 0.9 (0.6-1.3) 0.8 (0.6-1.2) 0.8 (0.6-1.2)
      
Number of days per week      
  1-2 days 14 20 0.5 (0.2-1.3) 0.5 (0.2-1.6) 0.5 (0.1-1.5)
  >2 days 133 135 1.0 (0.7-1.4) 0.9 (0.6-1.3) 0.9 (0.6-1.3)
      
Daily seated work      
   No 110 110 reference reference reference
   Yes 141 142 1.0 (0.7-1.4) 1.0 (0.7-1.5) 1.0 (0.7-1.5)
      
Number of days per week      
  1-2 days 12 16 0.4 (0.1-1.4) 0.7 (0.2-2.5) 0.7 (0.2-2.5)
  >2 days 129 126 1.1 (0.7-1.6) 1.1 (0.7-1.6) 1.1 (0.7-1.6)
      
Daily work-related seated travel      
   No 207 206 reference reference reference
   Yes 35 32 1.1 (0.6-1.9) 0.7 (0.4-1.3) 0.7 (0.4-1.3)
      
Number of days per week      
  1-2 days 9 13 0.5 (0.2-1.5) 0.3 (0.1-0.9) 0.2 (0.1-0.8)
  >2 days 26 19 1.5 (0.8-3.1) 1.0 (0.5-2.2) 1.1 (0.5-2.3) 
*Adjusted for age, sex, comorbidity
†Adjusted for age, sex, comorbidity and anticoagulant treatment
Data on anticoagulant treatment was not available for all participants (linkage successful 54%)
at baseline was 1.1 (95%CI; 0.4-2.6) (Table 4). In a sensitivity analysis in which we 
included seven participants who used a wheelchair but for whom we did not have a 
date of first use, we found similar results with an adjusted HR of 1.0 (95%CI, 0.4-2.2). 
24 Out of 47 patients with a wheelchair started using their wheelchair before the first 
thrombotic event. They did not have an increased risk of recurrence (HR 1.0; 95%CI, 
0.3-3.1) after adjustments for age, sex and comorbidity (Table 4). The other 23 patients 
who started using a wheelchair after the first thrombotic event developed 2 recurrences 
and did not have an increased recurrence risk (HR 1.2; 95%, 0.3-4.8 after adjustments). 
One of these recurrences was within one year after the start of using a wheelchair. 
Prophylactic anticoagulant treatment does not seem to explain our findings. Additional 
adjustments for anticoagulant treatment as a time-dependent variable did not change 
our results (Table 4). Of all 47 patients that reported to be bound to a wheelchair none 
started prophylactic anticoagulant treatment around the time of first use. Eight out of 
24 patients who started using a wheelchair before their first thrombotic event received 
long-term anticoagulant treatment after the event. Three out of 24 patients received 
only therapeutic anticoagulant treatment shortly after the thrombotic event and 
thirteen out of 24 patients had one or several periods of prophylactic treatment during 
follow-up. Out of 23 patients who started using the wheelchair after the first event, 15 
patients had no periods of anticoagulant treatment after the start of use, 5 patients 
had a period of long-term anticoagulant treatment after the start of use and 3 patients 
had one or several shorter periods of prophylactic treatment after the start of use.
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In this study we found no association between seated immobility, either through long-
haul travel, work-related seated immobility or through the use of a wheelchair and 
recurrent venous thrombosis. Odds ratios for long-haul air travel and long-haul non-air 
travel as compared with no travel were 0.8 (95%CI, 0.5-1.2) and 0.8 (95%CI, 0.5-1.1). 
Stratification for the duration of travel did not change results, although long-haul air 
travel >12 hours may be associated with an increased risk of recurrence. The risk of 
recurrent venous thrombosis was not increased during periods of daily seated work (OR 
1.0; 95%CI, 0.7-1.5) or work-related seated travel (OR 0.7; 95%CI, 0.4-1.3) and results 
were similar in subgroups of days per week with seated work. For patients confined to 
a wheelchair the risk of recurrent venous thrombosis was not increased compared with 
patients who did not use a wheelchair (HR 1.2; 95%CI, 0.4-2.6). 
Several studies that demonstrated a positive association between long-haul travel and 
first events of venous thrombosis have shown a dose-response relation with regard to 
increasing duration of travel and number of travels. In a large meta-analysis a dose-
response relationship was found with a 20% higher risk for venous thrombosis for each 
2-hour increase in travel duration.[2] Kuipers et al. have shown that the risk of a first 
event increases with exposure to more flights in a short time-frame and with increasing 
duration of flights.[15] A previous study has shown similarly increased risks of a first 
event after flying or traveling by car, bus or train.[16] For a first venous thrombotic 
event several studies have reported an association between both work- and computer-
related seated immobility.[3,17-19] A severe case of a first venous thrombotic event 
after periods of prolonged sitting at a computer has even led to the proposal of the term 
‘eThrombosis; the 21st century variant of venous thromboembolism associated with 
immobility’.[18] The association between the use of a wheelchair, use of prophylactic 
anticoagulation and venous thrombosis has received little attention in the literature. 
However, a study by Arpaia and colleagues reported a frequency of asymptomatic DVT 
of over 40% in patients with advanced multiple sclerosis admitted to a neurology center, 
who were either wheelchair-bound or bedridden.[20] Currently, the ACCP guidelines 
recommend against the routine use of thromboprophylaxis in chronically immobilized 
patients who either reside at home or at a nursing home.[21]
Although previous studies on the relation between seated immobility, such as 
during travel or work, and first venous thrombosis have shown moderately strong 
associations, we did not find such an association between immobility and recurrences. 
A factor such as prolonged immobility, leading to stasis of blood in the venous system, 
which is strongly associated with first venous thrombotic events, could be expected to 
be a risk factor for recurrences as well. We cannot fully exclude the possibility of an 
increased recurrence risk during periods of seated immobility. An explanation for our 
null findings with regard to long-haul travel could be the large proportion of controls 
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who undertook long-haul travel. The frequency of long-haul air travel >4 hrs over three 
months was 17% in our control participants. Controls were asked to report on long-haul 
travel during a random three-month exposure period over the past few years. Perhaps 
they did not remember the exact date of travel, and responded ‘yes’ to the question 
while their actual date of travel was just outside the three months exposure period. 
This would result in an overestimation of number of travels in controls. However, in a 
study by Martinelli et al frequencies of long-haul flights of >8hrs and of flights of any 
duration were approximately 6% and 23%, respectively, over a three months period.
[22] Our frequency of 17% for long-haul flights of >4hrs, lies in between these numbers. 
Another explanation may be that we may not have been able to correct for all potential 
confounding factors. Probably, patients who are able to travel have an overall better 
health status than patients who do not travel. We tried to correct for this by adjusting 
for comorbidities at baseline (at time of the first thrombotic event). However, we may 
not have had sufficient information on general health throughout the follow-up period. 
Such a ‘healthy traveller effect’ has been described before in a study on the association 
between air travel and first thrombotic events.[23] Another explanation for our null 
findings for both long-haul travel, seated work and confinement to a wheelchair is that 
we have not been able to correct for other prophylactic measures taken by patients 
themselves, such as compression stockings, or exercise. 
In summary, in a large follow-up study we studied the association between seated 
immobility and recurrent venous thrombosis. For several exposure categories, like 
prolonged travel, seated work or confinement to a wheelchair, we did not find an 
association with recurrences. For participants with long-haul air travel >12 hours the 
risk of recurrent venous thrombosis may be increased. We cannot make a definite 
conclusion as to whether preventive measures, like prophylactic anticoagulant 
treatment, exercise or stockings during periods of seated immobility, would be 
beneficial in patients with a history of venous thrombosis. Randomized clinical trials 
are needed to answer this question.
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Previous studies have suggested a role for transient infections in the etiology of 
venous thrombosis (VT). We aimed to study whether individuals who receive antibiotic 
treatment (as a proxy for infections) have an increased risk of first or recurrent VT and 
what the joint effect is of antibiotics and genetic thrombophilia.
Methods and Results
4731 patients with a first VT from 1999-2004 were included in the MEGA-study and 
followed for a median of 5.9 years for recurrence (1999-2010 MEGA follow-up study). 
Information on antibiotic use was obtained via linkage to SFK-data (Dutch Foundation 
for Pharmaceutical Statistics). We used the self-controlled case-series method to study 
the risk of first VT during antibiotic prescriptions. VT, either PE or DVT, might at first 
sight be misdiagnosed as an infection. Therefore, patients for whom misclassification 
certainly played a role were excluded and we stratified for types of antibiotics for which 
misclassification is unlikely. 2547 VT patients could be individually linked to SFK-data, 
in whom 114 first events occurred during antibiotic use. After exclusion of patients 
who were misclassified we found a five-fold increased risk of first VT during antibiotic 
treatment: (incidence-rate-ratio [IRR] 5.0; 95%CI, 4.0-6.1). The IRR of DVT in patients 
receiving antibiotics for urinary tract infections (no misclassification) was 3.2 (95%CI, 
1.9-5.6). By means of time-dependent Cox-regression, with correction for age and sex, 
antibiotic use was associated with a 2.0-fold (95%CI, 1.1-4.0) increased risk of recurrent 
VT, compared with no use. A joint risk of about 9 was found for antibiotic use and 
genetic thrombophilia (factor V Leiden or prothrombin G20210A mutation).
Conclusion
Individuals who receive antibiotics have a two to three-fold increased risk of a first VT 
or a recurrent VT during their antibiotic use, with highest risks during the first week of 
use.
Introduction
Venous thrombosis, defined as deep vein thrombosis (DVT) of the leg or pulmonary 
embolism (PE), is a major cause of mortality and morbidity. The incidence of venous 
thrombosis in the population is 1-2 per 1000 individuals per year[1], and the cumulative 
incidence of recurrent venous thrombosis within five years after a first event is 20-25%.
[2-4] In about half of the patients with venous thrombosis no provoking risk factor can 
be identified. This is clinically important, as such patients are considered candidates for 
long term anticoagulant treatment.[5] 
In 2006, Smeeth and colleagues observed an increased risk of venous thrombosis 
in patients who had a transient respiratory or urinary tract infection. The risk was 
highest in the first three months after diagnosis of an infection.[6] Also, as many as 
36% of patients with acute venous thrombosis report, when asked, symptoms or 
signs of a transient infectious or inflammatory disease during the four weeks prior to 
presentation.[7] This adds credence to the suggestion that transient infectious diseases 
are associated with an increased risk of venous thrombosis. Nevertheless, infectious 
diseases are currently not considered as a provoking factor for venous thrombosis.[5] 
Moreover, the influence of infection on risk of recurrence has only received anecdotal 
attention in the literature and little formal study.[8] The mechanism that underlies the 
association has only been obtained in patients with sepsis[9], or in laboratory studies.
[10]
We aimed to study whether individuals who receive antibiotic treatment (as a 
proxy for infection), have an increased risk of first and recurrent venous thrombosis. 
Additionally, we aimed to study whether the risk of venous thrombosis during antibiotic 
use is further increased in individuals with genetic thrombophilia. For this purpose we 
used three different study designs; a self-controlled case series design, a prospective 
follow-up design and a case-only analysis.
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Consecutive patients aged 18 to 70 years with a first DVT or PE were included in the 
Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis 
(MEGA) study. Details of the MEGA study have been described previously.[11,12] In 
short, 4956 patients were recruited in the period between February 1999 to September 
2004. 
Of the patients included, 225 did not consent to participate in a follow-up study on 
recurrent venous thrombosis. Therefore, 4731 patients were followed from their first 
venous thrombotic event until 2008-2010 when they completed a questionnaire on 
recurrent venous thrombotic events.[13] This study has been approved by the Medical 
Ethics Committee of the Leiden University Medical Center, and all patients gave written 
informed consent.
Outcome classification first venous thrombosis
Patients with a first objectively identified DVT of the leg or a first PE were identified at 
six anticoagulation clinics in the Netherlands. The anticoagulation clinics monitor the 
anticoagulant therapy of all patients in a well-defined geographical area, which allowed 
the identification of consecutive and unselected patients with venous thrombosis. 
Unprovoked venous thrombosis was defined as venous thrombosis without surgery, 
trauma, plaster cast, pregnancy or immobilization in the first three months before the 
event, prolonged travel in the first two months before the event, active malignancies 
in the first five years before the event or hormone use (oral contraceptives or hormone 
replacement therapy) at the time of the event. Patients who had one or more of these 
risk factors at time of their thrombotic event were classified as having had a provoked 
venous thrombosis.
Outcome classification recurrent venous thrombosis
During the same period when patients were asked to self-report on any recurrent 
thrombotic events during follow-up, information about recurrences was additionally 
retrieved from the anticoagulation clinics and from hospital discharge letters. 
Furthermore, between 2007 and 2009 the vital status of all patients was acquired from 
the central Dutch population register.[14] For the patients who died, the cause of death 
(ICD-10-CM encoded) was obtained from the national register of death certificates 
at the Central Bureau of Statistics. Deaths due to recurrent venous thrombosis were 
counted as fatal recurrent events. Information from the anticoagulation clinics, hospital 
discharge letters, questionnaires filled in by the patients and death certificates was 
combined and based on this, recurrences were classified into certain and uncertain 
recurrences, following a decision rule as described previously.[13]
Antibiotic exposure definition 
Information on antibiotic use was obtained by linkage to the SFK register (the Dutch 
Foundation for Pharmaceutical Statistics).[15] In the Netherlands, antibiotics are 
only available by prescription, and over 95% of the community pharmacies in the 
Netherlands are represented in this register. SFK contains information about patient 
specific drugs dispensed; the generic name of a drug, the Anatomical Therapeutic 
Chemical (ATC) classification, the date of prescription, and the number of days for 
which a drug was prescribed. Information from this register was available for the years 
1999 to 2009. Linkage was based on a combination of age, sex, 4-digit postal code and 
vitamin K antagonist use within the first month after the initial venous thrombosis. 
In total 2547 (54%) patients of the MEGA study could be individually linked with SFK. 
After linkage to the SFK register, all MEGA patients with one or more prescriptions of 
antibiotics in the period 1999-2009 were identified. 
Clinically, an early presentation of PE may at first be misdiagnosed as an infection. 
Early symptoms of PE are sometimes mistaken for a respiratory tract infection and 
antibiotics are prescribed. This misclassification would lead to spurious associations 
between antibiotic use and PE. For DVT and infections of the skin of the leg the same 
may be true. We reduced this possibility of misclassification step by step. First, we 
excluded patients in whom it was likely that such misclassification had taken place, from 
information of discharge letters. Second, we performed a subgroup analysis involving 
patients with DVT only, PE only or PE with or without DVT as the pathophysiology of 
DVT might be different from that of PE[16] and as misclassification (of for example an 
acute lung infection) is likely to be less for DVT than for PE. Furthermore, we stratified 
results for different types of antibiotics since misclassification will play a different role 
for different types of antibiotics. For example, we expect virtually no misclassification 
for antibiotics prescribed for urinary tract infections. We defined three main groups of 
antibiotics based on the condition for which these antibiotics are most often prescribed 
in the outpatient setting in the Netherlands: 1) penicillins, tetracyclines and macrolides 
(wide range of infections); 2) nitrofurane derivatives, sulphonamides and trimethoprim 
and quinolones (primarily urinary tract infections); 3) flucloxacillin (primarily skin 
infections). 
Genetic thrombophilia testing
Venous blood was collected at least three months after discontinuation of 
anticoagulant therapy following the first event, or during anticoagulant treatment 
in patients who continued for more than one year. Blood was collected in trisodium 
citrate and processed within four hours. For logistic reasons this was done until 
June 2002. Patients who were unable or unwilling to provide blood samples or were 
recruited after June 1, 2002 were sent buccal swabs to collect DNA for genetic profiling 
and blood group determination. DNA from either buccal swab or blood samples was 
obtained by standard methods. Blood group was determined by a 5’nuclease assay 
(Taqman;Applied Biosystems, Foster City, California) using a standard PCR reaction mix 
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(Eurogentec, Seraing, Belgium) and an allele specific fluorescent probe equipped with a 
minor grove binding moiety (applied Biosystems). DNA analysis for the factor V Leiden 
(G1691A; rs6025) mutation and the prothrombin (G20210A; rs1799963) mutation was 
performed using a combined polymerase chain reaction method.[12] 
Design and statistical analyses
Three designs were used to answer our research questions. 
1) Antibiotic use and first venous thrombosis risk
We used the self-controlled case-series (SCCS) method to study whether patients who 
received antibiotic treatment have an increased risk of first venous thrombosis. The 
SCCS method relies on intra-person comparisons in a population of individuals who 
have had the outcome of interest, thereby eliminating fixed confounding.[17] Only 
those patients with a first venous thrombosis and at least one prescription of antibiotic 
use during the observation period from February 1999 to September 2004 (inclusion 
period for MEGA case-control study) were included in this analysis (n=1584). 
We derived measures of the relative incidence of events during exposure to 
antibiotics as compared with all other observed time periods for each patient. The null 
hypothesis was that venous thrombotic event rates remain constant from day to day 
and are not affected by an acute exposure of antibiotic use. The period of exposure 
was defined as extending up to end of treatment with antibiotics. Additional analyses 
were performed in which only the first week after the prescription of an antibiotic was 
considered exposed person-time. All other observation time was taken as the baseline 
period (i.e., without exposure). This method and the time intervals used are illustrated 
in Figure 1. Conditional Poisson regression was used to estimate incidence rate ratios 
(with 95% confidence intervals [CIs]) for events occurring within the period of exposure 
as compared with the baseline period. Subgroup analyses were performed in patients 
Figure 1. Risk periods in the self-controlled case series analysis
Baseline period Risk period
      1st Day of exposure                1st Day of exposure
     Time
Start             End
1 February 1999             30 September 2004
As shown in this example, the effect of each infectious stimulus was analyzed separately
for the outcome of venous thrombosis. All individuals had at least one exposure to the
stimulus (prescription of antibiotic), and had at least one venous thrombotic event. Risk
periods were defined as total period of antibiotic drug use (not drawn to scale), which was
further divided into the first week of use.
with either DVT only, PE only or PE with or without DVT and in patients with either a 
provoked or unprovoked first event. Additionally, incidence rate ratios were estimated 
for the three types of antibiotics.
2) Synergy between antibiotic use with genetic thrombophilia to venous thrombosis risk
The combination of genetic and environmental factors is often accountable for 
the development of venous thrombosis.[18] It is therefore likely that if infections 
increase the risk of venous thrombosis, the risk will be highest in combination with 
thrombophilic abnormalities such as factor V Leiden. We therefore assessed the extent 
of a joint effect on a multiplicative scale between antibiotic use and the presence of 
factor V Leiden, blood group non-O or prothrombin G20210A mutation to the risk for 
venous thrombosis in a case-only study.[19,20] In a case-only study one examines the 
association between an exposure and a genotype among case subjects only. The case-
only study relies on the assumption that the two factors of interest are independently 
distributed in the general population which is a reasonable assumption for genetic risk 
factors and infectious diseases. Patients with first venous thrombosis were divided into 
those with a venous thrombotic event during a period of antibiotic use and patients 
who did not use antibiotics at the moment of the event. The odds ratios for genetic 
thrombophilia (i.e., factor V Leiden, the prothrombin mutation or blood group) then 
estimate the synergy index on the multiplicative scale.[20] This synergy index is the 
factor by which the odds ratios of genetic thrombophilia and antibiotic use have to be 
multiplied to obtain the joint odds ratio.
3) Antibiotic use and subsequent recurrent venous thrombosis risk
In a cohort study design we tested whether antibiotic use is associated with recurrent 
venous thrombosis. Duration of follow-up for recurrent venous thrombosis was 
estimated as the time at risk from the date of the index (first) thrombotic event to the 
end of follow-up. The end of follow-up was defined as the date of a recurrent event 
and in the absence of a recurrence, the date of filling in the follow-up questionnaire. 
If a patient did not fill in a questionnaire, they were censored at the last date we knew 
them to be recurrence free. This could be date of death (n=49), date of emigration 
(n=1), date of the last visit to the anticoagulation clinic (n=264) or the last moment 
known to be recurrence free from information of the MEGA case-control study (n=198). 
Details of assessment of end of follow-up have been described previously.[13] In the 
analyses we considered certain recurrent events only (n=367). Patients with uncertain 
recurrent events (n=120) were censored from this uncertain recurrent event onward.
Incidence rates of recurrent venous thrombosis were estimated as the number of 
events over the accumulated follow-up time and with person time split for periods 
with antibiotic treatment and periods without antibiotic treatment, without a wash-
out period. This means that a patient with antibiotic use during follow-up contributes 
with one or several observation periods of exposed and non-exposed person-time. The 
association between antibiotic use and recurrent venous thrombosis was estimated 
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by means of Cox regression analysis with antibiotic use entered as a time-varying 
variable. Hazard ratios with corresponding 95% confidence intervals were estimated 
and corrected for age and sex. Exposure to antibiotics was first set at the total period 
of antibiotic use by the patient and additionally set at the first week of antibiotic use. 
The rest of the time was set at non-exposed person-time. 
All statistical analyses were performed using SPSS, version 20.0 (IBM Corp., Armonk, 
NY) and Stata, version 12 (Stata Corp., College Station, Texas).
Table 1. Clinical Characteristics*
Patients linked 
to SFK
Patients not linked 
to SFK
Total
N (%) 2547 (54%) 2184 (46%) 4731 (100%)
Median age, years (range) 51 (18-70) 47 (18-70) 50 (18-70)
Male sex, n (%) 1197 (47%) 967 (44%) 2164 (46%)
DVT only, n (%) 1490 (59%) 1257 (58%) 2747 (58%)
PE +/- DVT, n (%) 1057 (41%) 927 (42%) 1984 (42%)
PE only, n (%) 826 (32%) 723 (33%) 1549 (33%)
Provoked† 1732 (68%) 1565 (72%) 3297 (70%)
   Malignancy 247 (14%) 174 (11%) 421 (13%)
   Trauma/surgery/immobilisation 1033 (60%) 869 (56%) 1902 (58%)
   Plaster cast 107 (6%) 112 (7%) 219 (7%)
   Estrogen use (women) 663 (61%) 687 (67%) 1350 (64%)
   Pregnancy/puerperium (women) 86 (8%) 87 (8%) 173 (8%)
   Travel >4 hours 367 (21%) 350 (22%) 717 (22%)
Unprovoked 742 (29%) 559 (26%) 1301 (28%)
Factor V Leiden, n (%) 344 (14%) 308 (14%) 652 (14%)
Prothrombin G20210A, n (%) 112 (4%) 106 (5%) 218 (5%)
Blood group non-O, n (%) 1590 (62%) 1323 (61%) 2913 (62%)
* At time of first venous thrombotic event
† Data were missing for some patients in some subgroups
Results
 2547 patients could be linked to the SFK data register and were included for analyses. 
Characteristics of these patients at the first venous thrombotic event are shown in 
Table 1. Median age of the patients was 51 years and 1197 (47%) patients were men. 
Most first venous thrombotic events were deep vein thrombosis (59%) and most first 
events were provoked by a provoking risk factor (68%). Baseline characteristics did not 
differ between those who could and could not be linked to SFK (Table 1).
1) Antibiotic use and first venous thrombosis risk
1584 patients with a first venous thrombotic event had at least one prescription of 
antibiotics in the period from February 1999 to September 2004. These patients were 
included in the SCCS analysis. During the aggregated period of antibiotic use the risk of 
a first venous thrombotic event was five-fold increased (Incidence rate ratio (IRR) 5.1; 
95%CI, 4.1-6.3) as compared with periods without antibiotic use (Table 2). During the 
first week of antibiotic use the IRR was 5.3 (95%CI, 4.2-6.6)). 
Clinically, a presentation of PE, and to a lesser extent DVT, may at first be 
misdiagnosed as an infection. We tried to reduce misclassification step by step. We 
excluded 13 individuals in whom such misclassification certainly played a role, based 
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on information from discharge letters. When we excluded these patients, the overall 
risk of venous thrombosis was 4.5-fold increased during antibiotic use (IRR 4.5; 95%CI, 
3.6-5.6). For DVT only, the IRR remained 3.2-fold increased (95% CI, 2.2-4.7) during 
antibiotic use. Incidence rate ratios for a first provoked venous thrombotic event were 
somewhat higher than for a first unprovoked thrombosis. 
Incidence rate ratios for the three types of antibiotics are shown in Table 3. There 
were 1357 patients who had at least one prescription of antibiotics for a wide range of 
infections, 218 patients who had at least one prescription of antibiotics mainly used for 
skin infections and 622 patients had at least one prescription of antibiotics mainly used 
for urinary tract infections. The risk of venous thrombosis was almost five-fold increased 
(IRR 4.7; 95%CI, 3.6-6.1) for the first group of antibiotics with a substantial difference 
between DVT (IRR~3) and PE (IRR~7). For antibiotics used mainly for infections of 
the skin the risk of venous thrombosis was about four-fold (IRR 4.1; 95%CI, 1.7-10.0) 
increased, with roughly similar risks for DVT and PE. For antibiotics used mainly for 
urinary tract infections the risk of both DVT and PE was three-fold increased, with IRR’s 
of 3.2 (95%CI, 1.9-5.6) and 3.0 (95%CI, 1.3-6.8) for DVT and PE, respectively.
 
2) Synergy between antibiotic use with genetic thrombophilia 
There were 114 patients with a first venous thrombotic event during a period of antibiotic 
use. Odds ratios, estimating the synergy indices for Factor V Leiden and prothrombin 
mutation, were both 1.0 (95%CI, 0.6-1.8) and 1.0 (95%CI, 0.4-2.5) respectively. This 
implies that the joint effect of both genetic factors and antibiotic use is equal to the 
product of the separate effects of both antibiotic use and the genetic factors (Table 
4).[21] Given the effects of genetic variants and antibiotic use, this implies a high joint 
risk, which is about 9 for the joint presence of a genetic variant and antibiotics use. 
The synergy index for blood group non-O was somewhat lower (0.7; 95%CI, 0.5-1.1) 
and therefore the joint effect of both antibiotic use and blood group non-O does not 
become high. 
3) Antibiotic use and subsequent recurrent venous thrombosis risk
Of 2547 patients included in this analysis 367 had a recurrent thrombosis, yielding 
an incidence rate of 29.1 /1000 person-years (95%CI, 26.3-32.3). During follow-up 
1401 patients (55%) had at least one prescription of antibiotics. The incidence rate of 
recurrent venous thrombosis was 56.2/1000 person-years (95%CI, 29.2-108.0) during 
antibiotic use, while it was 28.8/1000 person-years (95%CI, 25.9-31.9) for periods 
without antibiotic use. The recurrence risk was two-fold increased during the use of 
antibiotics (HR 2.0; 95%CI, 1.1-4.0). During the first week of antibiotic use, the risk was 
2.9-fold (95%CI, 1.4-6.1) increased.
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Total duration of antibiotic use
   Baseline period 12439 (2547) 358 28.8 (25.9-31.9) 1 (reference)
   Antibiotic use 160 (1401) 9 56.2 (29.2-108.0) 2.0 (1.1-4.0)
First week of antibiotic use
   Baseline period 12511 (2547) 360 28.8 (26.0-31.9) 1 (reference)
   Antibiotic use 89 (1401) 7 78.7 (37.5-165.0) 2.9 (1.4-6.1)
*Per 1000 person-years
†Adjusted for age and sex









- 84 1784  1.0 (0.6-1.8)
Prothrombin G20210A
+ 5 107
- 95 2005  1.0 (0.4-2.5)
Blood group non-O
+ 65 1519
- 35 586 0.7 (0.5-1.1)
Discussion
Summary of findings
We found an increased risk for both first and recurrent venous thrombosis during 
periods of antibiotic use. Both for first and recurrent venous thrombosis relative risks 
were highest during the first week of use.
Incidence rate ratios of a first venous thrombotic event ranged from three to 
seven. Since symptoms of a venous thrombotic event might mimic an infection, we 
took several steps to reduce misclassification. After exclusion of patients for whom 
misclassification was likely and including patients with DVT only (for which we expect 
less misclassification than in patients with PE) we still found a three-fold increased risk 
of venous thrombosis, indicating that our results are robust. For antibiotics prescribed 
mainly for urinary tract infection, for which we expect no misclassification, we found an 
increased risk of DVT of 3.2 (95%CI, 1.9-5.6) and an increased risk of PE of 3.3 (95%CI, 
1.7-6.5). In addition, we found a synergy index of around 1 between antibiotic use 
and both factor V Leiden and the prothrombin mutation, which leads to high joint 
relative risks. This appeared not to be the case for blood group non-O. We found a two-
fold increased recurrence risk for patients with a history of venous thrombosis using 
antibiotics as compared with those patients not using antibiotics. 
Previous studies
In the last decade several studies have been published that investigated the risk of a 
first venous thrombotic event after infections and inflammatory diseases.[6, 7, 22-24] 
In a large register study from Denmark over 15 000 cases with venous thrombosis 
were matched to controls from the general population.[24] Within three months after 
a hospital diagnosed infection the risk of venous thrombosis was increased three-
fold as compared with patients without infection (IRR 3.3; 95%CI, 2.9-3.8). The risk of 
venous thrombosis was almost three-fold increased after antibiotic treatment in the 
community (IRR 2.6; 95%CI, 2.5-2.8), with higher risks for antibiotics prescribed for both 
respiratory tract and skin or soft tissue infections than for antibiotics prescribed for 
urinary tract infections. The associations were strongest within the first two weeks and 
gradually declined thereafter. These results are quite similar to our findings. Ribeiro et 
al showed in the MEGA case-control study that self-reported pneumonia substantially 
increased the risk of venous thrombosis in the subsequent year (OR 4.8; 95%CI, 3.6-6.2) 
after adjustment for many confounding factors.[23] It was shown that the association 
could only partially be explained by a concurrent period of immobilization or lifestyle. 
In a large case-control study based on a general practice database from the UK 4.0% 
of DVT cases was reported to have a respiratory infection in the year before the index 
date as opposed to 2.3% in the controls.[22] An increased risk of DVT was found in the 
month following infection (OR 2.6; 95%CI, 1.6-4.3). In this study urinary tract infections 
were less strong risk factors for venous thrombosis than respiratory infections. There 
was only weak evidence for an association with subsequent DVT and no evidence of an 
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increased risk of PE following urinary tract infections. The authors suggest these latter 
findings might be explained by small numbers.
Misclassification of symptoms of either DVT or PE as an infection might have 
affected all of abovementioned studies. The study based on the UK general practice 
database[22] reduced possible misclassification by excluding patients with a 
respiratory infection in the month before PE. The other studies were not able to reduce 
misclassification. People with and without diagnosed infections probably are different in 
other aspects besides their infection, therefore comparison between individuals could 
be misleading and correction for potential confounders is crucial. In the large registry 
study from Denmark[24] correction for confounders affected results considerably and 
the covariate with the most influence was a measure of frailty or immobility. Although 
most of abovementioned studies corrected for many potential confounders, residual 
confounding remains possible. Smeeth and colleagues solved the part of the problem 
caused by intransient confounders by performing a self-controlled case study.[6] During 
the first week of a urinary tract infection the risk of both DVT and PE was increased 
two-fold. During the first week of a respiratory tract infection the risk of DVT was also 
increased two-fold (IRR 1.9; 95%CI, 1.5-2.4). Relative risks that we found are somewhat 
higher than the results from Smeeth (IRR ~3). This may be explained by the inclusion of 
objectively identified thrombotic events only, while events by Smeeth et al. came from 
an electronic database. 
One previous study showed a moderately strong relation between inflammatory 
bowel disease and recurrent venous thrombosis[25] with a relative risk of 2.5 (95%CI, 
1.4-4.2). This supports the hypothesis that infection/ chronic inflammation increases 
the risk of recurrent venous thrombosis as well.
Interpretation of our findings
Several explanations are possible for our findings of an increased risk of venous 
thrombosis during antibiotic use: 1) infections increase the risk of venous thrombosis 
through a systemic effect; 2) infections increase the risk of venous thrombosis through 
immobilisation/ bedrest; or 3) antibiotics have a direct effect on the risk of venous 
thrombosis. It has been described that oral application of some of the antibiotic drugs 
(i.e. macrolides, penicillins) can lead to overgrowth of Gram-negative bacteria in the 
gut.[26] This shift has been causally associated with entrance of Gram-negative bacteria 
into the blood stream and ultimately increased circulatory levels of lipopolysaccharides 
(LPS) inducing a pro-coagulant state.[27-29] This could lead to the hypothesis that 
some antibiotics might contribute to the development of clinical venous thrombosis 
by changing the gut microbiome. However, we have seen increased risks of venous 
thrombosis for all types of antibiotics and side-effects are rarely a class-effect. Since 
we have seen increased thrombosis risks for all types of antibiotics, amongst others 
antibiotics prescribed for urinary tract infection, immobilisation as the explanation for 
the increased risks is also improbable. This suggests the first explanation might be the 
right one.
Strong points
Strong points of this study are that for the association between antibiotic use and 
first venous thrombosis we used the self-controlled case series method. By using this 
method confounding by fixed factors, like the above mentioned frailty, is accounted for. 
Furthermore, since exposure to antibiotic treatment was recorded independent of the 
subsequent venous thrombotic event, biased ascertainment of exposure does not play 
a role. Requirements for the use of a self-controlled case series method are that the 
association concerns an acute event and a transient exposure, which was the case for 
our research question. Furthermore, the probability of exposure must not be altered 
by a previous event. We can safely assume that the probability of antibiotic use is not 
altered by a previous venous thrombotic event. 
Another strong point of this study is that both first and recurrent venous thrombotic 
events were objectively confirmed. Other studies relied on thrombotic events reported 
in electronic databases often without diagnostic information. In our study possible 
recurrences were classified into certain recurrences and uncertain recurrences and 
only certain recurrences were taken into account. The main purpose of this was to 
distinguish extensions of a first event from truly new thrombosis. 
Limitations
Some potential limitations should be mentioned as well. First, an early presentation of 
PE might be misdiagnosed as a respiratory tract infection. For DVT and infections of the 
skin of the leg the same may be true. To reduce this possibility of misclassification, we 
excluded patients for whom we were sure that such misclassification took place, from 
information of discharge letters. Furthermore, such misclassification will be unlikely 
for urinary tract infections and DVT and PE, and for skin infections and PE. During 
treatment for urinary tract infections the risk of both DVT only and PE only was still 3.2- 
and 3.3-fold increased in our study. In addition, the risk of PE during treatment for skin 
infections was 3.2-fold increased. Some misclassification of infectious diseases might 
have occurred since our definition of an infection was solely based on the antibiotic 
class that was prescribed. Second, our results may not be generalizable to all types of 
infection since we did not have data on antibiotic use during hospital stays and since 
we used antibiotic use as a proxy for infectious diseases, we do not have data on viral 
infections and the risk of venous thrombosis. Third, as cancer might increase the risk of 
both infections and venous thrombosis a diagnosis of cancer could account for some of 
the associations we observed. However, the results for patients with an unprovoked first 
venous thrombosis (in whom no patients with cancer were present) were in the same 
line as for total venous thrombosis; i.e. an increased risk of venous thrombosis at time 
of antibiotic use, especially in the first week after the start of antibiotic use. Therefore, 
cancer diagnoses do not explain our findings. Fourth, although we have used the self-
controlled case series method to study the association between antibiotic use and first 
venous thrombotic events, in which intransient confounders do not play a role, residual 
transient confounders might account for some of the association we observed. Fifth, 
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in our analyses on recurrent venous thrombosis we were, because of small numbers, 
unable to correct for additional variables besides age and sex and residual confounding 
factors might play a role in the association we found there. Additionally, because of 
small numbers, we were not able to study different types of venous thrombosis and/or 
different types of antibiotics, so that we can not exclude misclassification of events. For 
the same reason we were not able to study the combined effect of antibiotic use and 
genetic thrombophilia on the risk of recurrences. 
Conclusion
To conclude, individuals who receive antibiotics (which we used as a proxy for infection), 
have an approximately three-fold increased risk of a first venous thrombotic event and 
a two-fold increased risk of recurrent venous thrombosis. Our results should increase 
awareness of the risk of venous thrombosis in patients with infections, in treating 
physicians in and out of hospital. Furthermore, accuracy of treatment strategies 
might be improved by a revision of the current definition of ‘unprovoked’ events. 
Future clinical trials may be required to determine whether patients with prior venous 
thrombosis who use antibiotics should or should not receive thromboprophylaxis to 
decrease their risk of recurrence. 
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Aim of this thesis
 
Although a long list of risk factors has been described for a first venous thrombotic 
event, the risk profile for recurrent venous thrombosis is not that well known. Also, 
data on factors able to predict the risk of recurrence are scarce. The aim of this 
thesis was to study several (modifiable) risk factors and predictors for their relation 
with recurrent venous thrombosis. In this chapter I provide an overview of the main 
findings. Furthermore, I will consider the clinical implications of this work and discuss 
directions for future research.
Overview of main findings
Incidence of recurrent venous thrombosis and known risk factors for recurrence
In Chapter 2 the design and the first results from the MEGA follow-up study were 
described. Information on recurrent events from several sources of information was 
combined to obtain a valid estimate of the incidence of recurrent venous thrombosis. 
The overall incidence of recurrence in a group of patients with a first deep vein 
thrombosis of the leg or pulmonary embolism was 27.9 per 1000 person-years, with 
a 5-year cumulative incidence of 11%. These incidences were somewhat lower than 
reported in previous literature. This probably has to do with our use of a strict definition 
of a true recurrent event, to distinguish recurrence from an extension of the first. Men 
had about a two-fold increased risk of recurrent venous thrombosis as compared with 
women and a first idiopathic event was associated with a one and a half- to two-fold 
increased risk as compared with a first provoked event. Age did not affect recurrence 
risk. For deciding on the duration of anticoagulant treatment in patients with a first 
venous thrombotic event this information should be taken into account.
Cancer and (recurrent) venous thrombosis
A strong relation between cancer and venous thrombosis was identified already in 
the early 19th century. Chapter 3 presented an overview of all knowledge gained on 
the incidence of and risk factors for cancer-associated venous thrombosis over the 
years. About 20-30 percent of all venous thrombotic events is cancer-associated and 
cancer increases the risk of thrombosis about four- to seven-fold. The risk of venous 
thrombosis in patients with cancer depends on several factors, e.g., cancer type and 
stage, treatment measures and patient-related factors. This information provides a basis 
for the identification of high-risk patients who could benefit from thromboprophylaxis 
and for further development and refinement of prediction models. 
The risk of recurrent venous thrombosis in patients with cancer has not been 
studied extensively. In Chapter 4 the risk of recurrent venous thrombosis in patients 
with cancer was evaluated, also in relation to time of diagnosis of the malignacy 
and in several types of cancer patients. Patients with cancer and thrombosis had an 
increased risk of recurrent venous thrombosis compared with patients without cancer. 
Participants with cancer diagnosed before the first venous thrombotic event who died 
or had metastases had a two- to three-fold increased risk of recurrent thrombosis 
compared with patients without cancer, while patients with non-metastasized cancer 
or who did not die of cancer did not have an increased recurrence risk. Participants with 
cancer diagnosed after the first thrombosis had an increased recurrence risk, which 
was especially high in the first three months after cancer diagnosis (about five-fold 
compared with patients without cancer). Risk of recurrent venous thrombosis differed 
for different types of cancer, for different stages of cancer and for different time periods 
after cancer diagnosis. Currently, guidelines provide treatment recommendations for 
the group of patients with cancer and venous thrombosis as a whole.[1,2] Our study 
supports current thought that risk of recurrent venous thrombosis is not the same 
for all patients with cancer and that stratification of patients with cancer-associated 
venous thrombosis according to their recurrence risk is of relevance to offer these 
patients a better tailored treatment approach. 
The pathophysiology underlying the association between cancer and venous 
thrombosis is largely unknown. Furthermore, it is not known in what way patients with 
cancer who develop thrombosis are different from those who do not. In Chapter 5 
several plasma coagulation factor levels (procoagulant, anticoagulant and fibrinolytic) 
were studied in four groups of individuals with and without cancer and with and 
without venous thrombosis. Increased levels of procoagulant coagulation factors in 
participants with thrombosis without cancer and even higher levels of these factors 
in participants with both venous thrombosis and cancer were found, suggesting 
generalized effects of procoagulant pathways in patients with cancer and emphasizing 
the importance of coagulation in cancer-associated venous thrombosis. Results were 
most pronounced for factor VIII and von Willebrand factor. Levels of factor VII were 
increased in participants with cancer and were unaffected by the presence or absence 
of thrombosis. The finding of slightly increased levels of anticoagulant proteins, free 
protein S and TFPI in participants with cancer and venous thrombosis is suggestive of 
an additional role of anticoagulant pathways in cancer. These data give more insight 
into the relation between venous thrombosis and cancer.
Risk factors and predictors for recurrent venous thrombosis
In Chapter 6 the predictive value of coagulation factor VIII levels for recurrent venous 
thrombosis was studied. Recurrence rates steadily increased with higher factor VIII 
activity levels and patients in the highest category of FVIII (>200 IU/dL) had a three-fold 
higher recurrence rate than patients in the lowest category (≤100 IU/dL). Results were 
robust in several sensitivity analyses and factor VIII was able to predict recurrence rates 
over a long time period. Adding factor VIII to an existing prediction model (DASH-score) 
improved its predictive value, and after replacing D-dimer by factor VIII, the model 
performed equally well if not better. Factor VIII will be able to refine recurrence risk 
estimation at an individual level and factor VIII should be considered in recurrence 
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prediction tools. Whether measurement of factor VIII levels is to be preferred over 
D-dimer levels, which has as a major disadvantage that it can only be reliable measured 
after discontinuation of anticoagulant treatment, should be a topic for further research.
Despite guideline recommendations to discontinue hormonal contraceptive use 
after a first thrombotic event, still a sizeable proportion of women continue or start 
using hormonal contraceptives after a venous thrombosis. In Chapter 7 the effect 
of this use on the recurrence risk was studied in premenopausal women. Hormonal 
contraceptive use during follow-up was associated with a two-fold increased risk of a 
recurrence. In particular, the use of combined oral contraceptives was associated with 
an almost three-fold increased risk. The data suggest that it would be wise for women 
with a history of venous thrombosis to adhere to the guidelines and refrain from this 
modifiable risk factor. Recurrence rate among hormonal IUD users was similar as in 
non-users, suggesting that a levonorgestrel-releasing IUD may be safely used after a 
first event. 
The risk of thrombosis after long-haul travel in those with a history of venous 
thrombosis is not known, while thromboprophylaxis may be indicated in these patients. 
In Chapter 8 the relation between long-haul travel (>4 hours) and recurrent venous 
thrombosis was studied. The risk of recurrent venous thrombosis was not increased 
in participants with recent long-haul travel, either after a flight or after other types of 
long-haul travel. This would suggest thromboprophylaxis is not needed in individuals 
with a history of venous thrombosis undertaking a long-haul trip. However, the lack 
of an effect may also be explained by a different health status in people who travel 
versus those who do not that could not be completely adjusted for. Also, for immobility 
in daily life due to seated work or confinement to a wheelchair no association with 
recurrent venous thrombosis was found. Again, results might be explained by residual 
confounding or perhaps use of anticoagulant treatment which we could not fully adjust 
for. Further studies are needed to give a definite answer as to whether refraining or 
intervening on this modifiable risk factor is beneficial.
The aim of Chapter 9 was to study whether individuals who receive antibiotic 
treatment (as a proxy for infectious disease), have an increased risk of first or recurrent 
venous thrombosis. By means of a self-controlled case series study design the risks 
of both a first deep vein thrombosis and a first pulmonary embolism were found to 
be increased at least three-fold during antibiotic use. The major advantage of a self-
controlled case series design is that fixed confounders, like frailty, do not play a role. 
For recurrent venous thrombosis similar results were found, with a two-fold increased 
risk of recurrent venous thrombosis during periods of antibiotic use as compared with 
periods with no use. These results should increase awareness in clinicians of the risk of 
venous thrombosis in in- and out-patients who are ill and get antibiotics. Furthermore, 
acute infectious disease should be added to the list of provoking factors for venous 
thrombosis.
Directions for future research
This thesis adds to the current knowledge on risk factors and predictors for recurrent 
venous thrombosis. This type of research is sometimes called prognostic factor research, 
in which prognostic factors are defined as factors able to distinguish between groups 
of people with a different average prognosis.[3] Such prognostic factors, however, do 
not yet provide enough distinctive power on their own to classify patients individually 
at high or low risk of recurrence. After identification of such prognostic factors the next 
step would be to create a prognostic model, the aim of which is to develop, validate and 
test the impact of statistical models that predict individual risks of a future outcome. 
For an individual with a given state of health, in our case patients with a first venous 
thrombotic event, a prognostic model converts the combination of predictor values to 
estimates of the risk of experiencing a specific endpoint within a specified time period.
[4] Therefore, after this thesis, the next step should be to focus on taking all factors 
together and use them as building blocks for a prognostic model, which will be able to 
predict recurrences at a much more refined and individual level. 
Current Prediction models
Currently three prediction models have been published for recurrent venous 
thrombosis; 1) the Men continue and HERDOO2 rule; 2) the Vienna prediction model 
and 3) the DASH score.
1. The ‘Men continue and HERDOO2’ rule (see Table 1) was published in 2008 by 
Rodger and colleagues.[5] In this multicentre prospective study, over 600 patients 
with a first unprovoked venous thrombosis were followed for a mean of 18 months. 
Clinical characteristics as well as blood samples were collected during anticoagulant 
treatment five to seven months after the start of treatment. The authors sought 
to determine the clinical predictors or combinations of predictors that identify 
patients with an annual recurrence risk of less than 3% after taking six months of 
anticoagulant treatment, which they considered sufficiently low to discontinue oral 
anticoagulants. 
The authors found no combination of clinical predictors for identifying a low-
risk subgroup of men, which is why men were advised to continue anticoagulant 
treatment long-term. Additionally, women with ≥2 of the following risk factors: 
postthrombotic signs (hyperpigmentation, edema or redness in either leg), D-dimer 
level ≥250 μg/L, BMI ≥30 kg/m2 and age ≥65 years were advised to continue 
treatment. Authors concluded that women with a score of ≤1 (52% of women) 
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2. Two years after the ‘Men continue and HERDOO2 rule’ the Vienna prediction 
model (see Table 2) was published by Eichinger and colleagues.[6] In this 
multicentre prospective cohort study over 900 patients with a first unprovoked 
venous thrombosis were followed for recurrence with the aim to develop a 
simple risk assessment model. Median follow-up of the patients was 43 months 
after discontinuation of anticoagulant treatment. Blood was drawn shortly after 
discontinuation of treatment. Eichinger et al. found male sex, proximal deep vein 
thrombosis, pulmonary embolism and elevated D-dimer levels to be associated 
with recurrence. Using these variables a nomogram (see Figure) was developed 
that can be used to calculate risk scores and to estimate cumulative probabilities 
of recurrence. C-statistics for the models at 12 and 60 months were 0.67 and 0.65, 
respectively. Additionally, a web-based risk calculator was developed (http://
cemsiis.meduniwien.ac.at/en/kb/science-reserach/software/clinical-software/
recurrent-vte/), to calculate risk scores and cumulative probabilities of recurrence 
in an individual patient. Based on these predicted risks the physician can decide 
whether to stop or continue anticoagulant treatment.
Table 2. Vienna prediction model
Predictive values Points
Sex
   Males 60
   Females 0
Site of first venous thrombotic event
   Distal Deep Vein Thrombosis 0
   Proximal Deep Vein Thrombosis 70
   Pulmonary Embolism 90
D-dimer levels
   Continuous 0-100
Table 1. ‘Men continue and HERDOO2’
Predictive factors Advice
Men Long-term anticoagulant treatment
None
Women Long-term anticoagulant treatment if score ≥2
Score
•	 Postthrombotic signs 
	 (hyperpigmentation, edema or 
redness in either leg)
1
•	 D-dimer level ≥250 µg/L 
	 (during anticoagulant treatment)
1
•	 BMI ≥30 kg/m2 1
•	 Age ≥65 years 1
Figure from Eichinger S, Heinze G, Jandeck LM, Kyrle P. Risk assessment of recurrence 
in patients with unprovoked deep vein thrombosis or pulmonary embolism. Circulation 
2010;121:1634. With permission from Wolters Kluwer Health, Inc.
An update of the Vienna prediction model was published in 2014.[7] Over 500 
patients with an unprovoked venous thrombosis were seen at 3 weeks (baseline), 3, 
9, 15 and 24 months after discontinuation of anticoagulant treatment. At every time 
point blood for measurement of D-dimer levels was collected. Separate nomograms 
for the prediction of recurrent venous thrombosis were developed for each time 
point including the same variables as the original Vienna prediction model. Another 
web-based calculator was developed for this dynamic Vienna prediction model 
which allows prediction of recurrence from any points between baseline and 15 
months after anticoagulant treatment discontinuation (http://www.meduniwien.
ac.at/user/georg.heinze/dvpm/).
3. The DASH score (see Table 3) was developed in 2012 by Tosetto and colleagues by 
pooling individual patient data from seven prospective cohort studies.[8] Over 1800 
patients with an unprovoked venous thrombosis, treated for at least three months, 
were included for analyses and followed for a median of 22 months. Blood was 
sampled several weeks after discontinuation of anticoagulant treatment. Abnormal 
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Hormonal therapy (in women) were the main predictors of recurrence and were 
used to derive the DASH score. C-statistic for the model was 0.71. Patients with a 
score ≤1 had an annualized recurrence risk of 3%, while the risk was over 12% for 
patients with score ≥3. With 52% of patients falling into the first group, the authors 
concluded that in about half of the patients with unprovoked thrombosis life-long 
anticoagulation might be avoided.
Table 3. DASH score
Predictive factors Score
Elevated D-dimer levels one month after  
   discontinuation of anticoagulant treatment
2
Age <50 years 1
Male sex 1
Women taking oral contraceptives -2
Low risk of recurrence when the score ≤1
Before a prediction model can be adopted in practice it is necessary to show that 
predictions of the model are valid in another sample of patients than the specific 
context of the sample that was used for model development. This is important because 
the predictive performance of a model estimated on the development data is often 
optimistic, due to multiple testing with a limited sample size.[4] Such external validation 
of abovementioned models was not performed until recently which is probably why the 
models are not currently used in the clinic. The only model externally validated so far is 
the Vienna prediction model.[9,10] Pooled individual data from five prospective studies 
were used to test the prognostic value of the model.[9] The authors concluded that the 
ability to distinguish risk of recurrent venous thrombosis was at least as good in the 
validation cohort as in the derivation cohort, with a calibration slope of 1.17 (95%CI; 
0.71-1.64) and a C-statistic of 0.63 (vs 0.65 in the derivation cohort). Performance of 
the model was less in an external cohort of elderly patients.[10] Lastly, studies would 
have to be performed in which the impact of a prediction model on decision making 
and patient outcomes is investigated. 
Some disadvantages and differences between the three models should be outlined. 
In the ‘Men continue and HERDOO2’ model no combination of clinical predictors for 
identifying a low-risk subgroup of men was found and all men were advised to continue 
anticoagulant treatment on the long-term. The authors did not have an explanation 
for this finding, although it seems unlikely that risk prediction is not possible at all 
in men. In this thesis the predictive value of levels of factor VIII for recurrent venous 
thrombosis was described (Chapter 6). Recurrence rates increased steadily with 
increasing factor VIII also in men. This suggests that not all men have a similar risk of 
recurrent venous thrombosis. Furthermore, in the HERDOO2 model levels of D-dimer 
were measured while patients were on anticoagulant treatment. Although in the clinic 
it would be a major advantage to assess recurrence risks while patients are still on 
anticoagulant treatment, several studies have shown that only 5-12% of patients have 
increased D-dimer levels during treatment with vitamin K antagonists.[11-13] One of 
abovementioned studies has actually suggested to omit the D-dimer measurement 
during anticoagulation.[13]
The Vienna prediction model has recently been updated for several time points 
after discontinuation of anticoagulant treatment and the model has both been 
internally and externally validated with reasonable outcomes. The model enables to 
predict recurrence rates both in men and women and D-dimer levels were measured 
after withdrawal of anticoagulant treatment. However, the Vienna model is considered 
complex for routine use. The model does not provide a simple scoring system and cut-
off value for discontinuation or extension of anticoagulant treatment. This is probably 
the reason why this model is still not used much in the clinic.
The DASH-score provides a simple scoring system for both men and women 
and a cut-off value for when anticoagulant treatment may be safely discontinued. 
Interestingly, the DASH-model indicates age less than 50 as a risk factor for recurrence, 
while the Vienna model attributes a higher risk to age greater than 65. In the MEGA 
follow-up study age was not associated with recurrent venous thrombosis (Chapter 2). 
Additionally, hormone use at the first event (by women) is indicated to decrease the 
risk of recurrence, while in this thesis (Chapter 7) similar rates of recurrence for women 
who did or did not use hormones at time of the first event are reported.
Development of a prediction model in the MEGA follow-up study
The MEGA follow-up study is favourable for development of a prognostic model 
for recurrent venous thrombosis. In total, nearly 5000 patients with a first venous 
thrombotic event were followed over a long period of time for recurrences. 
Currently existing prognostic models (described above) all focus on patients with a 
first unprovoked event. This is because the recurrence risk is higher in these patients 
as compared with patients who had an event related to surgery or trauma for example.
[14] It is currently unknown for how long these patients should receive anticoagulant 
treatment. However, recurrent venous thrombosis in patients with a provoked first 
event is not uncommon.[15] In this thesis (Chapter 6) we have shown that although 
recurrence rates are low in patients with provoked first events, risk stratification is still 
possible in these patients. With a recurrence rate of 4% per year in patients with a 
provoked first event and factor VIII levels >200 IU/dL prolonged anticoagulation may 
still be warranted given the incidence rate of major bleeding of 1-2% per year.[16,17] 
Furthermore, the classification of an event as either unprovoked or provoked is artificial 
and controversial. In principle nearly all events are provoked by one or more factors. 
A prognostic model based on the MEGA follow-up study should take all patients into 
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In the MEGA study blood was collected only in patients with their date of first 
thrombosis before June 1st 2002. This was for logistic reasons only. After multiple 
imputation of the factors measured in blood, all participants of the MEGA follow-up study 
can be included for the development of a prognostic model. Often recommendations 
are made for the maximum number of preselected predictors that should be estimated 
in a prognostic model. The reason for this is that including too many predictor variables 
would lead to the situation of ‘overfitting’ of a model, which causes optimism about a 
model’s performance in new subjects out of the data under study. A common opinion 
is that the ratio of events to predictors (events per variable; EPV) should not be less 
than 10:1.[18] In 4731 patients included in the MEGA follow-up study, 673 recurrent 
venous thrombotic events were identified, meaning that 67 predictor variables may 
be preselected for the development of the prognostic model. This is more than the 
currently available prediction models could include, 9 (91/10), 17 (176/10) and 23 
(239/10) for the HERDOO2, Vienna and DASH models, respectively.[5,6,8]  
Since patients with a cancer-associated first venous thrombosis are so distinct from 
patients with a non-cancer associated event with regard to clinical characteristics and 
mortality risk, a separate prognostic model could be useful for this group of patients. 
Louzada et al. have published a prediction score for recurrent venous thrombotic events 
in patients with a cancer-associated first event, including four independent predictors 
(sex, primary tumor site, stage and prior venous thrombosis).[19] The performance of 
the score in an external cohort was reasonable.[20] 
A prognostic model for the prediction of recurrent events on the moment of 
discontinuation, or the moment of deciding on whether to discontinue or extend 
anticoagulant treatment, will be most useful for the clinic. This time-point is where 
follow-up should start in the MEGA follow-up study when developing a prognostic 
model. Ideally, the model includes factors that can be measured or collected during the 
anticoagulant treatment period, so that a decision can be made before anticoagulant 
treatment is unrightfully stopped (or continued). Factors that should in any event be 
preselected for the model, and are available in the MEGA follow-up study, are: age, sex, 
type of first event (provoked vs unprovoked), first PE vs DVT, proximal vs distal DVT, BMI 
and levels of factor VIII (given the results from Chapter 6). Of note, genetic factors might 
additionally play a role in a prognostic model for recurrent venous thrombosis, and 
should therefore be included in the list of preselected variables. The development of 
a prognostic model in the MEGA follow-up study should result in an easy to determine 
risk score and cut-off value for decisions on the duration of anticoagulant treatment.
To be able to predict the risk of recurrence at different moments in time, e.g., directly 
after the first event, at the moment of intended discontinuation of anticoagulant 
treatment or several years after a first event, a prediction model should be time-
dependent. For this, clinical characteristics as well as factors measured in blood should 
be collected at several time-points in a prospective follow-up study. Unfortunately, in 
the MEGA follow-up study we have data on factors measured in blood from one time-
point only. 
Conclusion
Secondary prevention of recurrent venous can be achieved in two ways, either by 
elimination of modifiable risk factors or by extending the anticoagulant treatment period 
in patients at high risk of recurrence. The aim of this thesis was to identify modifiable 
risk factors for as well as factors that might be able to predict recurrent venous 
thrombotic events. This thesis reports on an increased risk of recurrences in women 
who continue or start using hormonal contraceptives after a first venous thrombotic 
event, suggesting that refraining from this modifiable risk factor decreases the risk of 
recurrence. Furthermore, this thesis describes several factors, male sex, unprovoked 
first event, levels of coagulation factor VIII and antibiotic use to be associated with 
recurrent venous thrombosis. These factors should eventually be taken together and 
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Veneuze trombose, voornamelijk optredend als een diep veneuze trombose in het 
been of een longembolie, komt voor bij 1 tot 2 per 1000 mensen per jaar. Het is qua 
frequentie de derde cardiovasculaire ziekte wereldwijd en heeft in de vorm van een 
longembolie ernstige, soms dodelijke, gevolgen. Na een eerste veneuze trombose is 
de kans op een recidief trombose groot. Ongeveer 25% van de mensen met een eerste 
trombose krijgt binnen vijf jaar een recidief. Een recidief trombose kan voorkomen 
worden door het wegnemen van risicofactoren óf, wanneer dit niet mogelijk is, door 
het verlengen van de behandeling met antistollingsmiddelen. Antistollingsmiddelen 
kunnen bij patiënten echter resulteren in bloedingen. Om deze reden zou alleen bij 
patiënten met een hoog risico op recidief trombose de periode van behandeling met 
antistolling verlengd moeten worden.
Hoewel een lange lijst met risicofactoren beschreven is voor een eerste veneuze 
trombose, is het risicoprofiel voor een recidief trombose nog niet goed bekend. Ook is 
niet veel bekend over voorspellers van een recidief. 
Het doel van dit proefschrift was daarom om verschillende risicofactoren, met name 
die welke weggenomen kunnen worden, en voorspellers voor recidief trombose te 
bestuderen. 
Overzicht van de belangrijkste resultaten van dit proefschrift
Incidentie van recidief veneuze trombose en bekende risicofactoren
In Hoofdstuk 2 beschreef ik de opzet en eerste resultaten van de MEGA-vervolgstudie. 
Informatie over recidief trombose van verschillende bronnen werd gecombineerd om 
een precieze schatting te krijgen van de incidentie. De incidentie van recidief veneuze 
trombose was 27.9 per 1000 persoonsjaren in een groep patiënten met een eerste diep 
veneuze trombose van het been of een longembolie. De 5-jaars cumulatieve incidentie 
was 11%. Mannen hadden een tweemaal hoger risico op recidief veneuze trombose 
dan vrouwen en een eerste onverklaarde trombose was geassocieerd met een 
anderhalf tot twee keer verhoogd risico vergeleken met na een uitgelokte trombose. 
We vonden geen relatie tussen leeftijd en het recidiefrisico. Voor het bepalen van de 
juiste duur van behandeling met antistolling in patiënten met een eerste trombose 
dient deze informatie te worden meegenomen. 
Kanker en veneuze trombose
De sterke relatie tussen kanker en veneuze trombose werd al in de 18e eeuw 
beschreven. In Hoofdstuk 3 gaf ik een overzicht van de kennis over de incidentie van en 
risicofactoren voor kanker-geassocieerde trombose die sindsdien bekend is geworden. 





blijkt het risico op trombose vier tot zeven keer te verhogen. Het risico op veneuze 
trombose in patiënten met kanker hangt af van verschillende factoren, onder andere 
het type kanker en het stadium, behandelingen, en patiënt-gerelateerde factoren. 
Deze informatie vormt de basis voor de identificatie van hoog-risico patiënten die baat 
zouden kunnen hebben bij tromboseprofylaxe én voor het ontwikkelen en verfijnen 
van predictiemodellen.
Het risico op recidief veneuze trombose in patiënten met kanker is nog niet goed 
bestudeerd. In Hoofdstuk 4 heb ik dit risico in patiënten met kanker geëvalueerd, ook 
in relatie tot de tijd na de kankerdiagnose en voor verschillende types kanker. Patiënten 
met kanker en trombose hadden een verhoogd risico op recidief trombose, vergeleken 
met deelnemers zonder kanker. Patiënten met kanker die gediagnosticeered werd voor 
de eerste trombose hadden enkel een twee tot drie keer verhoogd risico op recidief 
trombose vergeleken met deelnemers zonder kanker, wanneer de kanker nog actief was 
na trombose (bij patiënten die uitzaaiingen hadden of de patiënten die later overleden 
aan kanker). Dit terwijl patiënten met kanker die waarschijnlijk in remissie was na 
trombose geen verhoogd risico hadden. Patiënten met kanker die gediagnosticeerd 
werd na de eerste trombose hadden ook een verhoogd recidiefrisico, dat met name 
hoog was in de eerste drie maanden na de kankerdiagnose (vijf keer verhoogd 
vergeleken met deelnemers zonder kanker). Het risico op recidief trombose verschilde 
voor verschillende types en stadia van kanker en voor verschillende tijdsperioden na 
de kankerdiagnose. Op dit moment geven de richtlijnen gelijke adviezen voor de hele 
groep patiënten met kanker en trombose tezamen. Hoofdstuk 4 laat zien dat het risico 
op recidief trombose niet voor iedereen gelijk is en dat het stratificeren van patiënten 
op basis van hun recidiefrisico belangrijk is om hen een beter passende behandeling 
te geven.
Het onderliggende mechanisme van de relatie tussen kanker en veneuze trombose 
is grotendeels onbekend. Bovendien is het niet bekend waarin patiënten met kanker 
die trombose ontwikkelen verschillen van patiënten die dat niet doen. In Hoofdstuk 
5 onderzocht ik concentraties van verschillende stollingsfactoren (procoagulant, 
anticoagulant en fibrinolytisch) in het bloedplasma van vier groepen deelnemers, 
deelnemers met en zonder kanker en met en zonder veneuze trombose. Wij vonden 
verhoogde spiegels van procoagulante stollingsfactoren in deelnemers mét trombose 
zonder kanker en nog hogere concentraties van deze factoren in deelnemers met zowel 
trombose als kanker. Dit suggereert dat procoagulante mechanismen een rol spelen in 
patiënten met kanker en benadrukt het belang van stolling in kanker-geassocieerde 
trombose. Resultaten waren het meest uitgesproken voor spiegels van stollingsfactor 
VIII en von Willebrand factor. Concentraties van stollingsfactor VII waren verhoogd in 
deelnemers met kanker en werden niet beïnvloed door de aan- of afwezigheid van 
trombose. Mijn bevinding dat de anticoagulante factoren, vrij proteïne S en TFPI in 
deelnemers met kanker en veneuze trombose verhoogd waren, suggereert een rol van 
de anticoagulante eiwitten in kanker. Deze data geven meer inzicht in de relatie tussen 
veneuze trombose en kanker. 
Risicofactoren en voorspellers van recidief veneuze trombose
In Hoofdstuk 6 onderzocht ik de voorspellende waarde van de concentratie van 
stollingsfactor VIII voor recidief veneuze trombose. De incidentie van recidieven nam 
gestaag toe met hogere factor VIII activiteit spiegels en deelnemers in de hoogste 
categorie van factor VIII (>200 IU/dL) hadden een drie keer verhoogd recidiefrisico 
vergeleken met deelnemers in de laagste categorie (≤100 IU/dL). De resultaten 
waren robuust in verschillende sensitiviteitsanalyses en deze informatie over factor 
VIII voorspelde de incidentie van recidieven over een lange tijdsperiode . Wanneer ik 
factor VIII toevoegde aan een bestaand predictiemodel, de DASH-score, verbeterde dit 
zijn voorspellende capaciteit, en na het vervangen van concentraties van D-dimer door 
factor VIII presteerde het model gelijk, zo niet beter. Factor VIII metingen kunnen de 
schatting van het recidiefrisico verfijnen en deze meting zou moeten worden betrokken 
in de ontwikkeling van predictiemodellen. Of het meten van factor VIII te prefereren is 
boven het meten van D-dimeer, dat als groot nadeel heeft dat het alleen betrouwbaar 
gemeten kan worden ná het stoppen met antistollingsmiddelen, zal in toekomstig 
onderzoek moeten worden uitgezocht.
Ondanks dat de huidige richtlijnen vrouwen na een eerste veneuze trombose 
aanraden te stoppen met het gebruik van hormonale anticonceptiva, gaat een aanzienlijk 
aantal vrouwen door of begint met het gebruik hiervan. In Hoofdstuk 7 onderzochten 
wij het effect van dit gebruik op het recidiefrisico in premenopauzale vrouwen. Het 
gebruik van hormonale anticonceptiva na de eerste trombose was geassocieerd met 
een tweemaal verhoogd risico op een recidief. In het bijzonder was het gebruik van 
gecombineerde orale anticonceptiva geassocieerd met een drievoudig verhoogd risico. 
Het is van belang dat de richtlijnen gevolgd worden wat betreft het afzien van het 
gebruik van orale anticonceptiva na een veneuze trombose. De incidentie van recidief 
trombose onder vrouwen met een hormoonafgevend spiraaltje was gelijk aan die in 
vrouwen die geen anticonceptiva gebruikten, wat suggereert dat een spiraaltje met 
levonorgestrel veilig kan worden gebruikt na een eerste trombose. 
Het risico op veneuze trombose na een lange reis in diegenen met een geschiedenis 
van trombose is niet bekend. Tromboseprofylaxe zou geïndiceerd kunnen zijn in 
deze patiënten. In Hoofdstuk 8 onderzocht ik de relatie tussen lange reizen (>4 uur) 
en recidief veneuze trombose. Het risico was niet verhoogd in deelnemers na een 
recente lange reis, zowel na een lange vliegreis als na een lange reis met een ander 
transportmiddel. Dit suggereert dat tromboseprofylaxe niet nodig is in patiënten met 
een geschiedenis van veneuze trombose die een lange reis gaan maken. Ook voor 
immobiliteit in het dagelijkse leven, bijvoorbeeld door het uitvoeren van zittend werk 
of het gebruik van een rolstoel, werd geen relatie met recidief trombose gevonden. Het 
is echter mogelijk dat ik niet voor alle confounding factoren heb kunnen corrigeren. 
Daarom zijn meer studies nodig om een definitief antwoord te geven op de vraag of 
patiënten baat hebben bij tromboseprofylaxe tijdens periodes van immobiliteit of dat 





Het doel van Hoofdstuk 9 was om te bestuderen of tijdens het gebruik van antibiotica 
(als een maat voor infectieziekten) het risico op een eerste of recidief veneuze trombose 
verhoogd is. Door middel van een ‘self-controlled case series’ studieopzet vond ik een 
tenminste drievoudig verhoogd risico op zowel een eerste diep veneuze trombose als 
een longembolie tijdens antibioticagebruik. Het belangrijkste voordeel van een ‘self-
controlled case series’ studie is dat niet-tijdsafhankelijke verstorende variabelen, zoals 
fitheid van de patiënt, geen rol spelen. Voor recidief trombose werden soortgelijke 
resultaten gevonden, met een verdubbeld risico op recidief trombose tijdens periodes 
van antibioticagebruik, vergeleken met periodes van geen gebruik. Deze resultaten 
laten zien dat artsen zich bewust moeten zijn van het risico op veneuze trombose bij 
zowel patiënten in als buiten het ziekenhuis die antibiotica krijgen. Verder zouden 
acute infecties toegevoegd moeten worden aan de lijst van uitlokkende factoren voor 
veneuze trombose.
Aanbevelingen voor toekomstig onderzoek
Dit proefschrift draagt bij aan de kennis van risicofactoren en voorspellende factoren 
voor recidief veneuze trombose. Dit type onderzoek wordt soms ‘prognostic factor 
research’ genoemd, waarin prognostische of voorspellende factoren gedefinieerd 
worden als factoren die groepen mensen kunnen onderscheiden met een verschillend 
risico op een bepaalde uitkomst. Zulke voorspellende factoren op zichzelf hebben 
echter nog niet voldoende onderscheidend vermogen om patiënten individueel te 
kunnen classificeren op een hoog of laag risico op recidieftrombose. Na identificatie 
van zulke voorspellende factoren is de volgende stap om een predictiemodel te maken. 
Voor een individu met een bepaalde gezondheidsstatus, in ons geval patiënten met een 
eerste veneuze trombose, zet een predictiemodel de combinatie van voorspellende 
factoren om tot schattingen van het risico op een specifiek eindpunt in een specifieke 
tijdsperiode. Daarom is de volgende stap alle factoren samen te voegen en deze te 
gebruiken als bouwstenen voor een model, dat recidief trombose op een meer verfijnd 
en individueel niveau zal kunnen voorspellen. 
De MEGA-vervolg studie is zeer geschikt hiervoor. Met bijna 5000 deelnemers en 700 
recidieven kunnen veel factoren geïncludeerd worden en getoetst op hun voorspellende 
waarde in het model. Anders dan de drie bestaande predictiemodellen voor recidief 
veneuze trombose zou dit model zich moeten richten op patiënten met zowel een 
uitgelokte als een idiopathische eerste trombose. Recidief veneuze trombose is niet 
ongewoon bij patiënten met een eerste uitgelokte trombose en stratificatie van het 
recidiefrisico is mogelijk en klinisch relevant in deze groep patiënten. 
Conclusie
Preventie van recidief veneuze trombose kan worden bereikt op twee manieren, óf door 
het wegnemen van risicofactoren óf door de behandeling met antistollingsmiddelen te 
verlengen in patiënten met een hoog risico op recidieven. In dit proefschrift heb ik 
risicofactoren voor recidief trombose onderzocht, alsmede factoren die een recidief 
kunnen voorspellen. Dit proefschrift laat een verhoogd recidiefrisico zien bij vrouwen 
die beginnen of doorgaan met hormonale anticonceptiva na een eerste trombose. 
Dit betekent dat het wegnemen van deze risicofactor het recidiefrisico zal verlagen. 
Verder laten we in dit proefschrift een associatie zien tussen verschillende factoren: 
man-zijn, een idiopathische eerste trombose, spiegels van stollingsfactor VIII en 
antibiotica gebruik, en recidief veneuze trombose. Deze factoren zullen uiteindelijk 
moeten worden samen genomen en gebruikt om een predictiemodel te bouwen, dat 
in staat zal zijn om recidief veneuze trombose te voorspellen op een meer verfijnd en 
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